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Epstein-Barr virus (EBV) is a human DNA herpesvirus which establishes a
persistent latent infection in vivo in B-lymphocytes. Iatrogenic immunosuppression
to prevent rejection of transplanted organs predisposes to EBV positive post-
transplant B-lymphoproliferative disease (PTLD).
This study followed 96 adult cardiothoracic transplant recipients for up to 1110
days (mean follow up time of 415 days) post-transplant. EBV load in peripheral
blood mononuclear cells (PBMs) was determined in each sample using a sensitive
semi-quantitative DNA PCR. RT-PCRs were developed to examine whether the
pattern of EBV gene expression changed following transplantation due to
immunosuppressive therapy and how these changes relate to PTLD development.
The results show that post-transplant EBV load significantly increases above
that detected in normal EBV seropositives in 55% of transplant recipients and
reaches levels equivalent to that detected in other patients with PTLD in 14% of
patients, and equivalent to patients with IM in 40%. Thus high EBV load is
associated with, but not diagnostic ofEBV associated disease.
Following transplantation EBV genes are expressed which are not detected in
normal EBV carriers which may be responsible for increased EBV load through a
combination of lytic replication and EBV-driven B-lymphoproliferation. The highest
EBV loads detected were in samples with lytic replication and unrestricted latent
gene expression. Despite detection of patterns of EBV gene expression and levels of
EBV equivalent to that in patients with PTLD, these patients did not develop
apparent disease. Therefore despite profound immunosuppression, and partial loss of
control of EBV infection following transplantation, PTLD did not develop. These
results suggest that additional factors are required for PTLD development.
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The development of tissue and organ transplantation has provided enormous
benefits both in patient treatment and advances in immunology. The idea of grafting
parts of the body is not new; there is archaeological evidence that teeth were
transplanted in man in ancient Egypt, Greece, North and South America, Italy and
China (Peer 1955).
Autotransplantation (where the donor and recipient are the same individual) of
a kidney in a dog was successfully performed for the first time in 1908 (Carel 1908).
In this operation, both kidneys were removed, and one replaced, following which it
functioned entirely normally demonstrating that surgical interruption of the kidneys
circulation and suture of the blood vessels and the ureter was possible.
It was realised that while autotransplantation was nearly always successful,
allogeneic transplantation (where the donor and recipient are genetically dissimilar
individuals of the same species), whilst often initially apparently successful, was
nearly always ultimately a failure. Allogeneic transplantation resulted in correct
function of the grafted organ for the first few days, but after six or seven days the
kidneys became congested and after seven or eight months they were found to be
sclerotic with a leucocyte infiltrate (Carel 1908). It was soon realised that loss of the
grafted organ was not due to avascular necrosis, infarction, infection or
inflammation, and the term 'rejection' was used to describe the process by which the
host animal was unable to accept the transplanted organ.
Progress in understanding the immunological basis of rejection led to the
development of immunosuppression techniques, including the use of whole-body
irradiation and irradiation of the graft. By 1962, all transplants between unrelated
individuals were performed under the influence of immunosuppressive drugs,
initially 6-mercaptopurine and subsequently a derivative of it, azathioprine (Schwartz
et al 1959, Murray et al 1963). Azathioprine inhibits DNA and RNA synthesis, but
also incorporates into DNA, resulting in chromosomal breaks (Bach 1975), which
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may in part explain why azathioprine recipients are at increased risk of developing
cutaneous malignancies. Initially the standard immunosuppressive regime for
transplantation was combined high doses of azathioprine and the corticosteroid
prednisolone. It was soon established that greatly reduced doses of steroid were
associated with fewer side effects and good graft outcome (McGeown et al 1980,
d'Apice et al 1984). The great breakthrough in immunosuppressive therapy came
with the development of cyclosporine (CsA), a fungal decapeptide discovered in
1976 (Borel et al 1976), which became accepted as the standard primary
immunosuppressive therapy by the early 1980's. CsA prevents proliferation and
clonal expansion of T-lymphocytes through inhibiting the effects of interleukin2
(IL2), which reduced acute rejection and gave a 10-20% improvement in one-year
graft survival (European Multicentre Trial Group 1983).
New immunosuppressive drugs have been developed recently which are more
specific and potent than CsA. FK506, or tacrolimus, is an inhibitor of IL2
production, and has wide ranging effects on the immune system (Goto et al 1991).
Rapamicin is structurally similar to FK506, but antagonises the interaction of IL2
with its receptor, preventing cytokine dependent T-lymphocyte proliferation 100
times more potently than CsA (Dumont et al 1990). B- and T- lymphocytes, unlike
other cells, rely on de novo purine and pyrimidine synthesis. Mycophenylate mofetil
and Leflunomide inhibit purine or pyrimidine synthesis respectively, specifically
inhibiting activation of lymphoid cells. Advances have also been made using anti-T-
lymphocyte monoclonal (such as OKT3) or oligoclonal antibodies (such as anti-
lymphocyte globulin (ALG)) to treat acute rejection (Kreis & Goldstein 1985).
The development of organ transplantation has been accompanied by
realisation of numerous complications. The intensive post-operative care required
means that patients are initially at risk from opportunistic and nosocomial diseases
common after any major surgery. However, since these patients are subject to severe
immunosuppression to prevent graft rejection, in particular, specific inhibition of
their cytotoxic T-cell responses, they may be unable to control infections which
would not cause severe disease in an immunocompetent individual. Transplant
recipients are at risk of developing bacterial infections including Mycobacterium
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tuberculosis, the majority of which occurs from reactivation of a latent infection,
with a frequency of 0.8 - 3% in renal transplant recipients, compared with 0.1% in
the general population or with Listeria monocytogenes (Delaney et al 1993, Quinbi et
al 1990). Immunosuppressed transplant recipients are also at increased risk of fungal
infection particularly in the first two months post-transplant with high mortality if
untreated (Paya 1993a). Over 80% of cases are caused by Candida albicans or
Aspergillus sp. (Weiland et al 1983). Pneumocystis carenii is the most common
parasitic infection in transplant recipients, and is particularly prevalent as a cause of
pneumonia following lung transplantation (Nicholson & Johnson 1994, Dummer et
al 1986).
Viral disease following organ transplantation may be due to primary infection
or reactivation of a latent or subclinical infection and tend to be more severe than in
normal individuals. Herpesviruses commonly associated with post-transplant disease
include Epstein-Barr virus (EBV), Cytomegalovirus (CMV), Varicella-Zoster virus
(VZV) and Herpes-simplex viruses 1 and 2 (HSV 1 and 2) (Roizman 1996). These
viruses are discussed in more detail in the next section. Human papillomavirus
(HPV) causes large and numerous warts in transplant recipients and is associated
with increased incidence of cervical carcinoma in these patients (Bavin et al 1992).
Hepatitis B virus (HBV) has a high incidence of recurrence in liver transplant
recipients following HBV liver disease (O'Grady et al 1992). This may result in a
spectrum of disease, from asymptomatic infection to fulminant liver failure. Donors
are screened for HBV surface antigen (HBsAg) and HBV positive organs rejected for
transplantation. Hepatitis C virus (HCV) causes similar, though less severe, disease
and therefore HBV and HCV positive donors should not be used for transplantation
(Valeri et al 1993).
Transplant recipients are at three times greater risk of developing cancers than
the general population (Sheil et al 1993). The Cincinatti Transplant Tumour Registry
(CTTR) monitored worldwide incidence of tumours in 5,753 transplant recipients
(Penn 1993). Of 6,123 cancers in this group, the most common type were skin
carcinomas (2,261 cases), representing 37% of the total. In areas with strong
sunlight, transplant recipients are forty times more likely to develop skin cancers
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than the general population (Penn 1994). In Australia, over 50% of transplant
recipients have developed cancer by twenty years after surgery and these tumours
tend to be more aggressive than in healthy people.
Lymphomas make up 5% of cancers in the general population, whereas they
comprise 12-33% of cancers in transplant recipients, with a high preponderance of
non-Hodgkins lymphoma (Sheil et al 1992, Penn 1994). Over 80% of these
lymphomas are of B-cell origin, 12.6% of T-cell origin, and 0.4% of null cell origin.
Multiple organ involvement occurs in 52% of transplant recipients with lymphoma,
and transplant recipients are at one thousand fold higher risk of cerebral lymphoma
(Sheil et al 1993a & b). The grafted organ is involved in 23% of cases, which may be
misdiagnosed as acute rejection (Penn 1993). Lymphomas occur on average 32
months post-transplant (range 1 to 254 months) with cerebral lymphomas presenting
earlier than diffuse lymphomas (average of 2 years and 6 years respectively) (Penn
1994 & 1995).
The greatest risk is from cancers with a viral aetiology, including lymphomas
(EBV), cancers of the perineum (HPV), skin cancers (HPV) and Kaposi's sarcoma
(HHV8). These tumours tend to occur just a few months or years post-transplant,
occur in younger individuals than would normally be expected and have a more
aggressive course with earlier dissemination (Sheil et al 1992).
1.2 Herpesviridae
The herpesvirus family, Herpesviridae, is characterised by virus structure,
having a linear double stranded DNA (dsDNA) genome encoding around 160 genes,
contained within an icosahedral capsid of lOOnm diameter, composed of 162
capsomers. The virion is surrounded by a layer of amorphous tegument enclosed in a
host-cell derived lipid envelope containing viral glycoproteins giving the enveloped
virion a total diameter of 150-200nm (Roizman 1996). All animals tested to date
have at least one associated herpesvirus. The wide distribution and host specificity
of herpesviruses suggests close co-evolution with their respective hosts.
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Eight human herpesviruses have been isolated so far, namely herpes simplex
virus 1 (HSV-1), herpes simplex virus 2 (HSV-2), human cytomegalovirus (HCMV),
varicella-zoster virus (VZV), Epstein-Barr virus (EBV), and human herpesviruses 6
and 7 and Kaposi's sarcoma associated herpesvirus (KSHV or human herpesvirus 8
(HHV8)). The classification and disease association of these viruses is summarised in
Table 1-1. The numerous members of the Herpesviridae are classified on the basis of
their biologic properties, principally the agents host range, length of replicative cycle,
site of latent infection and cytopathology (Roizman et al 1981). More recently, DNA
sequence analysis of Herpesviruses has provided the opportunity to review
classification. There are three subfamilies of herpesviruses: Alpha(a)-, Beta((3)- and
Gamma(y)- herpesviridae. Gammaherpesviridae includes two genera;
lymphocryptovirus, which includes EBV, and Rhadinovirus. Most Herpesviruses
would remain in their original classification, with the exception of Marek's disease
virus and HHV6, both of which would be classified as gammaherpesvirinae on the
basis of biologic criteria, but by objective criteria, they would be members of the
alpha and beta herpesvirinae respectively (Buckmaster et al 1988).
Lymphocryptoviruses have only been found in old world primates and
humans, each species carrying its own virus which is closely related to the other
viruses of the genera. This indicates that a common precursor of EBV-like viruses
once infected the hominid species which evolved into humans and the old world
primates (Rabin et al 1980).
Vernacular and approved names are used interchangeably for human
herpesviruses and members of each group. A summary of their classification is
shown in Table 1-1.
The known herpesviruses share four common properties:
i. They encode a large number of enzymes involved in nucleic acid metabolism
(eg thymidine kinase, dUTPase, ribonucleotide reductase etc.), DNA synthesis (DNA
polymerase, helicase, primase), and protein processing (eg protein kinase).The range
of enzymes encoded varies between herpesviruses.
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ii. Synthesis of viral DNA and capsid assembly occurs in the nucleus and the
capsid is enveloped as it transits through the nuclear membrane. The capsid may be
re-enveloped as it passes through the cytoplasm.
iii. Production of infectious progeny virus results in destruction of the host cell
(lytic replication).
iv. All herpesviruses described are able to remain latent in their natural hosts.
During latent infection, the genomes remain as closed circular episomes and a
minimal set of viral genes are expressed, allowing the virus to persist in the host.
Table 1-1. Classification of Human Herpesviruses
(adapted from Jawetz et al 1989)
Biologic properties Examples
Sub¬ Growth Cyto- Latent Name Common Disease associated
family cycle pathology infections name1 with 1° infection2
HHV-
alpha Short Cytolytic Neurons 1 HSV-1 Vesicular
(-18 hrs) 2 HSV-2 stomatitis
3 VZV Genital herpes
Chicken-pox
beta Long Cytomegali Glands, 5 CMV IM
(-70 hrs) c kidney 6 N/A Exanthum subitum
leukocytes 7 N/A Not known
gamma Variable Lympho- Lymphoid 4 EBV IM
proliferative Endothelium 8 KSHV Not known
1. HHV: Human Herpes virus. HSV: Herpes Simplex virus. VZV: Varicella
Zoster virus. CMV: Cytomegalovirus. EBV: Epstein-Barr virus. KSHV:
Kaposi's Sarcoma associated Herpesvirus.
2. IM: Infectious mononucleosis.
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Herpesviruses infect the host cell by fusion with the cell membrane following
binding of specific cellular receptors with virus envelope glycoproteins (Roizman
1996). The virus is then uncoated and the DNA becomes associated with the nucleus.
Lytic replication begins with expression of "immediately-early" genes, the protein
products of which transactivate expression of the "early" set of genes. The immediate
early and early gene products encode enzymes or DNA-binding proteins. Viral DNA
replication begins by a rolling circle mechanism involving cellular DNA polymerase
II and with participation of viral early proteins. "Late" genes are also transcribed
which provide structural components. Viral DNA is packaged in preformed
nucleocapsids in the nucleus and maturation occurs by budding through the nuclear
membrane where the virus gains its envelope, and transportation of the virus particles
to the cell surface for release. Herpesvirus replication leads to death of the host cell.
The ability of herpesviruses to establish a life-long latent infection relies on
evasion of the host cellular immune system. In the setting of inherited, acquired or
iatrogenic immunodeficiency, loss of immune control of herpesvirus infection can
lead to fatal disease. The most common cause of herpesvirus infection in the first
month post-transplant is CMV, which causes symptoms including malaise, fever and
lethargy and can result in interstitial pneumonitis, hepatitis, colitis or retinitis, and
may lead to disseminated life-threatening disease from hypotension and respiratory
failure (Peterson et al 1980). Patients most vulnerable to CMV disease post-
transplant are CMV seronegative transplant recipients receiving an organ from a
CMV positive donor (Paya et al 1993b). Therefore it is recommended that donors
and recipients are CMV matched (Nicholson et al 1994) and transplant centres
employ prophylaxis to prevent CMV disease using ganciclovir (Meriden et al 1992)
and immune globulin (Snydman et al 1987).
Herpes simplex virus 1 and 2 generally cause disease in transplant recipients
through reactivation of virus from their site of latency in trigeminal ganglia. HSV
disease is generally seen between the first week and first month after transplantation
and results in marked localised ulceration or widespread dissemination, leading to
local or disseminated skin rash or cold sores, oesophagitis, pneumonitis, hepatitis or
encephalitis. Ophthalmic infection can result from patients rubbing their eyes.
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Treatment for HSV disease is through the routine prophylactic use of the inhibitor of
DNA replication acyclovir (ACV) in the early post-operative period (Saral et al
1983).
VZV also generally causes disease through reactivation from dorsal root ganglia,
leading to shingles early post-transplant. Patients may have extensive vesicles
involving the epidermis and dermis which are often haemorrhagic or necrotic.
Disseminated disease has a high mortality, and patients who undergo primary
infection with VZV post-transplant suffer from an aggressive chicken pox with a
high risk of mortality. VZV disease can be prevented through use of live attenuated
vaccine prior to transplantation or treated with ACV (Kitai et al 1993).
Transplant recipients are also at risk of developing HHV-8 associated Kaposi's
sarcoma (Sheil et al 1993a). EBV is associated with post-transplant
lymphoproliferative disease (PTLD), which is discussed further in section 1.3.11.8.
1.3 Epstein-Barr virus (EBV)
1.3.1 Introduction
In 1958, Dennis Burkitt, a British surgeon working in Uganda, described a
malignancy of the jaw occurring in African children which is now known as Burkitt's
lymphoma (BL), a tumour of B-cell origin (Burkitt 1958). The distinct geographical
restriction of BL in equatorial Africa suggested an infectious origin of the disease
and because of its coincidence with the distribution of malaria it was suggested that
mosquitoes provided the vector for the agent (Burkitt 1962). Cell lines were
subsequently established in vitro from BL tumour material and electron microscopy
of these cells identified herpesvirus particles which were later shown to be unique
and named Epstein-Barr virus (EBV) (Epstein & Barr 1964, Epstein, Achong and
Barr 1964). BL is discussed in detail in section 1.3.11.1.
EBV infects B-, T- and epithelial cells in vitro and in vivo and like the other
herpesviruses maintains a lifelong infection, termed latency, which allows
persistence of the virus in infected cells through repression of lytic replication. EBV
is the causative agent of infectious mononucleosis (IM) (Henle et al 1968) and
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aetiologically associated with a number of epithelial and lymphoid tumours in the
immunocompetent and immunosuppressed host (Rickinson & Kieff 1996).
1.3.2 EBV genome
EBV is a large (around 120nm) gammaherpesvirus with a linear dsDNA
genome of 172 kilobase-pairs. EBV was the first herpesvirus whose genome was
completely sequenced (Baer et al 1984). The laboratory prototype strain of EBV is
B95-8, which was derived from marmoset B-cells infected with EBV from throat
washings from a patient with infectious mononucleosis (Miller et al 1973). The EBV
genome has a guanosine-cytosine (G-C) content of 60%, and has a characteristic
arrangement of repeat regions. These are a reiterated 0.5kbp terminal repeat (TR)
region of variable length and a reiterated 3kbp internal repeat (IR1) which divides the
genome into short and long largely unique sequence domains (US and UL). Within
the unique long (UL) region are three specific repeats IR2, 3 and 4. Covalent linking
of the TR regions forms a circular episome in the nucleus of a latently infected cell
(Nonoyama & Pagano 1972. Lindahl et al 1976). An individual cell infected with
EBV contains multiple identical (clonal) copies of the EBV episome, replicated by
cellular DNA polymerase (Sugden et al 1979).
The EBV genome sequence was derived from a Bam HI fragment cloned
library, and therefore genome organisation of open reading frames (ORFs), genes or
transcription sites are named with reference to Bam HI fragments. EBV genes have a
four-letter and number acronym based on the restriction fragment in which
transcription begins; for example BZLF1 refers to the first (1) leftward (L) ORF (F)
of the Bam HI (B) Z fragment (Z) of the EBV genome (Baer et al 1984). The
organization of the EBV genome is represented in Figure 1-1.
1.3.3 EBV Types
EBV has two prototype virus types; A and B (or type 1 and 2) based on
genome sequence differences (Dambaugh et al 1980). The types differ in the
sequence of genes encoding Epstein-Barr virus encoded nuclear antigen 2 (EBNA2)
EBNA 3a, b and c (Rowe et al 1989, Sculley et al 1989, Sample et al 1990) and the
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EBV encoded small RNAs (EBERs) 1 and 2 (Arrand, Young and Tugwood 1989).
The role of these genes is described in Section 1.3.7. There is a geographical and
ethnic difference in the frequency of the two types of EBV although both types exist
worldwide (Zimber et al 1986, Sixby et al 1989). Type 2 EBV is more common in
African populations and type 1 more common in European or US populations
(Zimber et al 1986). Although type 2 EBV is less efficient at transforming B-
lymphocytes in vitro (Rickinson et al 1987), the different EBV types are not
preferentially associated with specific diseases (Lung et al 1988).
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Figure 1-1. Diagram of the layout of the linear EBV genome and BamH1
restriction enzyme map
Upper panel: A schematic diagram of the linear EBV genome.
IR: internal repeat sequence. TR: Terminal repeat sequence. US: Unique short
sequence. UL: Unique long sequence.
Lower panel: A schematic diagram of the linear EBV genome indicating the BamEll
restriction enzyme fragments obtained by enzymatic digestion of the prototype EBV
strain, B95-8. Acronyms denote open reading frames of the known latent genes, the
exons of which are indicated on the diagram.












































































































EBV isolates can be characterised on the basis of the number of sequence
repeats within repeat regions present in the viral genome. In practice, the isolates are
identified by genotyping or EBNO-typing. Genotyping is carried out by restriction
fragment length polymorphism (Katz et al 1988) or by PCR analysis (Sixby et al
1989). EBNO-typing is performed by generating lymphoblastoid cell lines (LCLs)
and analysis of EBNA protein size polymorphism by immunoblotting (Gratama et al
1990, 1994). Normal healthy EBV seropositive donors carry a single EBV isolate
which is consistently detectable in both blood and throat washings (Yao et al 1991).
Immunosuppressed patients may carry multiple EBV isolates (Miller et al 1987, Yao
et al 1996a and b).
1.3.5 EBV encoded transcripts and proteins
The large genome ofEBV (172 kbp) contains 84 major unique ORFs (Baer et
al 1984). EBV is able to express different combinations of genes in latency and lytic
infection through differential promoter usage. Viral messenger RNA (mRNA)
transcription is mediated through host cell RNA Polymerase II since herpesviruses
do not encode their own RNA polymerase.
1.3.6 Models of EBV Latency
EBV expresses different combinations of latent genes, which are
characteristic of particular cell types or disease states. These combinations have been
broadly classified in three groups termed Latency I, II and III, described in detail
below (Rowe et al 1992). EBERs and Bam HI A and EBNA1 transcripts are detected
in all forms of latent gene expression.
Differential expression of the EBV latent genes is through use of alternative
promoters. Transcription of the EBNA gene complex occurs from a single
transcriptional unit spanning 100 kilobases of the EBV genome. One of two
promoters, Cp or Wp, drive transcription of the EBNAs, and alternative splicing
13
leads to synthesis of mature EBNA transcripts (Kieff 1996). Following infection of
B-lymphocytes in vitro, EBNAs are initially transcribed from Wp and promoter
usage subsequently switches to Cp (Woisetschlager et al 1990). Cp or Wp operate
mutually exclusively in individual EBV infected cell lines in vitro (Woisetschlager et
al 1989). During Latency I in vitro and in vivo, transcription from Cp or Wp is
repressed through methylation and EBNA1 is transcribed from a distinct promoter,
Qp (Nonkwelo et al 1996, Paulson & Speck 1999). Cp and Wp are extensively
methylated in EBV episomes from normal healthy EBV carriers and in tumours and
cell lines displaying restricted EBV latency, whereas Qp is consistently
hypomethylated (Schaefer, Strominger and Speck 1997, Paulsson & Speck 1999).
Demethylation of Cp/Wp by 5-azacytidine, a methyltransferase inhibitor, leads to
activation of EBNA gene transcription from Cp/ Wp (Masucci et al 1989, Altiok et
al 1992, Jansson, Massuci and Rymo 1992, Robertson et al 1995). EBNA1 positively
regulates Cp and Wp promoter activity whereas it negatively regulates transcription
from Qp (Puglielli, Woisetschlager & Speck 1996, Sample, Henson and Sample
1992, Schaefer, Strominger and Speck 1997). This is reflected in the variable
detection of Qp initiated EBNA1 transcripts in healthy EBV carriers since in
quiescent memory B-cells, there may be sufficient EBNA1 to repress Qp activity.
1.3.6.1 Latency I
This form of latent gene expression is characterised by transcription of
EBNA1 from the Qp promoter with no transcription of the other EBNAs from the
silent Cp or Wp promoters (Nonkwelo et al 1996, Schaefer et al 1995). The LMPs
are not transcribed (Brooks et al 1995, Chen et al 1995). This pattern of EBV gene
expression is detected in Burkitt's lymphoma cells in biopsy material and early
passage BL lines (Rowe et al 1986, 1987).
1.3.6.2 Latency II
Latency II is characterised by expression of EBNA1 from Qp with no
transcriptional activity from Cp or Wp. In addition, one or more of the LMP
promoters are active, resulting in expression of LMP1, LMP2a and/or LMP2b (Kerr
et al 1992). This form of latent gene expression is detected in Reed-Sternberg cells in
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Hodgkin's disease (HD) and in the malignant epithelial cells of nasopharyngeal
carcinoma (NPC) (Brooks et al 1992, Deacon et al 1993).
1.3.6.3 Latency III
This form of gene expression is detected in latently infected cells in LCLs
and in peripheral blood mononuclear cells (PBMs) in early infectious mononucleosis
(IM) and PTLD tumour cells (Thomas et al 1990a, Rickinson and Keiff 1996). The
Cp or Wp promoters are active, resulting in expression of all the EBNAs and all three
LMPs.
In vitro passage of BL cell lines frequently leads to drift from latency I to
latency III pattern of EBV gene expression, with a concomitant loss of viral gene
methylation (Minarovits et al 1991). It appears that EBV utilizes the host cell
methylation system to regulate expression of antigenic latent proteins, allowing the
virus to evade the host immune system and establish a lifelong latent infection.
1.3.7 Latent cycle transcripts
In vitro infection by EBV of mature, surface immunoglobulin (slg) positive
B-lymphocytes results in cellular activation and the establishment of an immortalised
B-LCL, blocked in the lymphoblastoid stage of B-lymphocyte differentiation
(Thorley-Lawson & Mann 1985). The majority of LCL cells contain multiple copies
of the non-replicating episomal form of the EBV genome and only a small proportion
of cells contain replicating virus (Lindahl et al 1976). LCLs provide a model for
Latency III since they express all nine viral latent antigens (See Table 1-2). This
includes six EBNAs: -1, -2, -3a, 3b and 3c and Leader protein (-LP)) and three
LMPs: 1, 2a and 2b (Reviewed in Kieff 1996). Abundantly expressed EBERs 1 and 2
are transcribed but not translated (Clemens 1993) and the transcript from the Bam
EllA reading frame is translated into protein(s) although its nature and function are
unclear (Brooks et al 1995, Fries et al 1997). Promoter activity and transcribed genes
in latency I and III is shown in Figure 1-2.
Deletion analysis has shown that EBNAs -1,-2, -3a and 3c and LP and LMP1
are essential for host cell growth immortalisation (Reviewed in Rickinson & Keiff
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1996). The function of these proteins is described in this chapter (section 1.3.6).
There is an alternative nomenclature for the EBV latent antigens; EBNA-LP is also
known as EBNA-5 and EBNAs 3a, 3b and 3c are known as EBNA-3, -4 and -6
respectively. LMP1, 2a and 2b are known as LMP, terminal protein (TP) 1 and 2
respectively.
Individual mRNAs are generated by differential splicing, poly (A) site
selection and alternative promoter usage (Speck & Strominger 1985, Woisetschlager
et al 1989, Sample el al 1991). The role and function of the individual EBNA
proteins are described below.
Table 1-2 EBV latent transcripts
(Adapted from Johannessen and Crawford 1999)
Protein ORF Molecular
weight (kDa)
Cellular site Required for
immortalisation
EBNA 1 BKRFl 65-97 Nucleus Yes
EBNA 2 BYRF1 75-105 Nucleus Yes
EBNA 3a BLRF3/ BERF1 130-195 Nucleus Yes
EBNA 3b BERF2a/ b 145-160 Nucleus No
EBNA 3 c BERF3/ 4 130-195 Nucleus Yes
EBNA LP BWRF1 20-130 Nucleus Yes
LMP1 BNLF1 58-63 Membrane Yes
LMP2a BARF1/BNRF1 54 Membrane No
LMP2b BNRF1 40 Membrane No
EBER 1/2 BCRF1 Nucleus/
cytoplasm
No
Bam HI A BARFO - cytoplasm No
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Figure 1-2. EBV transcription in latency
(Adapted from Farrell and Sinclair 1994)
Latent promoter activity in EBV immortalised B-cell lines (LCL):
Latency III
Cp
Latent promoter activity in Burkitt's lymphoma cells
Qp
Diagrams show the gene layout in immortalised cells compared to Burkitt's
lymphoma. EBV promoter activity and expressed latent genes are shown. Arrows
show active promoters and the direction of transcription. The coding segments of
EBNA1, 2,3a, 3b, 3c, lmp1, 2a and 2b are illustrated as filled boxes in the upper




EBERs 1 and 2 are the most abundantly expressed EBV transcripts in latently
infected B-cells (Rymo 1979, Arrand and Rymo 1982). These small (167 and 172
nucleotides respectively), non-translated RNAs (Clemens 1993) are transcribed from
hypomethylated transcription units by host cell RNA polymerase III (Clarke et al
1992, Minarovits et al 1992). EBERs exist in the nucleus as ribonucleoprotein
particles complexed with the ribosomal protein L22 (Toczyski et al 1994). The L22
gene is a target for chromosomal translocation in certain patients with myeloid
leukaemia and EBERs may therefore have a role in stabilizing cellular
transformation. EBERs are also detected in the cytoplasm where they bind p68, an
interferon-induced dsRNA dependent protein-kinase, which may protect EBV protein
synthesis from interferon induced inhibition (Schwemmle et al 1992, Clarke et al
1991 & 1992). EBERs are not essential for B-cell immortalisation in vitro
(Swamminathan et al 1991). However studies in the BL cell line Akata in which
EBV negative clones were transfected with EBERs constructs indicated that they
contribute to apoptosis resistance and the malignant phenotype (Komano et al 1999).
1.3.7.2 EBNA-1
EBNA1 is the only EBV encoded protein to be expressed in all EBV
associated malignancies (Klein 1989, 1994). It is a nuclear antigen encoded by the
BKRF1 gene containing a variable length internal repeat (IR3) encoding the amino
acids glycine and alanine (gly-ala repeat) flanked by arginine rich sequences
(Henessy & Keiff 1983). Other important domains of EBNA1 include a DNA
looping region, nuclear localization signal, DNA binding and dimerisation domain
and a C-terminal tail (Mackey et al 1995, Bochkarev et al 1996, Kieff 1996).
EBNA1 is essential for maintenance of the viral episome through binding to
the EBV origin of replication (OriP) (Middleton & Sugden 1994) and is also
responsible for partitioning of progeny EBV genomes to daughter cells in mitosis
through associating with the host cell chromosomes (Adams 1987, Yates & Guan
1991, Davenport & Pagano 1999). Although the EBV origin of replication (OriP) is
independently capable of recruiting human cellular replication factors and initiating
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genome replication, EBNA1 is required to ensure continued replication and
transcription (Polvino-Bodnar & Schaeffer 1992, Aiyar et al 1998). Oz'P is
composed of two clusters ofEBNA1-binding sites (Rawlins et al 1985, Reisman et al
1985). EBNA1 interacts with a human single stranded DNA binding protein, (hSSB,
also called RPA), which may facilitate recruitment of other host replication proteins
to replicate the EBV genome (Zhang et al 1998).
Ori? is also a transcriptional enhancer through which EBNA1 supports the
activity of at least two EBV promoters: Cp and the LMP1 promoter (Puglielli et al
1996 & 1997, Gahn & Sugden 1995, Reisman & Sugden 1986, Sugden & Warren
1989). Unless Cp/ Wp are inactivated through methylation, EBNA1 activates
transcription from these promoters and represses Qp activity (Paulsson & Speck
1999).
Although the principal role of EBNA1 appears to be in maintaining the EBV
genome, the fact that it is expressed in all EBV-associated tumours suggests a
potential role in tumorigenesis. Wilson et al (1996) demonstrated that EBNA1
transgenic mice develop lymphomas at increased frequency. It has been shown that
EBNA1 upregulates expression of recombinase activating genes (RAG) which are
involved in regulating immunoglobulin gene VDG rearrangement (Srinivas & Sixby
1995). Aberrant VDJ recombination in EBV infected B-cells could potentially
facilitate MYC translocation to immunoglobulin loci, the characteristic translocation
in Burkitt's lymphoma.
Differentially expressed transcripts of EBNA1 are produced by alternative
promoter usage. This occurs from the Cp or Wp promoter in LCLs or the Qp
promoter in BL cell lines (Sample et al 1991). In cells undergoing lytic replication,
EBNA1 is the sole EBNA complex gene expressed, in this case transcribed through
another EBNA1 promoter, Fp (Ernberg et al 1976, Weigel and Miller 1983, Weigel
et al 1985). EBNA1 regulates its own expression from Qp through interaction with a
binding site within the Bam HI Q fragment (Rawlins et al 1985, Sample et al 1992).
Zetterberg et al (1999) performed RNAse protection assays to quantify the levels of
EBNA1 transcripts in B-lymphoid cells in EBV latency and under induction of lytic
replication. During lytic replication low levels of FpQ/ U/ K spliced EBNA1 were
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present in all cells. In addition high levels of transcripts initiating in Fp were
detected, some of which contain the U exon, but which did not contain the EBNA1
encoding K exon, and map to unknown 3' sequences (see Figure 1-3) (Schaefer et al
1995).
Figure 1-3. Promoter activity in EBNA1 transcription
Latent transcription ofEBNA1
Qp
EBNAl Promoter activity in lytic replication
Fp
EBNAl transcription during Latency III
Figures represent different patterns of promoter usage and exon transcription in alternative
programs of EBV latency and lytic replication, as described in the text (Section 1.3.7.2). Transcribed
exons are represented by boxes with linking diagonal lines representing slicing across introns. The
EBNAl coding exon (K) is shown as the pointed box. Promoters are indicated (Qp, Fp, Cp/Wp ).
Transcripts initiating from Fp splice to the U exon, or bypass it, but the downstream splice sites are
not known, indicated by the arrows leading to question marks.
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Despite the fact that EBNA1 is antigenic and raises an antibody response
(Dillner et al 1984), cytotoxic T-cell (CTL) responses are not usually detected
against EBNA1 (Rickinson & Moss 1997). This is due to inhibition of the
ubiquitin/proteosome dependent degradation pathway by the gly-ala repeat sequence
of EBNA1 which prevents the production of peptides for major histocompatability
complex (MHC)-l restricted presentation (Levitskaya et al 1995, 1997). CTL
responses can be raised against EBNA1 if antigen-presenting cells process the
protein exogenously in vitro, and this pathway may be responsible for the occasional
detection of CTL reactivities against EBNA1 epitopes (Blake et al 1997). EBNA1
homologues are found in other primate lymphocryptoviruses yet despite a high
degree of conservation and the presence of gly-ala repeats rhesus monkey and
baboon isolates do not inhibit antigen processing and presentation (Blake et al 1999).
1.3.7.3 EBNA-2
EBNA2 is a 75-105kDa protein, which, with EBNA LP, is one of the first
EBV genes expressed following in vitro infection of B-lymphocytes. EBNA2 is
essential for B-cell immortalisation and reintroduction of wild-type EBNA2 into B-
lymphocytes infected with P3HR1, a strain of EBV in which EBNA2 is deleted,
restores immortalising activity (Hammerschmidt & Sugden 1989, Cohen et al 1989).
EBNA2 has a strong transactivating domain which does not bind DNA directly but
can interact with multiple constituents of the RNA polymerase II complex (Tong et
al 1995 a, b & c). The function of EBNA2 mimics signalling through the Notch
pathway (Strobl et al 2000, Hsieh et al 1997). EBNA2 upregulates expression of
LMP1 (Abbott et al 1990, Wang et al 1990) and LMP2a and b (Zimber-Strobl et al
1991 & 1993) and mediates promoter switching from Wp to Cp following initial
transcription from Wp immediately after B-cell infection (Woisetschlager et al 1991,
Jin & Speck 1992). Thus EBNA2 has an autoregulatory function through
upregulating its own promoter (Cp) (Puglielli et al 1997). EBNA2 binding to
enhancer elements upstream of these promoters is mediated by recombinant signal
binding protein (RBP) Jk, also known as CBF1 (C promoter binding factor 1) (Tsang
et al 1991, Zimber-Strobl et al 1993, Henkel et al 1994, Krauer et al 1999). It can
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also be recruited to promoters by cellular factors including PU1 or transcription
factors of the POU family (Pit-Oct-Unc) (Johannsen et al 1995). RBP is a
transcriptional repressor which regulates cell differentiation, and in LCLs it is
sequestered from the cytoplasm to the nucleus where it is bound in chromatin by
EBNA2 and EBNAs 3a, b and c (Krauer et al 1999). Around half of the cellular RBP
is associated with EBNAs in LCLs and the majority of EBNA2 in an LCL is
associated with RBP (Johannsen et al 1996). Sequestering of RBP by EBNAs may
block further differentiation in infected cells (Hsieh et al 1997).
EBNA2 also transactivates a number of cellular genes, including CD21
(Cordier et al 1990), CD23 (Wang et al 1991), c-fgr (Knutson 1990) and directly
transactivates the proto-oncogene c-myc (Kaiser et al 1999). EBNA2 also acts as a
suppressor, efficiently suppressing IgM expression (Jochner et al 1996). If c-myc is
overexpressed in an inducible system, B-cell proliferation can continue in the
absence of EBNA2 and LMP1 (Polack et al 1996). This indicates a mechanism for
continued proliferation of cells containing a MYC/Ig translocation as seen in
Burkitt's lymphoma, independently ofEBNA2 and LMP1 expression. In cooperation
with EBNA-LP, EBNA2 can induce cyclin D2 and cyclin-dependent kinase 4 (cdk4)
in resting B-lymphocytes causing cell cycle progression from GO to G1 (Sinclair et al
1994). Thus EBNA2 plays a vital role in the process B-cell immortalisation by EBV
through inducing proliferation and blocking differentiation by a variety of
mechanisms.
1.3.7.4 EBNA 3a, 3b and 3c
EBNAs 3a, 3b and 3c derive from three tandemly located genes within the
Bam HI E fragment, each transcript consisting of a shared leader sequence followed
by a short and long exon. EBNA3a is encoded by BLRF3 and BERF1, EBNA3b by
BERF2a and BERF2b and EBNA3c by BERF3 and BERF4. EBNA3a and 3c vary in
size from 130 to 195kDa and EBNA3c from 145- 160kDa (Ricksten et al 1988).
EBNA3a and 3c are essential for B-lymphocyte immortalisation whereas
EBNA3b is not (Tomkinson & Kieff 1992). EBNA3b up-regulates the cytoskeletal
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protein vimentin and the activation antigen CD40, but down regulates the BL
associated antigen CD77 when it is stably expressed in the BL cell line DG75 (Silins
& Sculley 1994).
EBNA3c is an immortalising oncoprotein with similar properties to the pRb
inactivating proteins of other DNA tumour viruses (for example adenovirus ElA and
papillomavirus E7), driving the cell cycle through G1 under conditions which would
normally signal growth arrest (Parker et al 1996, 2000). It is a DNA binding protein
containing a basic leucine zipper motif, characteristic of c-fos and c-jun (Vinson et al
1989, Allday et al 1993) and can cooperate with (Ha)-ras in co-transfection assays to
immortalise and transform rat embryo fibroblasts (Parker et al 1996). EBNA3a and
3c interact with RBP Jk and repress the effects of EBNA2 mediated transcription
through destabilizing RBP Jk binding to DNA (Waltzer et al 1996, Hsieh et al 1997a
& b). Thus EBNA3a and 3c inhibit the transactivation of LMP1 and 2 by EBNA2
which may be important in preventing toxicity through over expression of LMP1 (Le
Roux et al 1994, Marshall and Sample 1995, Robertson et al 1995). EBNA3a and 3c
directly repress transcription in vitro when tethered to a promoter via the DNA
binding domain of yeast Gal4 protein (Bain et al 1996, Waltzer et al 1996, Bourillot
et al 1998). EBNA3c inhibits Cp transcription through Jk (Radkov et al 1997, Bain
et al 1999), providing autoregulation of EBNA gene expression. EBNA3c also
inhibits transcription through promoting nucleosome formation by modulating
histone deacetylase function (Cotter & Robertson 2000, Radkov 1999). Since
EBNA2 can transactivate via RBP Jk or PU1, inhibition of RBP Jk mediated
transcription by EBNA3 may provide differential regulation of viral and cellular
genes including upregulation ofCD21, CD23 and LMP1 (Wang et al 1990, Allday &
Farrell 1994).
1.3.7.5 EBNA-LP
EBNA-LP (leader protein) is so called because its coding sequence precedes
the other EBNA coding sequences in all EBNA transcripts. The size of the EBNA-
LP protein varies between 20 to 130kDa protein due to alternative splicing of
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multiple repeat exons in the Bam HI W exon which link onto the short coding
sequences in the Bam HI Y fragment (Dillner et al 1986, Dillner & Kallin 1988).
EBNA-LP affects cell growth, providing a role in enhancing B-lymphocyte
immortalisation by EBV. The efficiency of EBV in producing LCLs following
infection of primary human B-lymphocytes in vitro is reduced by 90% if EBNA-LP
is deleted. LCLs produced in the absence of EBNA-LP require a feeder layer for
growth, and are not long lived (Mannick et al 1991, Allan et al 1992). EBNA-LP
localises to areas in the cell nucleus called ND10, (also known as PML (pro-
myelocytic leukaemia) bodies and associates with the interferon induced chaperone
protein heat shock protein 70 (hsp70) (Petti et al 1990, Mannick et al 1995, Szekeley
et al 1996, Kitay et al 1996). In vitro, EBNA-LP weakly binds p53 and pRb
(Szekeley et al 1993) but it does not affect their role in transcriptional regulation
(Inman & Farell 1995). EBNA-LP has a regulatory role in cellular immortalisation,
acting in cooperation with EBNA2 in mediating activation of the LMP1 promoter,
and of the LMP1 and LMP2b bi-directional transcriptional regulatory element. The
stimulatory activity of EBNA-LP resides in an amino terminal sixty-six amino acid
repeat domain and c-terminal regulatory domains (Harada & Kieff 1997).
1.3.7.6 LMP1
LMP1 is encoded by the BNLF1 open reading frame, generated from a bi¬
directional promoter (LMPlp), which also transcribes LMP2b (Laux et al 1989). The
promoter has two upstream enhancer elements, one of which is EBNA1-dependent
(Gahn & Sugden 1995), and the other EBNA2 dependent (Abbott et al 1990).
LMP1 is a 386 amino acid protein consisting of six hydrophobic membrane
spanning domains which mediate oligomerisation, required for its function
(Floettmann & Rowe 1997, Gires et al 1997). Immunofluorescence demonstrates
aggregates of LMP1 in the cytoplasmic membrane which occur through association
of LMP1 with the cytoskeletal protein vimentin (Liebowitz et al 1987, Mann et al
1985, Liebowitz et al 1986, Mann & Thorley-Lawson 1987). Three loops of the
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protein are exposed on the outer surface of the cytoplasmic membrane and both
termini are cytoplasmic (Liebowitz et al 1986).
LMP1 is the major oncogene of EBV and is essential for immortalisation of
B-lymphocytes (Kaye et al 1993). Rodent fibroblasts transfected with LMP1 are
morphologically transformed and are tumorigenic in nude mice (Wang et al 1985,
Baichwal & Sugden 1988). Transgenic mice with constitutively active LMP1 in
epidermis have hyperplasia (Wilson et al 1990, Kulchwit et al 1998). Transient
expression of LMP1 in primary B-lymphocytes in vitro leads to cellular enlargement,
upregulation of B-lymphocyte activation markers and adhesion molecules and
transient induction of DNA synthesis (Peng & Lundgren 1992). LMP1 induces
prolonged cell viability although in the absence of EBNA2 is not capable of
sustaining B-lymphocyte proliferation (Zimber-Strobl et al 1996). LMP1 has also
recently been shown to be secreted by LCLs in vitro and have direct
immunosuppressive effect through suppression of T-lymphocyte activation (Dukers
et al 2000).
LMP1 forms aggregates in the cell membrane which mimic a constitutively
active CD40 cellular receptor and induces extrafollicular B-lymphocyte
differentiation, but unlike CD40, LMP1 blocks the germinal centre phenotype
(Martin & Sugden 1991, Gires et al 1997, Uchida et al 1999).
The C-terminus of the protein is essential for in vitro immortalisation of B-
lymphocytes (Kaye et al 1995, Kilger et al 1998). The C-terminus contains two
functional domains, termed C-terminal activating regions (CTAR) 1 and 2 (Huen et
al 1995). CTAR1 mediates direct interaction between LMP1 and tumour necrosis
factor receptor (TNFR) associated factor (TRAF) and CTAR2 interacts with TNFR-
associated death domain (TRADD), leading to activation of the cellular transcription
factor NFkB (Hammerskjold & Simurda 1992, Laherty et al 1992, Mitchell &
Sugden 1995). Thus LMP1 expoits the signal transduction pathways activated by
TNF leading to upregulation ofNFkB responsive genes (Mosialos et al 1995). LMP1
upregulates the anti-apoptotic genes bcl-2 (Henderson et al 1991, Rowe et al 1994)
and the zinc-finger protein A20 (Laherty et al 1992, Fries et al 1999, 1996). A20 also
modulates transcriptional activation by LMP1 by blocking NFkB activation
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(Eliopoulos et al 1999). LMP1 induces activity of API, a dimer of Jun-Jun or Jun-
Fos family of proto-oncogenes, specifically via the c-jun N-terminal kinase 1 (JNK1)
pathway (Gires et al 1999, Eliopoulos & Young 1998, Kieser et al 1997 & 1999).
LMP1 also activates the JAK/ STAT pathway which is activated in uninfected cells
by almost all cytokines (Gires et al 1999, Briscoe et al 1996).
LMP1 has diverse and profound effects on infected cell growth, promoting
cellular activation and differentiation through numerous pathways whilst inhibiting
apoptosis (Izumi et al 1999).
1.3.7.7 LMP 2a and 2b
LMP2a and 2b are highly hydrophobic proteins of 54kDa and 40kDa
respectively. They are encoded by sequences situated at either end of the EBV
genome, in the BARF1/BNRF1 open reading frames and can only be transcribed
when the genome is circularised to form an episome (Laux et al 1988). The
transcripts are encoded across the fused TR of the EBV episome, initiated from
separate promoters. The LMP2b promoter is bidirectional, and also initiates
transcription of LMP 1 (Laux et al 1989, Sample et al 1989). The mRNAs encoding
each protein have a unique 5' exon and eight exons common to both transcripts. Both
proteins have twelve transmembrane domains which aggregate in the plasma
membrane (Longnecker & Keiff 1990) but LMP2a has an amino terminal
cytoplasmic domain whereas LMP2b does not. Neither LMP2a nor 2b are essential
for B-lymphocyte immortalisation although they are both expressed in viral latency
and in lytic replication (Longnecker et al 1992, 1993 a&b. Speck et al 1999). They
are believed to play a role in facilitating the immortalisation process (Brielmeier et al
1996).
LMP2a forms patches in the plasma membrane of B-lymphocytes and is
phosphorylated on the tyrosines and serines in its cytoplasmic domain by members of
the src family of mitogen activated protein kinases (MAPK) (Fruehling &
Longnecker 1997, Panoussis & Rowe 1997, Fruehling et al 1998). MAPK directly or
indirectly participate in growth factor receptor regulation through phosphorylation of
26
receptors and associated molecules (David et al 1995, Morrison et al 1996). When
stably expressed in the EBV negative BL cell line BJAB, LMP2a significantly
inhibits elevation of intracellular calcium ion levels which normally follows surface
immunoglobulin (slg) receptor or MHCII cross-linking (Burkhardt et al 1991, Miller
et al 1994). In epithelial cells, LMP2a phosphorylation is triggered by cell adhesion
in in vitro assays through csk, a negative regulator of src (Scholle et al 1999). An
ITAM motif on the amino-terminus is required for LMP2a function, thus LMP2a but
not 2b inhibits src activation (Miller et al 1993). Thus LMP2a prevents MAPK
activity, leading to inhibition of B-lymphocyte receptor mediated signal transduction
(Freuhling & Longnecker 1997). Following surface Ig (slg) cross-linking of LCLs in
vitro, LMP2a blocks induction of BZLF1 expression leading to suppression of viral
replication (Miller et al 1994, 1995) inhibiting EBV reactivation from latency to lytic
replication. LMP2a probably has a similar role in vivo (Babcock et al 1998).
In transgenic mice constitutively expressing LMP2a, B-lymphocytes
expressing LMP2a survive despite the absence of normal B-lymphocyte receptor
signals. This indicates that LMP2a may enable cellular longevity by minimising
normal B-lymphocyte receptor signalling (Caldwell et al 1998). LMP2b may have a
role in regulating the activity of LMP2a by modulating the spacing between
individual LMP2a molecules in aggregates in the plasma membrane (Longnecker &
Miller 1996).
1.3.8 EBV Lytic Replication
EBV lytic replication results in release of progeny virus and host cell death.
The majority of cells in an LCL contain non-replicating episomal EBV DNA and
only 0.1-5% of cells undergo spontaneous switching to lytic replication with release
of infectious virus (Henle & Henle 1966, Zur Hausen et al 1978). Lytic replication
can be further induced by slg crosslinking, phorbol ester or sodium butyrate
treatment, processes which induce B-lymphocyte maturation and plasma-cell marker
expression (Crawford & Ando 1986).
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Switching of the latent to lytic cycle is initiated by the EBV immediate early
gene products encoded by the open reading frames BZLF1 and BRLF1 (Countryman
& Miller 1985, Rooney et al 1989, Takada and Ono 1989, Cox et al 1990).
Following initiation of the lytic cycle, three sets of gene products are expressed in
sequential order, referred to as the immediate early, early antigen complex (EA) (Cho
et al 1985 a & b), and the late genes encoding the viral capsid antigen (VCA)
complex (Vroman et al 1985) and membrane antigen (MA) complex (Beisel et al
1985).
1.3.8.1 Immediate early gene products: BZLF1 and BRLF1
The immediate early genes are expressed early after induction of lytic
replication, independently of new protein synthesis, and are required for
transactivation of lytic replication (Cox et al 1990). Induction of lytic replication by
phorbol esters or slg cross-linking mimics terminal differentiation signals and/ or
cause cell cycle arrest (Kieff 1996). The two principal immediate early proteins are
encoded by a lkb mRNA from BZLF1, encoding the protein ZEBRA (also called Z
or Zta) and 2.8kb BRLF1 mRNA encoding Rta (Takada & Ono 1989). These genes
co-ordinately transactivate early lytic gene expression from two key early promoter
regulatory elements within the tandem direct repeat regions DL and DR (duplication
L and R). DL and DR encode abundant early mRNAs (Freese et al 1983, Dambaugh
et al 1982, Nuebling & Mueller-Lantzch 1989) and include the origins of lytic viral
DNA replication (OriLyt) within the promoter upstream regulatory domain
(Hammerschmidt & Sugden 1988). Promoters within DL include those for BHLF1
and BHRF1 (Cox et al 1990).
ZEBRA is encoded by a spliced mRNA including three exons (Lieberman &
Berk 1990). The protein has homology to c-fos and contains a transactivating domain
(Chi & Carey 1993, Flemington et al 1992, Lieberman & Burk 1991) and a strongly
basic leucine zipper domain which mediates dimerization (Farrell et al 1989). The
protein functionally and physically interacts with NFkB (Gutsch et al 1994) and can
downregulate Cp, the latency III promoter, facilitating transition from latency to lytic
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replication (Kenney et al 1989, Sinclair et al 1992). BZLF1 autoregulates its own
promoter, Zp, and that of BRLF1 through several AP-l-like binding sites. This
mediates promoter activation in the presence of low levels of ZEBRA and repression
with high levels of ZEBRA (Taylor et al 1991). ZEBRA also binds CREB binding
protein (CBP), a histone acetylase and transcriptional coactivator (Bannister &
Kouzarides 1996), which leads to dissociation of histones in chromatin and enhances
ZEBRA mediated transcription of early promoters (Adamson & Kenney 1999).
ZEBRA also exhibits inhibitory effects on Rta's capacity to activate the late gene
BLRF2 (Ragoczy & Miller 1999). BZLF1 also induces expression of cyclin
dependent kinase inhibitors p21 and p27 and associates with p53, inhibiting p53
induced transcription (Zhang et al 1994). Thus ZEBRA promotes growth arrest, but
inhibits apoptosis in response to lytic EBV DNA replication (Rodriguez et al 1999)
and triggers progression through the lytic cycle in both B-lymphocytes and epithelial
cells (Cayrol & Flemington 1996a & b, Countryman et al 1987, Grogan et al 1987).
Rta is a sequence-specific DNA transactivator with distant homology to c-myb
(Manet et al 1991, Gruffat & Sergeant 1994). It interacts directly with Rb (Cannel et
al 1996) and activates transcription of several genes including EBV DNA
polymerase and c-myc and disrupts latency in epithelial cells and certain B-
lymphocyte cell lines (Flemington et al 1994, Gutsch et al 1994, Ragoczy et al 1998,
Ragoczy & Miller 1999).
1.3.8.2 Early genes
In EBV the early lytic gene complex includes at least 30 proteins encoded by
genes intermingled throughout the EBV genome. Most early genes products have
enzymatic functions required for viral DNA replication. The early gene products
were first characterised from the nuclear and cytoplasmic staining pattern observed
using anti-EBV sera against the cell line Raji, which does not express late genes
(Henle, Henle & Klein 1971). These early lytic proteins are termed the early antigen
complex (EA).
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BALF2 is a 135kDa DNA binding protein important in EBV DNA replication
(Hummel & Kieff 1982, Fixman et al 1992). Also BHRF1, an 18kDa hydrophobic
membrane spanning signal peptide with an N-terminal hydrophilic domain and a
short C-terminal domain (Pearson et al 1987). BHRF1 has homology to bcl-2, is
abundantly expressed and may have a role in preventing apoptosis during EBV lytic
replication (Henderson et al 1993).
Other early genes encode a 117kDa DNA polymerase (BALF5), which
associates with several other EBV nuclear proteins (Chiou et al 1985, Kiehl et al
1991). The EBV DNA polymerase is essential for replication of the EBV episome
following induction of lytic replication, which leads to increased numbers of EBV
episomes in the infected cells and production of concatomeric linear EBV DNA
(Hammerschmidt & Sugden 1988, Pfuder & Hammerschmidt 1996).
EBV also encodes a major DNA binding protein (BALF2), ribonucleotide
reductase (BORF2 and BaRFl), Thymidine kinase (BXLF1) and alkaline
exonuclease (BGLF1).
1.3.8.3 Late Gene expression
Late gene induction leads to expression of EBV proteins required for
structural components of the virion and cleavage of progeny viral genomes,
packaging and envelopment of virions and egress of infectious virus particles.
The major nucleocapsid protein pi60 is encoded by the BALF4 ORF
(Hummel & Kieff 1982). Also amongst the late genes are numerous glycoproteins
(gp) including gp350/ 220, encoded by the BLLF1 ORF, which is the most abundant
viral protein in the plasma membrane of the lytically infected cell and the viral
envelope. Only small amounts are detected in the nuclear membrane, indicating that
the virus particle acquires its envelope at the plasma membrane. Other glycoproteins
include gpllO (BALF4), one of the most abundant late proteins, and gp85 (BXLF2)
(Torrisi et al 1989, Gong & Kieff 1990).
BCRF1 encodes a homologue of human IL10 which is 90% similar in amino
acid sequence (Hsu et al 1990. Vieira et al 1991). This may antagonise the effect of
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gamma-interferon following cytotoxic inhibition of lytic replication by natural killer
cells or cytotoxic T-lymphocytes (Garner et al 1984, Koizumi et al 1992.
Swaminathan et al 1993).
1.3.9 In vitro EBV infection
EBV is capable of infecting three cell types in vitro; resting B-lymphocytes
(Pattengale et al 1973), thymocytes (Watry et al 1991) and squamous epithelial cells
(Sixbey et al 1983).
1.3.9.1 In vitro infection of B-lymphocytes
EBV infects resting B-lymphocytes in vitro through attachment of the
envelope glycoprotein gp350/220 to the cell surface complement receptor CD21 (or
CR2R), expressed on all mature B-lymphocytes (Fingeroth et al 1984). Penetration
of the cellular membrane and release of the capsid to the cytoplasm involves
interaction of additional viral glycoproteins including gp25, gp42 and gp85 with
cellular receptors (Li et al 1997). The viral genome is transported to the cell nucleus
by cytoskeletal transport (Dales and Chardonnet 1973, Keiff 1996). Despite 5% of
internalised linear genomes reaching the nucleus (Ehirley & Thorley-Lawson 1988),
only one copy of the EBV genome is circularised to form an episome and
subsequently undergoes amplification to 10-500 clonal copies per cell while the
linear genomes are lost (Sugden et al 1979).
Immediately following infection, EBV gene transcription is initiated from the
Wp promoter, leading to expression of EBNA2 and EBNA- LP, which are detectable
by twelve hours post infection (Alfieri et al 1991). EBNA2 mediates switching of
promoter usage to the Cp promoter, leading to expression of the other EBNA
proteins (Woisetschlager et al 1989, 1990). EBNA2 also transactivates the cellular
genes (CD21, CD23 and c-fgr) and the EBV latent membrane proteins (LMP1, 2a
and 2b). EBNA and LMP proteins are detectable by thirty-two hours after infection,
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and EBERs transcripts are detectable by seventy hours post-infection (Alfieri et al
1991).
Infection of B-cells results in establishment of immortalised LCLs which are
continually cycling and capable of proliferating indefinitely (Pope et al 1968, Steel et
al 1977, Tosato et al 1985). LCLs phenotypically resemble activated B-lymphocytes,
which have been antigenically stimulated and secrete immunoglobulin. LCLs form
tumours in T- and B-lymphocyte deficient severe combined immunodeficient (SCID)
mice (Rowe et al 1991, Bosma et al 1983, Mosier 1996). LCLs express cellular
activation markers including CD23, CD25 (IL2 receptor), CD30, CD39, CD40,
CD70, CD71 (transferrin receptor) and MHCII. The activated blastogenic phenotype
is in part induced by LMP1 which mimics constitutively active CD40 leading to
upregulation of the cellular adhesion molecules (CAMs) and bcl-2 (Thorley-Lawson
& Mann 1985, Gregory et al 1988).
1.3.9.2 Infection of T-cells in vitro and in vivo
EBV is associated with a number of T-cell tumours (Jones et al 1988,
Harabuchi et al 1990). Thymocytes, peripheral T-cells and T-cell lines express the
EBV receptor CD21 (Tsoukas & Lambris 1988, Fingeroth et al 1988, Sauvageau et
al 1990, Fischer et al 1991, Delibrias et al 1994) and in vitro, EBV can infect
thymocytes (Watry et al 1991) and T cell lines (Eledrick et al 1992, Sinha et al
1993). In vitro infection of thymocytes leads cellular proliferation and an activated
phenotype but the cells are not immortalised (Paterson et al 1995). In T-cell lines and
T-cell malignancies, EBV expresses a latency II pattern of viral gene expression
(Chen et al 1993, Minarovits et al 1994, Yoshiyama et al 1995, Imai et al 1996.),
that is expression of EBNA1 in the absence of the other EBNAs, and variable
expression of LMPsl, 2a and 2b (Kerr et al 1992).
1.3.9.3 EBV infection of epithelial cells in vitro
Squamous epithelial cell express a homologue of the CD21 EBV receptor
(Young et al 1989, Birkenbach et al 1992). Infection of epithelial cells in vitro results
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in detection of EBV DNA in differentiated layers and desquamated cells, and
expression ofEA, VCA or EBNAs (Sixbey et al 1983).
1.3.10 In Vivo EBV infection
Establishment of a persistent infection is key to the life cycle ofEBV in vivo.
Over 90% of the adult population worldwide is infected with EBV (Henle & Henle
1979). Neonates are protected from EBV infection in the first six months by maternal
IgG antibodies (Biggar et al 1978) and primary infection generally occurs in
childhood, with seroprevalence increasing with age. Initial infection of B-
lymphocytes in pharyngeal lymphoid tissues follows transmission of the virus
through salivary exchange. In non-industrialised societies, EBV infection generally
occurs by three years of age (Henle and Henle 1969, Lang et al 1977). Greater
concern with hygiene in the industrialised world is responsible for delay in primary
infection, which may not occur until adolescence (Henle & Henle 1979).
Seroepidemiological studies have demonstrated that there are two peaks in primary
infection in the United Kingdom, one occurring between the ages of one and six
years, and the second at fourteen to twenty years (Crawford & Edwards 1990).
Primary infection is usually asymptomatic, although a self-limiting
lymphoproliferative disease, Infectious Mononucleosis (IM), occurs in around 50%
of individuals who become infected with EBV in adolescence (Niederman et al 1970,
Sawyer et al 1971). Since infection with EBV is usually asymptomatic, studies on
primary infection and the development of immune responses to the virus have
generally been carried out on individuals with IM.
1.3.10.1 Infectious Mononucleosis (IM)
IM is commonly known as 'kissing disease', since it is occurs in adolescents
following transmission by salivary exchange. Hoagland (1955) suggested a salivary
route of transmission for the agent causing IM, but evidence that EBV was the
causative agent was gained by chance when a laboratory technician became EBV
seropositive in the course of the disease (Henle and Henle 1969). Subsequent studies
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of a group of young adults (Niederman et al 1970) demonstrated that in subjects who
developed IM, antibodies against EBV were consistently absent prior to disease, but
appeared during IM and persisted. IM is usually a self-limiting disease which
resolves after a few weeks. In some cases however, IM may be chronic or even fatal.
EBV is detectable in the saliva of individuals with IM and normal healthy EBV
seropositives (Gerber et al 1972) and it has also been detected in genito-urinary tract
secretions from males and females, indicating the possibility of a sexual route of
transmission (Sixbey et al 1986, Israele et al 1991). The cellular site of EBV
replication producing infectious virus is discussed in the next section.
Following virus transmission, EBV infects B-lymphocytes, demonstrated by
the ability of B-lymphocytes, obtained during the incubation period or during overt
IM, to spontaneously outgrow in vitro to produce LCLs and by detection of EBV
DNA by PCR in B-lymphocytes (Pope et al 1967, Diehl et al 1968, Svedmyr et al
1984, Neidobitek et al 1997). During acute IM, around 2000/104 circulating B-cells
in peripheral blood are infected with EBV (Laroche et al 1995) and the latency III
pattern of gene expression is detected in infected cells (Tierney et al 1994,
Niedobitek et al 1997a). There is also evidence that lytic replication occurs during
acute IM; BZLF1 and BCLF1 transcripts have been detected indicating switching to
lytic replication (Tierney et al 1994, Prang et al 1997, Niedobitek et al 1997a).
Immediate early transcripts and capsid-antigen-encoding transcripts were detected in
enriched B-cell populations from 50% and 25% of samples respectively with the
corresponding proteins detected in 0.01 to 1.09% of peripheral B-cells (Prang et al
1997). EBV DNA has also been detected in the serum of patients with early acute
IM, possibly indicating transient viremia (Gan et al 1994, Laroche et al 1995).
Clinical signs and symptoms of IM include fever, pharyngitis, generalised
lymphadenopathy, myalgia, fatigue and in some cases splenomegaly and mild
hepatomegaly (Epstein & Crawford 1998). The disease is characterised by
lymphocytosis consisting of'atypical' lymphocytes which are largely antigen-driven
oligoclonal CD8+ve T-lymphocytes directed against EBV latent and lytic antigens
(Misko et al 1980, Callan et al 1996). These T cells secrete multiple lymphokines,
which are the probable cause of the symptoms of IM (Foss et al 1994).
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During acute IM, serum IgM and IgG antibodies to VCA and IgG anti-EA
antibodies appear early, whereas anti-EBNAl antibodies do not appear until
convalescence (Elenle W & Henle 1979). On recovery IgM anti-VCA and IgG anti
EA disappear but IgG antibodies to VCA and EBNA1 are maintained for life (Henle
G& Henle 1979).
It is not known why primary infection in childhood is generally asymptomatic
whereas 50% of adult infections result in IM. This may be due to the dose of virus
transmitted, since it is assumed that higher doses of virus are transmitted by salivary
exchange between adults by kissing than from transmission to children by aerosol
droplets or sucking contaminated objects. It is possible that the EBV-driven B-cell
proliferation following a large initial dose may exceed a threshold beyond which the
florid T-cell response is activated, resulting in immunopathological effects, and
disease. There have also been reports of post-perfusion IM, resulting from
transfusion of seropositive donor blood into a seronegative recipient (Gerber et al
1969, Blacklow et al 1971).
1.3.10.2 Persistent EBV Infection
Like all other human herpesviruses, EBV is able to establish a life-long
infection in immunocompetent hosts. Healthy EBV seropositive individuals,
regardless of whether their infection resulted from subclinical infection or IM,
harbour low numbers of EBV infected B-cells in the circulation, detectable by PCR
or their ability to produce LCLs in vitro. EBV seropositives also continue to shed
infectious virus into the buccal fluid throughout life, detectable by PCR or co-culture
of throat-washings with susceptible EBV-negative cord-blood lymphocytes (Yao,
Rickinson and Epstein 1985). EBV is detectable in the peripheral blood or throat
washings of 94% ofEBV seropositive individuals (Faulkner et al 1999).
The primary site of persistent infection with EBV is still unclear. Two models
have been proposed: persistence in squamous epithelium or in B-lymphocytes,
although the balance of evidence supports B-lymphocytes as the reservoir of latent
infection.
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1.3.10.3 Epithelial cells as the site of latent virus
The hypothesis that epithelial cells act as the source of infectious virus
postulates that basal stem cells of squamous epithelium in the oropharynx become
latently infected with EBV during primary infection. These cells are self-renewing,
and during differentiation, the cells stratify and keratinise, during which EBV
undergoes lytic replication and release from the upper layers. This model provides
for release of infectious virus into the oropharynx and suggests that B-lymphocytes
passing through the epithelium become infected and return to the peripheral
circulation and lymphoid tissue (Moss et al 1981, Sixby et al 1983, Allday &
Crawford 1988).
Epithelial cells are infected in vivo with EBV in two situations:
nasopharyngeal carcinoma (NPC) and oral hairy leukoplakia (OHL). In NPC, EBV
DNA is invariably found in malignant cells, and displays a restricted pattern of viral
latency. In OHL replicating EBV is detected in differentiated squamous cells layers
at the superficial layers of the lesions, but not in the basal layers (Niedobitek et al
1991). EBV infected epithelial cells have not been detected in the tonsil of patients
with IM or normal individuals, although EBV infected intra-epithelial B-
lymphocytes are detected. (Niedobitek et al 1992, 1997b, 2000, Anagnostoupoulos et
al 1995, Tao et al 1995, Karajannis et al 1997).
1.3.10.4 B-lymphocytes as the site of latent virus
EBV-positive B-cells are dispersed throughout the body, and are detectable in
the peripheral blood and within all lymphoid tissues (Nilsson et al 1971, Yao et al
1985). In the peripheral blood, EBV is found exclusively in resting memory B-cells
(Babcock et al 1998).
This model places B-cells as the site of persistent infection with EBV, and as
source of infectious virus. It postulates that the complete life cycle of EBV is
completed within B-lymphocytes. It is proposed that transient latency III EBV gene
expression induces infected lymphoblast multiplication, providing a circulating pool
of latently infected B-cells. B-cells in the oropharyngeal epithelium also undergo
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lytic replication, producing infectious virus which is released into the saliva,
providing a route of virus transmission. Virus particles may also infect other naive B-
cells in the submucosal epithelium. A combination of B-cell proliferation and lytic
replication could therefore maintain the pool of latently infected B-cells in an
individual.
The first direct evidence for B-cells as the site of EBV latency came from the
finding that following cytotoxic treatment to destroy haematopoietic tissue prior to
bone marrow transplantation in EBV positive individuals, the resident EBV infection
is eradicated (Gratama et al 1988). If EBV replication is blocked by sustained
acyclovir therapy, there is no reduction in the number of latently infected B-cells in
the peripheral blood despite a reduction in the levels of oropharyngeal excretion of
EBV (Yao et al 1989). This suggests that lytic replication is not essential for
maintaining EBV infection. EBER positive lymphocytes, but not epithelial cells,
have been detected in the nasopharyngeal epithelium and stroma of EBV positive
carriers, and in the tonsillar epithelium of patients with IM (Anagnostopoulos et al
1995, Tao et al 1995). Evidence that B-cells in the epithelium undergo lytic infection
has been shown through detection of BZLF1 protein in lymphocytes in the
nasopharyngeal epithelium of patients with nasopharyngitis (Senba et al 1994).
Further insight into the site of EBV latency came from study by Faulkner et
al (1999) of patients with X-linked agammaglobulinaemia (XLA), a disorder caused
by a mutation in Bruton's tyrosine kinase gene which prevents development of pre-
B-lymphocytes into mature functioning B-lymphocytes (Reviewed in Smith et al
1998). XLA patients have no antibodies and are therefore particularly susceptible to
bacterial infections, but have functional CTL responses against viruses. The 6
patients studied were not infected with EBV, despite infection with the T-
lymphotropic herpesvirus HHV-6, indicating that B-lymphocytes are required for
infection with EBV.
The precise pattern of EBV gene expression in latently infected cells in
healthy EBV seropositives is not clear since the transcripts detected vary between
reports, probably due to differences in the sensitivity of the RT-PCR reactions used.
Also, RT-PCR of cell populations does not show the pattern of gene expression
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within individual cells, rather it shows the combined expression. It is evident that
infected cells express a restricted pattern of EBV latent gene expression which does
not include the growth-promoting latent genes (Qu & Rowe 1992). The reservoir of
EBV infection has been proposed as resting cells in GO with expression of LMP2a
transcripts and variable expression of EBNA1 (Miyashita et al 1997). Other reports
support the expression of LMP2a and EBNA1 transcripts in normal EBV positives
(Qu & Rowe 1992, Tierney et al 1994, Chen et al 1995) or expression of EBNA1
and LMP1 (Gonella et al 1997). Cp and Wp promoter activity is not detected,
indicating that the other EBNAs are not expressed. However, in one study,
immediate early (BZLF1) and early (BALF2) transcripts were detected in the
absence of late BCLF1 transcripts in purified B-cells indicating induction, but not
completion, of lytic replication (Prang et al 1997).
These studies propose that in primary infection with EBV, the virus infects
and activates B-lymphocytes in the oropharyngeal epithelium which become
proliferating blasts with full latent viral gene expression and undergo an initial
polyclonal expansion to become memory B-cells (Babcock et al 1998). The restricted
pattern of EBV gene expression in these memory B-lymphocytes allows infected
cells to persist in the face of immune responses against latent and lytic antigens.
EBNA1 is required for maintaining the EBV genome, and its variable expression
may indicate that it is only expressed transiently in dividing cells. Thus an LMP2a-
only latency program is proposed as the pattern of gene expression in the true site of
EBV persistence (Babcock et al 1998). The role of LMP2a in EBV latency is
suggested to prevent reactivation of latently infected cells by preventing switching
from latent to lytic cycle (Miller et al 1994). It is proposed that in lymphoid tissue
latently infected cells undergo antigen mediated activation leading to EBV
replication or expression of the latency III pattern of unrestricted latent gene
expression, and proliferation of EBV infected blasts, which subsequently undergo
promoter switching and return to the LMP2a only pattern of gene expression, thus
maintaining the pool of latently infected cells.
38
1.3.11 Host Immune Responses
Despite the potent cell growth transforming potential of EBV, in
immunocompetent individuals the virus persists and is maintained as an
asymptomatic infection. A balance between virus and host is controlled by immune
responses against EBV.
Humoral and cellular immune responses against EBV arise during primary
infection, are maintained for life and control life-long infection with EBV. The
development of immune responses in primary infection has been studied during IM.
Early in IM, antibodies develop against the EA and VCA complexes of proteins.
Antibodies against MA also develop, and those against gp350/ 220 are neutralizing
(Thorley-Lawson & Geilinger 1980). By the onset of clinical symptoms of IM, high
levels of anti-VCA IgM and IgG as well as IgG against EA and MA can be detected.
IgA against VCA and EA may also be transiently expressed during this period (Henle
& Henle 1979b). IgG antibodies to EBNA1, and less consistently EBNAs 2, 3a, b, c
and LP, develop late in IM and levels are often still rising during recovery (Henle et
al 1987). In addition to the EBV specific antibody response, serum heterophile
antibodies can be detected in around 85% of cases of acute IM (Epstein & Crawford
1998). These form the basis of the diagnostic Paul-Bunnel and Monospot tests.
In convalescence from IM and in healthy EBV carriers, stable levels of IgG
antibodies are detected against VCA, MA and EBNA1 (Henle & Henle 1979b, Henle
et al 1987). Neutralizing antibodies against gp350/ 220 may contribute to preventing
superinfection with EBV isolates other than the resident virus (Thorley-Lawson and
Poodry 1982). 21-30% of virus carriers have IgA antibodies against gp350 in serum,
and in 12-19% of carriers these antibodies can be detected in saliva, which may
prevent superinfection at mucosal surfaces (Yao et al 1991).
The cell mediated immune response is particularly important in controlling
EBV infection. A characteristic feature of IM is the presence of high numbers of
'atypical' lymphocytes, predominantly CD8 +ve activated T-cells (Callan et al 1996
& 1998). These transiently expanded monoclonal or oligoclonal populations, as
determined using monoclonal antibodies or PCR to detect TCR V(3 transcripts
(Callan et al 1996), recognise EBV antigens and control initial EBV driven B-cell
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proliferation. CD4+ve T-cells also contribute to a lesser extent to lymphocytosis in
IM (Callan et al 1996).
Following primary infection long term memory T-cell responses against EBV
latent antigens provide immune surveillance to control persistent infection. CTL
responses in healthy carriers are detected by in vitro assays against all EBNA
proteins with the exception of EBNA1 (Murray et al 1988 & 1992, Khanna et al
1992, Bogedain et al 1995, Levitskaya et al 1995, Steven et al 1997), which is in
agreement with the ability of EBNA1 to inhibit MHCI presentation in vitro. In a
study of fifteen normal donors, all had CTL responses against at least two latent
antigens, with particular prevalence ofCTL responses against EBNA3c (Murray et al
1990), with less frequent reactivity against EBNA2, EBNA-LP LMP1 and LMP2.
Reactivities to particular immunodominant peptide epitopes have been mapped to
specific HLA epitopes (Rickinson and Moss 1997).
CTL responses may also be involved in control of the EBV lytic cycle. MHCI
restricted CTLs have been detected against the immediate early (BZLF1 and BRLF1)
and early (BMLF1, BMRF1 and BALF2) antigens (Steven et al 1997). MHCII
restricted CD4+ve CTL responses may also have a role in controlling latent and lytic
EBV infection since CD4+ve proliferative responses have been detected in normal
EBV carriers against EA and gp350/ 220 (Ulaeto et al 1988, Pothen et al 1991), and
against EBNA2 (Khanna et al 1997).
1.3.12 EBV Associated Diseases
EBV is associated with a number of human malignancies in the context of
persistent infection. These are discussed separately and summarised in Table 1-3.
1.3.12.1 Burkitt's Lymphoma
Burkitt's lymphoma (BL) was the human tumour from which a virus was first
isolated (Epstein et al 1964a & b), and is the most common childhood malignancy in
equatorial Africa. There are two distinct forms of BL, endemic (eBL), which occurs
in equatorial Africa and sporadic (sBL), which occurs worldwide at 20 to 100 fold
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lower frequency than eBL (O'Conor et al 1965). EBV is detected in around 95% of
eBL tumours whilst the virus is found in only 1-25% of sBL occurring in Europe and
North America (Lenoir et al 1986, Magrath 1990) and in less than 50% of AIDS BL
tumours (Subar et al 1988, Ballerini et al 1993). Tumour cells in 97% of cases of
EBV positive eBL harbour multiple clonal episomes of EBV, indicating that virus
infection occurs before expansion of the tumour cell population (zur Hausen &
Schulte-Holthausen 1970, Rowe & Gregory 1989, Neri et al 1991). EBV therefore
appears to play an important role in BL.
Table 1-3. EBV-associated diseases
Condition References
African (endemic) Burkitt's lymphoma Epstein et al 1964a & b
Zur Hausen et al 1970
Neri et al 1991
Sporadic Burkitt's lymphomas (a subset) O'Connor etal 1965
Lenoir 1986
Magrath 1990
Gutierrez et al 1992
Undifferentiated nasopharyngeal carcinoma Old et al 1966
Nonoyama et al 1973
Wolf et al 1973
Non-Hodgkin's lymphoma in immunosuppressed
patients
Crawford et al 1980
Peterson et al 1985
Purtilo et al 1985
Hodgkin's disease (subset) Weiss et al 1989
Oral Hairy leukoplakia Greenspan et al 1985
T/NK cells lymphoma (subset) Jones et al 1988
Harabuchi et al 1990
Other tumours with suspected EBV-association:
anaplastic gastric carcinoma, salivary gland
neoplasia, smooth muscle tumours, breast
tumours
Imai et al 1994
Raab-Traub et al 1991
Lee et al 1995
McClain et al 1995
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BL usually presents in children who are not apparently immunosuppressed
and even cases of AIDS associated BL tend to occur early rather than as a late
manifestation of AIDS. BL tumours develop extranodaly, commonly in multiple
sites, including the jaw, gastrointestinal tract, kidneys, adrenal glands, gonads and
bone marrow (Burkitt 1958, Burkitt & O'Connor 1961). BL tumour cells show a
germinal centre cell phenotype, and express the common lymphocytic leukaemia
antigen CD10 and the BL-associated antigen CD77 (Gregory et al 1988, 1990), and
cell surface IgM (Pelicci et al 1986). BL tumour cells lack lymphocyte activation
antigens and cellular adhesion molecules which are characteristic of LCL-like cells.
BL tumour cells show a latency I phenotype, in which EBNA1, Bam HIA and
EBERs are expressed, although upon explantation in vitro, BL tumour cells grow
into cell lines which often drift towards a latency III phenotype (Rowe et al 1987,
Sample et al 1991).
BL cells, and cell lines derived from them, consistently display one of three
characteristic reciprocal chromosomal translocations: t(8; 14), t(8;2), t(8;22), which
place the c-myc oncogene under transcriptional control of an immunoglobulin gene
locus (Leder et al 1983, Klein & Klein 1985). This leads to deregulation and
constitutive expression of c-myc (Lenoir et al 1986). The characteristic chromosomal
breakpoints in the IgH locus on chromosome 14 occur within the JH region in eBL or
in the switch (S) region in sBL, suggesting that eBL arises during heavy chain
switching in an immature B-cell, and sBL arises in a mature B lymphocyte during Ig
class switching.
The observation that eBL geographical distribution coincides with that of
holoendemic malaria in Africa and Papua New Guinea suggests that malaria may be
a co-factor for eBL pathogenesis. It has been postulated that malaria induces a high
level of B-cell turnover, increasing the chance of chromosomal translocation during
immunoglobulin gene rearrangement, and EBV infection subsequently confers the
final malignant change (Lenoir & Bornkamm 1987). In addition malaria reduces T-
cell responses resulting in altered CD4/ CD8 ratios (Whittle et al 1984). Increased
numbers of EBV infected B-lymphocytes are detected in individuals with malaria
(Lam et al 1991) and EBV may drive an initial B-cell proliferation as a result of
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malaria induced immunosuppression which increases the chance of chromosomal
translocation, and emergence of a malignant clone (Klein 1987).
1.3.12.2 Nasopharyngeal carcinoma
Nasopharyngeal carcinoma (NPC) is another EBV associated malignancy
which shows a distinct geographical distribution. It is a squamous epithelial tumour
which occurs at a rate of less than 1 in 105 of the population in Europe and the USA,
whereas the incidence in South China and South East Asia is 100-fold higher. An
intermediate incidence is seen in Inuits of North America and Greenland and in
certain North African populations (Shanmugaratnam 1971, 1978). The differences in
incidence rate worldwide probably reflect genetic predisposition in different racial
groups (Simons et al 1974, Chan et al 1983) and the influence of local environmental
or dietary factors. Substances that have been identified as potential co-factors in NPC
development include carcinogenic nitrosamines in traditional salted fish (Huang, Ho
& Gough 1978, Shao et al 1988) and phorbol esters in traditional Chinese medicines
taken as snuff (Hirayama & Ito 1981) and domestic wood smoke (Zheng et al 1994).
NPC tumours are undifferentiated in type in around 70% of cases, the
remainder showing squamous differentiation. Tumour cells in undifferentiated NPC
are consistently EBV positive, regardless of the population in which they occur
(Klein 1979, Niedobitek et al 1991, Raab-Traub 1992), and tumours
characteristically show a latency II pattern of EBV gene expression (ie EBNA1, and
variable levels of LMP1 and LMP2a or b) (Young et al 1989, Brooks et al 1992).
NPC tumours show a characteristic histological appearance, with considerable
infiltration of the tumour mass with non-malignant CD4+ve T-lymphocytes. This
appears not to be a specific immune response, rather a response to lymphokine
release by the tumour cells (Busson et al 1987). Characteristic serum antibody
profiles are detected in patients with NPC which is effective in diagnosis and
screening of susceptible populations (Zeng et al 1982). Serum IgG and IgA
antibodies against VCA and EA-D are raised and IgA against these antibodies is
detected in saliva (Klein 1979) Detection of anti-VCA IgA suggests that lytic
replication at a mucosal site precedes NPC development. However, full lytic
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replication has not been demonstrated in NPC, despite detection of the lytic
transactivator BZLF1 in a few tumour cells (Cochet et al 1993).
The pathogenesis of NPC raises questions about infection by EBV of
epithelial cells. It has been proposed that the anti-EBV IgA responses may facilitate
entry of EBV to epithelial cells by transport of IgA complexes across epithelial
membranes (Sixbey & Yao 1992).
1.3.12.3 Hodgkin's Disease (HD)
HD is the most common malignant lymphoma in the Western world with two
peaks of incidence occurring at 15-35 years and over 50 years of age. The socio¬
economic epidemiology ofHD mirrors that of IM, and there is a 4- to 6-fold increase
in the incidence of HD within 5 years of IM (Munoz et al 1978, Bernard et al 1987,
Mueller et al 1989). EBV DNA is present in tumour cells in around 60% of cases of
HD, localised to the malignant Reed-Sternberg (RS) cells and Hodgkin's cells which
are characteristic of HD, and are proposed to be of immature B-lymphoid origin
(Anagnostopoulos et al 1989, Weiss et al 1989, Herbst & Niedobitek 1994).
Southern blot analysis of the EBV terminal repeat region has demonstrated
monoclonality of EBV episomes in HD (Anagnostopoulos et al 1989, Gulley 1994)
EBV in HD shows a Latency II pattern ofEBV gene expression (EBNA1, LMP1 and
LMP2a and b) (Herbst et al 1991, Pallessen et al 1991, Deacon et al 1993, Grasser et
al 1994, Niedobitek et al 1997). There is some evidence for a role of genetic changes
in HD, including mutation of p53 (Gupta et al 1993, Niedobitek et al 1993) and Rb
(Morente et al 1997).
HD tumours are divided into four groups according to the Rye classification:
lymphocyte predominant, lymphocyte depleted, nodular sclerosing and mixed
cellularity (Rappaport et al 1971). Over 80% of the more aggressive mixed
cellularity and lymphocyte depleted forms and around 30% of nodular sclerosing HD
are EBV positive, and less than 10% of lymphocyte predominant HD are EBV
positive (Herbst et al 1990, 1992).
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1.3.12.4 T-cell lymphomas
Although T cells have been shown to express the EBV receptor CD21 (Fisher
et al 1991), EBV infection of T-cells is uncommon (Niedobitek et al 1992,
Anagnostopoulos 1995). However a number of EBV associated malignancies of T-
cell origin have been described, although the pathology of EBV associated T-cell
neoplasia is unclear. EBV is associated with 84% of nasal T-cell lymphomas
(midline granuloma) in adults (Harabuchi et al 1990), up to 97% of cases of
peripheral T-cell lymphomas of angioimmunoblastic lymphadenopathy type (Ott et
al 1992), and 46% of peripheral T-cell lymphomas (Jones et al 1988). In peripheral
T-cell lymphomas and midline granuloma, EBV shows a latency II phenotype, as
seen in NPC and HD (Minarovits et al 1994).
1.3.12.5 Oral Hairy Leukoplakia (OHL)
Oral hairy leukoplakia is a benign superficial epithelial lesion mainly of the
lateral boarders of the tongue which occurs in immunosuppressed individuals (mostly
HIV positive patients). Epithelial cells in the outer, more differentiated layers, but
not the basal layers contain EBV DNA and express EBNA1 (Thomas et al 1991).
The lesions mark a site of EBV replication (Greenspan et al 1985) although the viral
genome has not been detected in the basal layers of the lesion (Niedobitek et al
1991b, Thomas et al 1991). OHL responds to acyclovir treatment, and recurs when it
is withdrawn, demonstrating the role of lytic replication in the lesion (Resnick et al
1988).
1.3.12.6 AIDS related lymphoma
Up to five percent of AIDS patients develop lymphoma, 60% of which are
immunoblastic lymphomas (alL), 21% are Burkitts lymphoma (aBL), and 19%
primary AIDS related central nervous system (CNS) lymphomas (aCL) (Beral et al
1991, Herndier et al 1994). EBV is associated with virtually all aCLs and around
80% of alLs, whereas only around a third of aBL are EBV associated (Hamilton-
Dutoit et al 1993a & b). alL lesions show latency I, II or III phenotypes and a
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proportion of them show early lytic gene expression (Pallessen et al 1991b,
Hamilton-Dutoit et al 1993b).
1.3.12.7 X-linked lymphoproliferative syndrome (X-LPS)
X-LPS was first identified following a report of fatal acute IM or malignant
lymphoma in six male kindred of the same family (Purtillo et al 1974, 1975). The
syndrome is caused by a defective gene on the X-chromosome called SAP
(Signalling lymphocytic activation molecule (SLAM) associated protein), which is
an inhibitor of T-cell signal transduction following ligand binding, functioning to
modulate T-cell activation (Sylla et al 2000, Sayos et al 1998). It is thought that loss
of SAP function results in an uncontrolled CTL response following primary infection
with EBV and inability to control B-cell proliferation caused by EBV (Skare et al
1987). This results in fulminant and rapidly fatal acute IM or less commonly chronic
disease which often progresses to fatal B-cell lymphoma. Death occurs in all cases by
40 years of age, most commonly due to vital organ failure caused by tissue
destruction caused by the uncontrolled CTL response (Grierson & Purtillo 1987). X-
LPS is characterised histologically by solid organ lymphoproliferations of EBNA
positive B lymphoblastoid/plasmacytoid cells of polyclonal origin mixed with T, NK
cell and phagocytic cells (Purtillo et al 1981a & b, Mroczek et al 1987, Thomas et al
1991c).
1.3.12.8 Post Transplant Lymphoproliferative Disease (PTLD)
PTLD is a rare but frequently fatal complication of iatrogenic
immunosuppression. The term PTLD encompasses a spectrum of B-cell
lymphoproliferations ranging from reactive plasmacytic hyperplasia to monomorphic
B-cell lymphoma (Harris, Ferry and Swerdlow 1997). The tumours are almost always
associated with EBV, and the malignancies reflect an imbalance in the normal
control of EBV infection. The disease is characterised by rapid onset, aggressive
behaviour and high mortality, even with treatment.
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1.3.12.8.1 Incidence
Iatrogenic immunosuppression following organ transplantation predisposes
patients to a variety of cancers (Hanto et al 1981). The incidence of NHLs in
transplant recipients, termed PTLD, is 28 to 100-fold higher than that observed in
age-matched controls (Kinlen et al 1979, Penn 1993). The incidence of PTLD varies
with transplant type and in different transplant centres (Nalesnik 1998). Reported
incidence of PTLD in kidney transplant recipients is 0.4 - 2.5% (Birkeland 1983,
Starzl et al 1984), 2.3 - 13.7% in liver (Renard et al 1991, Cox et al 1995), 0.2 -
1.6% in bone marrow (Beveridge et al 1984, Shapiro et al 1988), 1.8 - 3.4% in heart
(Nalesnik et al 1988, Armitage et al 1991) and 4.6 - 9.4% in heart/ lung recipients
(Nalesnik et al 1988, Randhawa et al 1989).
1.3.12.8.2 Risk Factors
The development ofPTLD is thought to be the result of interplay of a number
of factors. These include genetic predisposition (Penn 1979), defective humoral and
cellular immunity caused by primary disease (Sheil 1986), chronic antigenic
stimulation by the allograft (Gleichmann et al 1975), impaired immunosurveilance
(Klein & Klein 1977), and long term immunosuppression (Calne et al 1979,
Nagington & Gray 1980). The principal risk factors for PTLD development are
duration and degree of iatrogenic immunosuppression given to prevent graft
rejection, and primary EBV infection following transplantation. Paediatric transplant
recipients are more frequently EBV seronegative, and in a retrospective serological
study, the majority of children developing PTLD had undergone primary EBV
infection in the six months prior to developing PTLD (Ho et al 1985, 1988, Penn
1991, Sokal et al 1993, Thomas et al 1995).
The introduction in 1979 of cyclosporin A (CsA) as the principal
immunosuppressive drug used to prevent graft rejection was accompanied by a large
increase in the incidence of PTLD (Penn 1988). The commonly used triple therapy
approach of combined CsA, azathioprine (AzA) and prednisolone has been
associated with an increase in NHL in kidney and heart transplant recipients
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(Wilkinson et al 1989). Increased incidence of PTLD has also been associated with
use of more potent and specific immunosuppressive drugs including antithymocyte
globulin (ATG) (Sokal et al 1997), FK506 (Nalesnik et al 1991, Shapiro et al 1999)
and the murine anti-CD3 monoclonal antibody OKT3 (Swinnen et al 1990). The risk
of PTLD is also increased in patients who undergo retransplantation, due to the
increased cumulative dose of immunosuppression (Weintraub & Warnke 1982,
Opelz & Henderson 1993).
In a multicentre study with a ten year follow-up of 45,141 kidney and 7,634
heart transplant recipients, both groups had a high incidence ofPTLD in the first year
post-transplant (0.2% of kidney and 1.2% of heart transplant recipients, which is 20
and 120 times higher than the incidence in the general population respectively)
(Opelz & Henderson 1993). This coincides with the period of the most aggressive
immunosuppressive therapy, and the incidence of PTLD reduced to 0.04% and 0.3%
per year in kidney and heart recipients respectively in subsequent years, reflecting the
reduced level of maintenance doses of immunosuppression. The highest rates of
PTLD incidence are in heart, lung and liver transplant recipients, who receive the
highest doses of immunosuppression required to prevent life-threatening graft
rejection.
1.3.12.8.3 Clinical Presentation
The diversity of clinical and histological presentation of PTLD makes
diagnosis difficult, and the course of the disease is frequently aggressive and fatal.
PTLD most commonly occurs in the first year following transplantation. This
"early onset" PTLD frequently presents as an IM-like illness with localised or
generalised lymphadenopathy (Nalesnik et al 1998). This presentation is most
commonly seen in patients who are EBV seronegative pre-transplant and 50% of
cases of PTLD develop in transplant recipients who had undergone primary infection
with EBV in the previous six months (Ho et al 1985, Thomas & Crawford 1990).
PTLD in EBV seropositive transplant recipients tends occur over one year post
transplant, and may develop after many years. These Tate onset' tumours tend to be
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extranodal, arising as localised tumours in single or multiple sites (Ho et al 1988).
Extranodal lesions occur in 69% of cases and 51% of lesions have been found in
multiple organs (Penn 1993). PTLD commonly develops in sites that are unusual in
the context of other lymphomas including the central nervous system, gastrointestinal
tract or grafted organ. Lesions develop in the CNS in 12% of cases of PTLD,
compared with 1-2% of lymphomas in the general population (Penn & Porat 1995).
Graft involvement is most common in lung transplant recipients, probably due to
presence of lymphoid tissue in the lung which is not present in other grafted solid
organs (Nalesnik 1998, Thomas & Crawford 1990, Penn and Porat 1995).
1.3.12.8.4 Classification
PTLD is usually of B-lymphocyte origin, although some T-cell lymphomas
have been reported (Penn 1994, Leblond et al 1998). PTLD lesions can be
polyclonal, oligoclonal or monoclonal, on the basis of cell surface and cytoplasmic Ig
expression or Ig gene rearrangements (Frizzera et al 1981, Hanto et al 1982, Cleary
& Sklar 1984, Knowles et al 1995). Individual lesions arising in the same patient can
show diverse clonality, containing poly-, oligo- or mono-clonal B-lymphocytes
(Shearer et al 1985). Assessment of tumour cell clonality is of limited use in
providing clear prognostic information in PTLD due to the unpredictable nature of
these lesions. However, polyclonal lesions tend to be more responsive to
conservative treatment such as reduction of immunosuppression (See Treatment
section 1.3.12.8.7) whereas monoclonal tumours are often more aggressive.
Progression of PTLD from polyclonal to more aggressive monoclonal lesions
regularly occurs in untreated cases or in recurrent lesions (Nalesnik 1998), and
probably involves additional cellular genetic changes, although this appears to be
inconsistent feature (Locker and Nalesnik 1989). There have been reports of changes
in the tumour suppressor gene p53 and oncogenes c-myc and N-ras (Knowles et al
1995, Chadburn et al 1997). An unusual EBV positive BL-like PTLD has been
reported in a heart transplant recipient, which carried the characteristic t8;14 c-myc
translocation (Hunt et al 1996).
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PTLD lesions have recently been classified into five groups on the basis of
tumour histology and presentation (Harris, Ferry and Swerdlow 1997). This
classification is summarised in Table 1-4.
Table 1-4 Histological classification of PTLD lesions (Harris, Ferry and
Swerdlow 1997)
PTLD Type Histological Classification
1 Early lesions including IM-like reactive plasma cell hyperplasias
2 Polymorphic PTLD which may be polyclonal or monoclonal
3 Monomorphic PTLD of diffuse large B-cell lymphoma
(immunoblastic, centroblastic or anaplastic) or Burkitf s type
4 T-cell lymphoma
5 Other, including Hodgkin's disease, plasmacytoma-like lesions and
myeloma
1.3.12.8.5 EBV Association
Involvement of EBV in PTLD was demonstrated by detection of EBV
antigens in tumour tissue sections (Crawford et al 1980) and detection of EBV DNA
in tumour cells (Weiss & Mohaved 1989). The detection of clonal EBV in
monoclonal PTLD suggests that EBV infection occurs at an early stage in PTLD
development before expansion of the tumorigenic clone (Patton et al 1990).
PTLD is EBV associated in the majority of tumours ofB-cell origin, and one-
third of T-cell cases (Young et al 1989, Thomas et al 1990, Dockrell et al 1998).
However in one report eleven of thirty-four cases (32%) of post-solid organ
transplant NHL were EBV negative (Leblond et al 1998). These cases were late
onset, many occurring over five years post-transplant.
In solid organ transplant recipients who are EBV negative pre-transplant, the
donor organ can act as the source of infectious virus (Cen et al 1991, van Gelder et al
1994, Haque et al 1996). In bone marrow transplant recipients, bone marrow
destruction prior to transplantation can result in loss of the recipients original EBV
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isolate, which can be followed by transmission of a new EBV isolate in transplanted
bone marrow (Gratama et al 1988, 1990). Ablation of the recipients' bone marrow
pre-transplant and reconstitution of the immune system with donor cells means that
PTLD is usually of donor cell origin (Shapiro et al 1988).
The serological profile of primary infection in transplant recipients differs
from that seen in normal healthy individuals, is often of little value in the diagnosis
of PTLD and may be misleading due to the severe immune dysfunction of these
patients. IgM responses to VCA heterophile antigen are not reliably detected (Henle
& Henle 1981, Thomas & Crawford 1990). Patients who are EBV carriers pre-
transplant commonly show a serological profile suggestive of a viral reactivation,
diagnosed by raised levels of IgG against VCA and EA but not to EBNA (Henle &
Henle 1981, Ho et al 1985, Thomas & Crawford 1990).
EBV gene expression in PTLD tumours is typically latency III, with LCL-like
expression of all latent genes (Young et al 1989c, Thomas et al 1990). In some cases
latency I or II are seen, and EBV gene expression within a tumour may be
heterogeneous (Cen et al 1993, Neidobitek et al 1997). In a minority of cells within
the tumour there is evidence of EBV lytic replication by detection of linear EBV
DNA and immediate early transcripts, and less commonly early and late viral
proteins (Katz et al 1989, Rea et al 1994). Tumour cells express B cell activation
markers and cellular adhesion molecules (CAMs) (Young et al 1989c, Thomas et al
1990).
1.3.12.8.6 Pathogenesis
In vitro experiments have shown that immunosuppressive drugs are potent
suppressors ofEBV specific CTLs (Crawford et al 1981, Tsoukos et al 1982, Kino et
al 1987, Burman & Crawford 1991). In vivo, EBV-specific CTL activity becomes
low or undetectable in all EBV seropositive transplant recipients following
transplantation (Haque et al 1997). Loss of CTL activity creates a favourable
environment for EBV infected cells to persist and express additional latent and lytic
proteins without elimination by EBV-specific CTLs.
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Bone marrow transplant recipients frequently have underlying
immunodeficiencies which represent an independent risk factor for PTLD in this
group (Bhatia et al 1996) and following transplantation are severely immunodeficient
due to destruction of their bone marrow by chemotherapy or radiotherapy and
through immunosuppression to prevent graft versus host disease (GVHD). The risk
of PTLD in bone marrow transplant recipients is increased if the donor marrow is
depleted of T-cells prior to infusion to reduce GVHD since HLA-matched donor T-
cells would be capable ofmounting a defence against development ofPTLD of donor
B-cell origin (Shapiro et al 1988). However, if B-cells are removed from the graft
before transplant (Cavazzana-Calpo et al 1998) or if the donor marrow is depleted of
T-cells and coincidentally of B-cells by counterflow elutriation this risk factor is
reduced (Gross 1998).
Following transplantation increased levels of EBV are shed in saliva and
higher concentrations of EBV infected B-lymphocytes and EBV DNA have been
detected in the circulation (Wagner et al 1992, Preiksaitis et al 1992, Savoie et al
1994, Riddler et al 1994, Kenagy et al 1995, Rowe et al 1997). High levels of EBV
are thought to reflect the loss of immune control of EBV infection, with uncontrolled
proliferation of EBV infected B-cells. This is termed a 'reactivated' EBV infection,
although in most cases no disease ensues. However in a minority of patients it is
thought that uncontrolled EBV-driven B-cell proliferation leads to PTLD. In an EBV
seronegative transplant recipient, an efficient CTL response cannot be established if
primary infection with EBV occurs post-transplantation, and it is thought that
proliferation of infected B-cells leads to the polyclonal immunoblastic lesions seen in
early onset PTLD. Although high levels of EBV DNA have been detected in most
cases of PTLD, this is not always the case, and similar levels can be detected in
patients who do not develop disease (Savoie et al 1994, Kenagy et al 1995). EBV
DNA has also been detected in the serum of patients with PTLD, indicating that
some cells undergo lytic replication in PTLD (Scichman et al 1998, Limaye et al
1999). EBV DNA has previously been detected in the serum of patients with IM
(Gan et al 1994) and NPC (Yamamoto et al 1995). Babcock et al (1999) reported
that increased EBV load following transplantation is due to an increase in the number
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of circulating latently infected resting memory B-cells or lytic replication rather than
proliferating lymphoblasts. A model for PTLD development in the context of normal
latency is described in the Discussion, section 4.3.3.
In tumour biopsy material, EBV positive cells may make up only a small
proportion of the tumour mass, with an extensive EBV negative infiltrate comprising
predominantly CD4+ve T-lymphocytes (Perera et al 1998). In vivo experiments in
SCID mice, where PTLD-like tumours can be generated following injection of
human peripheral blood mononuclear cells, show that T-cells are necessary for
development of these tumours (Veronese et al 1992). This suggests a role for the
non-tumour element in PTLD development, possibly in supplying essential growth
factors. RT-PCR and in-situ hybridisation studies of SCID tumours have
demonstrated that tumour cells produce cytokines which stimulate B-lymphocytes in
an autocrine fashion (Johannesen & Crawford 1999). It is likely that additional
factors are involved in rendering particular organs more favourable as sites for PTLD
development. Occurrence of PTLD in the transplanted organ, for example, may
reflect the complex immunologic interactions taking place during graft rejection or
dysfunction, which can enhance cytokine production and possibly aid tumour
development (Tosato et al 1993, Wakasugi et al 1987).
A recent study suggests an association between PTLD and CMV disease
(Manez et al 1997). This may reflect the combined loss of immune control for EBV
and CMV with high dose immunosuppression, but it is also possible that reactivation
of CMV has profound effects on the immune system by inducing cytokine
production which directly transactivates EBV genes (Aalto et al 1998).
1.3.12.8.7 Treatment
Despite the use of a variety of treatment strategies, mortality from PTLD
remains high, and can be up to 70% (Armitage et al 1991). Published studies tend to
be small scale, anecdotal and complicated by the diversity in presentation of PTLD
and histological differences between cases. In general however, since the observation
by Startzl et al (1984) that lesions could regress spontaneously following reduction in
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immunosuppression, this is now the first line of treatment for PTLD in solid organ
transplant recipients. There is no definitive classification for predicting the response
of these tumours to reduced immunosuppression, although early onset polyclonal
PTLD associated with primary EBV infection is usually more responsive than
monoclonal tumours appearing in EBV seropositive individuals over one year post-
transplant (Nalesnik et al 1998, Chadburn, Cesarman and Knowles 1997, Harris et al
1997). Clearly this strategy carries with it the risk of graft rejection, so cases must be
carefully monitored and treatment tailored to clinical events. High doses of the
antiviral drugs acyclovir or ganciclovir, which inhibit EBV DNA polymerase and
lytic replication (Colby et al 1980, Datta et al 1980, Collins et al 1983) are often
included as a treatment in combination with reduced immunosuppression (Hanto et
al 1982, Pirsch et al 1989, Davis 1998). However, since these drugs only block
herpesvirus replication their value in PTLD, where most EBV infected cells are
latently infected, remains unclear. There have been reports of EBV negative patients
acquiring the virus after transplant and developing PTLD whilst still on high dose
acyclovir (Haque et al 1996)
Surgical resection, irradiation or chemotherapy are used to treat PTLD where
initial reduction in immunosuppression fails (Gross et al 1998b, Hanto et al 1983). In
one study a 75% complete remission rate was achieved using a multiple cytotoxic
drug regime in eight heart-transplant patients who presented with monoclonal PTLD
refractory to reduction of immunosuppression (Swinnen et al 1995). Interferon alpha
has also been effective at inducing complete remission in both polyclonal and
monoclonal lesions although the precise mode of antitumour action is not known
(Davis et al 1998, Faro 1998). There has also been success in using monoclonal
antibodies against the B-lymphocyte surface markers CD21 and CD24 to treat PTLD
(Benkerrou et al 1998, Fischer et al 1991).
New treatment strategies involving adoptive T-cell immunotherapy are now
being assessed since PTLD presents an ideal target for this type of therapy for several
reasons (Haque & Crawford 1999). Firstly, immunogenic EBV antigens are
expressed only on tumour cells and not on normal cells, so the therapy is specific for
the tumour. Secondly, CTLs are relatively easy to culture in vitro to high numbers.
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Thirdly, immunotherapy carries less risk of damage to the grafted organ than
reduction of immunosuppression. This is of particular importance in heart/lung and
liver transplants where loss of the graft would be fatal. Finally, immunotherapy is
non-toxic and therefore preferable to chemotherapy.
EBV specific CTL activity can be restored in bone marrow transplant
recipients through adoptive transfer of EBV specific polyclonal T-cells of donor
origin (Rooney et al 1995). A pilot study has demonstrated restoration of EBV
specific CTL activity in healthy EBV seropositive liver and kidney transplant
recipients following infusion of in vitro expanded autologous CTLs (Haque et al
1998). The CTLs were retained, remained functional for at least 3 months post-
infusion, and caused reduction in levels of EBV DNA detectable in the blood.
Nalesnik et al (1997a & b) reported regression of EBV positive PTLD in four solid
organ transplant recipients following treatment with autologous mononuclear cells
which had been depleted of monocytes and stimulated in vitro with IL2 for ten to
eleven days prior to infusion, producing lymphokine activated killer cells (LAK
cells). Advances have also been made in using chemically engineered major
histocompatability complex tetramers which could be used to enrich populations of
antigen specific CTLs (Altman et al 1996). These complexes have already been used
by Callan et al (1998) to directly visualize antigen specific CD8 +ve T-cells during a
primary immune response to EBV in vivo in humans.
The strategy for adoptive CTL therapy in bone marrow transplant recipients is
more straightforward than in solid organ transplant recipients, since in most cases the
marrow donor is available. As the recipient has adopted donor lymphoid tissue, and
any developing PTLD is generally of donor cell origin, CTLs obtained from the
donor can be used for therapy. In solid organ transplant recipients however, where
the organ is usually of cadaveric origin, autologous CTLs must be grown in vitro
from T-cells obtained pre-transplant for use at a later date if PTLD should arise. This
would be a costly and time-consuming procedure since ideally T-cells should be
grown for each transplant recipient. An alternative strategy is to use allogeneic CTLs
grown from healthy donors on a best HLA-match basis (Trainor et al 1991). This
strategy is now being developed by Dr Tanzina Haque in our laboratory such that a
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panel of frozen HLA typed EBV specific CTLs is banked and ready to infuse into
patients with PTLD.
1.3.12.8.8 Prevention of PTLD
The transfer of donor EBV isolates to an EBV negative recipient must
initially involve EBV lytic replication to release infectious virus and infect the new
host. This could be avoided by matching EBV status of donor and recipient. This is
impractical due to the urgency of transplantation and scarcity of EBV seronegative
donors. An alternative approach could be to prevent infection of the recipient using
neutralizing antibodies against the EBV envelope glycoprotein gp340 which would
prevent virus binding to the cell surface receptor CD21. A vaccine to induce
antibodies against gp340 is under production, although clinical trials are not yet
completed. Alternatively EBV negative transplant recipients could be passively
immunized with neutralising anti-gp340 monoclonal antibodies to prevent infection
in the critical period of intense immunosuppression when there is high risk of PTLD.
A pilot study using this approach is currently underway in paediatric liver transplant
recipients (Personal communication: Haque, Crawford and Mieli-Vergani).
Another approach would be to use a peptide-based vaccine to induce EBV
epitope-specific CTL responses in EBV seronegative transplant recipients. The
choice of peptide vaccine would be tailored to the HLA Class I allele of individual
recipients or alternatively multiple CTL epitopes could be combined to cover the
HLA restriction of up to 80% of the Caucasian population (Moss et al 1998).
Alternatively a DNA plasmid vaccine could be used which encodes multiple minimal
CTL epitopes. This approach has proved effective at inducing protective CTL
epitopes in mice (Thomson et al 1998).
Early identification of patients at risk of developing PTLD is crucial to the
success of any therapeutic approach. Increased EBV load has been cited as a
predictive marker of PTLD development, and it has been suggested that transplant
recipients should be monitored for sustained elevation of viral load (Stevens et al
1999, Swinnen 2000). However, since not all patients with high EBV load go on to
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develop PTLD (Savoie et al 1994, Kenagy et al 1995. Rowe et al 1997), a more
reliable method of predicting PTLD is required.
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2 AIMS
This study set out to monitor the course of EBV infection in adult cardiothoracic
transplant recipients in order to relate changes in EBV copy number and EBV gene
expression to development ofPTLD.
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3 Materials and Methods
3.1 Reagents
Reagent Supplier
lKbp DNA ladder Gibco BRL
32P-y-dATP Amersham International
Bovine serum albumin (BSA) Sigma
Bromophenol blue Sigma
DNA polymerisation mix Pharmacia biotech
Ethidium Bromide (EtBr) Gibco BRL
Ficoll-400 Pharmacia Biotech
Ficoll-Hypaque Pharmacia Biotech




Mixed bed resin Sigma
NICK™ sepharose columns Pharmacia Biotech
NuSieve 3:1 agarose FMC BioProducts
Oligonucleotides Oswel
RNAzol™ B Cinna/ Tel Test Inc
RT-PCR kit Stratagene
Sheared salmon sperm DNA 5'-3' Inc
T4 Polynucleotide kinase Promega
Taq DNA polymerase Promega
Tissue culture media Gibco BRL
Trypan Blue Flow
X-ray fixer and developer Photosol
cj)Xl74 DNA/ Hae III markers Promega
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3.2 Suppliers
5'-3' Inc, Boulder, Colorado, USA
American National Can, Neenah, Wisconsin, USA
Amersham International Pic, Little Chalfont, Buckinghamshire, UK.
Anachem, Luton, Bedfordshire, UK.
BDH Ltd, Poole, Dorset.
Beckman Instruments, Palo Alto, California, USA.
Beckton-Dickinson Ltd, Cowley, Oxfordshire, UK.
Bibby Sterilin Ltd, Stone, Staffordshire, UK.
Bio-Rad laboratories Ltd, Hemel Hempstead, Hertfordshire, UK.
Cinna/Tel-Test Inc., Friendswood, Texas, USA.
ECACC, Salisbury, Wiltshire, UK.
Flow-ICN (UK), Thame, Oxfordshire, UK.
Flowgen, Lichfield, Staffordshire, UK.
FMC Bioproducts, Rockland, Maine, USA.
Gibco BRL, Paisley, Scotland
Heraeus, Brentwood, Essex, UK.
Hybaid Ltd, Teddington, Middlesex, UK.
Invitrogen Corporation, San Diego, California, USA.
Jencons, Leighton Buzzard, Bedfordshire, UK.
Marathon Laboratory Supplies (Falcon), London, UK.
MSE (Sanyo-Gallenkamp), Uxbriodge, Middelsex, UK.
Nunc, Naperville, Illinois, USA.
Oswel DNA services, Southampton, Hampshire, UK.
Perkin-Elmer Cetus, Beaconsfield, Bedfordshire, UK.
Pharmacia Biotech, Uppsala, Sweden.
Phillip Harris, London, UK.
Photosol, Basildon, Essex, UK.
Promega, Madison, Wisconsin, USA.
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Scotlab, Coatbridge, Lancashire, UK.
Sera-lab, Crawley Down, West Sussex, UK.
Shandon Scientific, Runcorn, Cheshire, UK
Sigma Chemical Corporation, St Louis, Missouri, USA.
Sterilin, Hounslow, Middlesex, UK.
Stratagene Cloning Systems, La Jolla, California, USA.





Cell culture flasks and plates
Cryotubes
Disposable gloves
Dry ice (solid C02)
Filter Units (0.45pm, 0.60pm)
Hybond N+ nylon membrane
Hyper-MP film




Plastic universal tubes (25ml)
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Fuji Photo Film Company
'Mini-monitor 900 GM type E', Mini-
Instruments
UVP with Phoretix 2D advanced
scanning densitometry analysis software
Gibco BRL




















3.5 Materials and Solutions
Cell culture
Culture Medium




Foetal calf serum 10% v/v
Wash Medium
(Made up in sterile dH20)
Penicillin lOOu/ml
Streptomycin 1OOpg/ml
Foetal Calf serum 2% v/v
7.5% Sodium Bicarbonate 2.7% v/v
1M Hepes buffer 2% v/v
1 OX RPMI 1640 10% v/v
Freezing Medium
Foetal Calf serum 90% v/v
Dimethylsulphoxide (DMSO) 10%v/v






Polymerase Chain Reaction (PCR) and Reverse-transcription (RT-) PCR
analysis
10X Tris-borate-EDTA solution
(made up in dH20)
Tris
Boric acid

























20X Standard saline citrate (SSC)












Deionised in 10% mixed bed resin
IX Tris-EDTA buffer
(made up in dH20)
Tris-HCl pH 8.0 lOmM
EDTA pH8.0 ImM
Pre-Hybridisation solution
(made up in dH20)
Formamide 50% v/v
20X SSC 25% v/v
5OX Denhardt's solution 10% v/v
SDS 5% w/v
Sheared Salmon sperm DNA 1% v/v
Hybridisation solution
As Pre-hybridisation solution with 32P-labelled oligonucleotide probe and fresh 1%
v/v sheared salmon sperm DNA
Post-Hybridisation Wash solutions
2X SSC/ 0.1% w/v SDS
IX SSC/ 0.1% SDS
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3.6 Cell Lines
The cells types shown in Table 3-1 were used as experimental controls as
described in the appropriate sections:
Table 3-1. Control cell lines
Cell name Description Reference
B95-8 EBV transformed marmoset cell line. Miller et al 1972




Namalwa BL tumour derived cell line containing




BJAB EBV negative BL derived cell line Rowe et al 1987
C19 NPC derived tumour material passaged
in SCID mice
Busson et al 1988
M148 EBV positive BL derived cell line Rowe et al 1987
Cell lines were cultured in a humidified incubator (Leec) at 37°C and at 5% C02 with
twice weekly feeding with culture medium.
3.6.1 Cell viability assay/ cell counts
Cell viability was assessed using the principal that live cells are able to
exclude the dye Trypan blue, whereas dead cells take up the stain. lOpl of 0.5% w/v
Trypan blue in PBS solution was mixed with lOpl of cell suspension, and the mixture
placed into the chamber of a haemocytometer. Viable cells (unstained) were counted
by light microscopy.
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3.6.2 Thawing of cell lines and establishment of cultures
Vials of viably frozen cells were thawed in a water bath at 37°C and
resuspended by dropwise addition of 1ml of culture medium and transferred to 9ml
of culture medium in a universal tube. Cells were centrifuged at 160g for 7 minutes,
resuspended at 1 x 106 cells/ml in culture medium and transferred to a 25ml tissue
culture flask for propagation in a C02 incubator as described.
3.6.3 Storage of cell lines
Cells were counted as described using the Trypan blue exclusion method to
determine cell viability, aliquoted into freezing medium at 1 x 107 cells vial in
cryotubes and slowly frozen at -70°C. Vials were transferred to the vapour phase of a
liquid nitrogen tank for long-term storage.
3.6.4 Snap freezing of cells
Cells to be used for DNA and RNA extractions were counted and washed in
PBS. Aliquots of up to 1 x 107 cells were placed in sterile cryovials and centrifuged
at 160g for 7mins. The PBS was aspirated off and the vial placed in liquid nitrogen to
'snap-freeze' the cell pellet. The vial was then stored at -70°C overnight and
transferred for long term storage in liquid nitrogen.
3.6.5 Cell line dilution series
Ten-fold dilution series of cell lines were established to provide a means of
quantifying PCR reaction sensitivity. Dilutions of EBV positive cells were made in a
background of negative cells. Thus viable EBV positive and negative cultured cells
were counted as described and each diluted to 1 x 106 cells/ ml. 9ml of EBV negative
cells (9 x 106 cells), were aliquoted into universal tubes and 1ml of the EBV positive
cells (1 x 106 cells) added to the first tube, mixed and 1ml removed and transferred to
the next tube, and so on to give a ten fold dilution series of cells from undiluted
positive cells to 1 EBV positive cell in a total of 1 x 107 cells. The mixtures were
centrifuged at 160g for 7 minutes washed in PBS and the cell pellets snap frozen and
stored at -70°C for DNA or RNA extraction.
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3.6.6 Establishment of tumours in SCID mice
CB17 Severe combined immunodeficient (SCID) mice, maintained under
aseptic conditions were injected intraperitoneally with a sterile suspension of cells
teased from PTLD biopsy material. On showing signs of being unwell, or after a
predetermined time point, animals were culled by cervical dislocation, dissected
aseptically and tumour mass and macroscopically affected organs removed. This
material was divided into four pieces for processing: a) snap-frozen in a sterile
cryovial in liquid nitrogen for subsequent DNA and RNA extraction and PCR
analysis, b) Fixed in neutral buffered formalin, or c) snap frozen in OCT for cryostat
sections to be cut for histopathological/ immunohistopathological analysis and d) a
portion of tumour was aseptically processed to produce a single cell suspension for
passage into another SCID mouse. This work was carried out by Dr. Ingolfur
Johannessen.
3.7 Clinical samples and controls
3.7.1 Separation of peripheral blood mononuclear cells (PBMCs) from
heparinised whole blood
Heparin-treated fresh whole blood (103IU/ml) was layered onto an equal
volume of Ficoll-Hypaque and centrifuged at 540g for 20 minutes (Boeyum 1968).
The upper layer of plasma was harvested and stored at-20°C for serological analysis.
The interface, containing PBMCs was harvested and washed twice in wash medium
by centrifugation at 160g for 7 minutes. Viable PBMCs were counted by Trypan-
blue dye exclusion and aliquoted to be either snap-frozen in liquid nitrogen for DNA/
RNA extraction or frozen viably as described.
3.7.2 Serological analysis
Previous infection with EBV was determined by detection of IgG antibodies
against EBV viral capsid antigen (VCA) by indirect immunofluoresence (Henle &
Henle 1966). Test slides were prepared by placing 5 x 104 washed cells of the EBV
containing P3HR1 cell line onto each of 12 wells on a microscope slide. The cells
68
were allowed to dry at room temperature (RT) and then fixed in acetone for 5
minutes. The slides were air dried at RT and stored at -20°C.
To detect anti-VCA antibodies, slides were thawed at RT and the test sera,
diluted in PBS at 1:5 and 1:10 were added to separate spots on the slide alongside
known VCA-positive and VCA-negative control sera. The slides were incubated for
1 hour at 37°C in a humidified chamber then washed in PBS at room temperature.
10pl of FITC conjugated rabbit anti human IgG (diluted 1:50 in PBS) was added to
each well. Slides were incubated for 1 hour at RT and washed in PBS. PBS:glycerol
(1:1) was used to mount coverslips before viewing under an epifluorescent
microscope. EBV seronegativity was assumed if staining of the cells was not visible
upon repeated testing of the serum at 1:5 dilution.
3.8 Polymerase Chain Reaction (PCR)
PCR amplification was performed to detect EBV and human gene sequences
and RNA molecules in nucleic acid extracts. The methods used derive from those
described by Saiki et al (1985, 1988) and Hart et al 1988.
3.8.1 Extraction of Nucleic Acids
3.8.1.1 General Precautions
During extraction of nucleic acid for use in PCR analysis, care was taken to avoid
contamination of samples with amplified PCR products which could give rise to false
positive results. This was achieved by separating the processing and storage of PCR
products from the laboratory where extractions were performed and PCR reactions
set up, and using sterile plasticware and pipettors and racks kept exclusively for each
procedure.
Additional safeguards were necessary for processing and handling RNA
samples due to the risk of contamination with RNAse enzymes from the
environment. RNAse-free microfuge tubes and pipette tips containing filters
(Anachem) were used for all procedures involving RNA and gloves were changed
frequently.
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3.8.1.2 Extraction of DNA
Genomic DNA was extracted from stored frozen pellets of cultured cells or
PBMCs using a kit ('EZ-DNA' Invitrogen), following the methods described in the
manufacturers protocol. Briefly, 1 x 106 cells were resuspended in 200pl PBS and
350pl alkaline lysis solution (solution A) added. The mixture was vortexed until the
cells were evenly dispersed and incubated at 65°C for 10 mins. 150pi of solution B
was added and vortexed until the mixture became uniformly viscous. 500pl of
chloroform was added and vortexed until the mixture became homogenous. The
mixture was centrifuged for 15 mins at 12 OOOg to separate the aqueous and organic
phases and the upper aqueous phase removed and transferred to a fresh microfuge
tube. The DNA was precipitated from solution by addition of 1ml 100% Ethanol
which had been pre-chilled to -20°C and incubation on ice for 30 mins. The DNA
was separated by centrifugation for 15 mins at 12 OOOg and the ethanol removed. The
DNA pellet was washed in 500pl 80% ethanol, centrifuged for 2 mins, the ethanol
removed and the DNA pellet resuspended in 50ptl of nuclease free water (Gibco
BRL). Contaminating RNA was degraded by treatment with RNAse supplied with
the kit (final RNAse concentration (40pg/ ml). DNA concentration was determined
by measuring the samples absorbance at 260nm and 280nm in a Perkin Elmer DNA/
RNA calculator and all samples were diluted to lOOng/pl and stored at -20°C for
subsequent use. DNA samples extracted in this way had a 260/ 280 ratio between
1.8-1.9.
3.8.1.3 Extraction of RNA
Total cellular RNA was extracted by homogenisation of frozen cell pellets by
pipetting several times in RNAzol B solution (Cinna/ Biotecx) (2ml/ 107 cells).
Frozen tissue samples were homogenized in the solution using sterile RNAse free
homogenizer rods. The manufacturers protocol was followed. Briefly, following
complete disruption of the cells or tissue in RNAzol B, 100pl of chloroform was
added per 1ml of homogenate and the samples were then tightly capped and shaken
vigorously for 15 seconds and kept on ice for 5 mins. The mixture was then
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centrifuged in a microfuge at 12 OOOg for 15 mins at +4°C to separate the aqueous
and organic phases and the upper aqueous phase removed to a fresh RNAse-free
microfuge tube. RNA was precipitated by addition of an equal volume of isopropanol
and storage at +4°C for 15 mins. The RNA was pelleted by centrifugation at 12000g
for 15mins and the supernatant removed. The RNA pellet was washed once in 800pl
of 75% ethanol and centrifuged for 8 mins at 7 500g. The supernatant was removed
and the RNA pellet resuspended in 50pi nuclease free water (Gibco BRL). RNA
concentration was determined by spectrophotometry as above and the sample diluted
to lOOng/pl. To avoid degradation by repeated freeze/ thaws or contamination, all
samples were separated into two aliquots for storage at -70°C and one aliquot was
used for subsequent studies with the second as back up.
3.8.1.4 Complementary DNA (cDNA) synthesis
cDNA was synthesized by reverse transcription of lug of total RNA using
Moloney Murine Leukaemia virus (MMLV)-reverse transcriptase (RT) and random
hexamer primers (Pro-star RT-PCR kit, Stratagene). The reaction was set up as
shown below, and incubated at 37°C for one hour following which cDNA















to 50pl total volume
3.8.1.5 PCR Primers
Oligonucleotide primer sequences were either obtained from published
sources, or were designed for this study. All primers and probes are described in
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Table 3-2. New primers were designed ensuring there was no sequence
complementarity within or between the primer pairs to avoid self-annealing.
Validation and optimisation experiments were performed as described in this section
to ensure that the correct sequences were amplified with the greatest possible
sensitivity and specificity. Oligonucleotides were synthesised by Gibco BRL and
diluted to lOOng/pl for storage in aliquots at -20°C to avoid degradation or
contamination.
3.8.1.6 Optimisation of PCR Reaction conditions
Optimisation experiments were performed to ensure the reaction conditions
gave maximum efficiency and specificity to the amplification. The most important
factors tested were MgCl2 concentration and annealing temperature. The starting
point for optimising annealing temperature was to calculate the melting temperature
through an equation based on the relative amounts ofGC and AT nucleotides in each
primer:
Melting Temperature (Tm°C) = 4 x (GC) + 2 x (AT) - 5
Initial PCR reactions were carried out on replicates of appropriate control
material under standardised reaction conditions (ie 92°C 1 min, mean annealing
temperature of the primer pair (Tm°C) 1 min, 72°C lmin for 30 cycles), with titration
of MgCl2 concentrations. The MgCl2 concentrations tested were ImM, 1.5mM,
2mM, 2.5mM and 3mM. The optimal MgCl2 concentration was determined
subjectively by viewing ethidium bromide (EtBr) stained gels of PCR products and
autoradiographs. That which gave the best combination of high sensitivity (bands
visible at greater dilutions of positive cells) and low levels of non-specific bands was
selected.
Using the optimal MgCl2 concentration determined from this experiment, the
PCR annealing temperature was optimised. Four identical sets of reactions were set
up to amplify sequence from the control material with the same reaction mixture
containing the optimised MgCl2 concentration. The four sets of reactions were
simultaneously placed in thermal cyclers under identical conditions other than
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annealing temperature. The annealing temperatures tested were based upon the
melting temperature of the oligonucleotides: Tm, Tm-5, Tm +5, Tm-10°C. The
criteria for determining the optimal annealing temperature were a combination of
reaction sensitivity and specificity as described.
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Table 3-2. Oligonucleotide Primers
Target sequence Oligonucleotide sequence (5'-3')





Human (3-actin 5' GTGGGGCGCCCCAGGCACAC "
Human (3-actin 3' CTCCTTAATGTCACGCACGATTTC ~
Human P-actin probe GGATAGCAACGTACATGGCT 450bp
EBER1 5' AAAACATGCGGACCACCAGC3 6629-6648
EBER1 3' AGGACCTACGCTGCCCTAGA3 6795-6777
EBER1 probe ACGGTGTCTGTGGTTGTCTT3 6718-6737 166bp
EBNA3c 5' GGCTGTCAAGAATCGCACCT 98721-98815
EBNA3c 3' GTGTTTAGAGTTCGTGCCGC 99107-99087
EBNA3c 5' nested CATCTTGTGCTTCGTGATGG 98864-98883
EBNA3c 3' nested TAACATGATGCTGTCAGCCC 99062-99043
EBNA3c probe GGCGACATTGGCTTCTAACA 98947-98966 198bp
LMP1 5' ACACACTGCCCTGAGGATGG1 169490-169470
LMP1 3' ATACCTAAGA/CAAGTAAGCA' 168956-65/9042-51
LMP1 5' nested ACAATGCCTGTCCGTGCAAA 169081-169100
LMP1 3' nested CTTCAGAAGAGACCTTCTCT 169262-169243
LMP1 probe CTACTGATGATCACCCTCCT1 169216-169119 182bp
LMP2A 5' ATGATCCATCTCAACACATA1 166874-166893
LMP2B 5' CAGTGTAATCTGCACAAAGA1 169819-169838
LMP2A/B 3' TCACCAGAACGTAAATGCCT1 361-380
LMP2A/B 5' nested CTCGTGTTTCACGGCCTCAG 124-143
LMP2A/B 3' nested AAGGTGGGTCCTCAATCCTC 401-382
LMP2A/B probe CTCTCACTTCTACTCTTGGC 176-200 260bp
Gp350 5' CACAGGCCCCACTGTATC2 2402-2422
Gp350 3' GAGGTGGAGCTGGTCATTG2 2544-2524
Gp350 probe AGATGGACTTGGTGTCAC2 2460-2480 142bp
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Oligonucleotide primer sequences from previously published sources: 1. Brooks et al
1992. 2. Rochford & Mosier 1995. 3. Tierney et al 1994. All other oligonucleotide
sequences were designed for this study.
3.8.2 Gel electrophoresis of PCR products
PCR products were resolved and visualised by gel electrophoresis according
to the protocols of Sambrook, Fritsch and Maniatis (1989). A 2.5% agarose gel was
made by melting Low viscosity NuSieve 3:1 agarose (3 parts agarose, 1 part SeaKem
agarose) by microwaving in IX TBE buffer. Following cooling the dissolved agarose
to 'hand-hot' temperature by holding the flask under running water, EtBr (10 pg/ml)
was added to lpg/ml. The agarose was poured into a gel casting tray with combs
inserted and allowed to set. The gels were placed in the electrophoresis tank
(Scotlab), covered with lx TBE buffer, and the combs carefully removed.
To load the PCR products, 25pi (25% of the total volume) was mixed with
5pi of 6X loading buffer and carefully pipetted into the appropriate wells. Two sets
of DNA size markers were loaded on each gel: 32P labelled Hinfl-digested <))X174
DNA and non-radiolabelled lKbp DNA ladder (Gibco BRL). Electrophoresis was
carried out at 80mA and EtBr stained DNA was visualised under a UV
transilluminator gel documentation system (UVP) and a photograph taken for record.
3.8.3 Southern Transfer of PCR products
Following electrophoresis of PCR products, the DNA was transferred onto
Nylon membrane according to the method of Southern (1975). The gel was first
rinsed in dH20 and soaked in an alkaline DNA denaturing solution for 30 minutes
and then transferred to a pEl 7.2 neutralising solution for 30 minutes. To transfer the
DNA from the gel to a nylon membrane, the gel was placed on top of a strip of 3MM
blotting paper laid across a glass plate supported over a tray of 10X SSC solution.
The 3MM paper had been soaked in 10X SSC before being laid over the plate, and
both ends of the paper hung over the edges into the solution to act as a wick. The area
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around the gel was surrounded closely with cling film to prevent the subsequent
layers from getting wet from the surrounding paper. Three pieces of 3MM paper and
one piece of positively charged nylon membrane (Hybond N+) were cut to the exact
size of the gel, and layered on top of the gel: firstly the membrane followed by a 10X
SSC wetted piece of 3MM paper, and the remaining pieces of paper. Care was taken
to exclude air bubbles from between the layers. Finally a stack of dry paper towels
was placed on top of the paper followed by a glass plate and a 500g weight. This
arrangement causes 10X SSC solution to be wicked upwards through the gel,
transferring the DNA from the gel onto the nylon membrane. Following transfer at
room temperature overnight, the apparatus was dismantled and the membrane
marked to indicate orientation. The membrane was then rinsed briefly in 2X SSC,
dried on 3MM paper and then the DNA was fixed onto the membrane by cross-
linking in a Stratalinker™ at 120, 000 pi UV.
3.8.4 Hybridization of Membranes
PCR products were detected by Southern hybridisation of the DNA fixed
onto nylon membranes using a 32P labelled oligonucleodide probe.
3.8.4.1 Pre-Hybridization
To reduce non-specific binding of labelled probe, the membranes were
blocked by incubation in a Hybaid hybridisation oven for two hours at 42°C in pre-
hybridization solution containing 1% v/v denatured and cooled sheared salmon
sperm DNA.
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3.8.4.2 32P End labelling of Oligonucleotide probes
Specific oligonucleotide probes were designed and are detailed in the Table
3-2. Working solutions of probes were diluted to 10pM and stored at -20°C.
Oligonucleotides were 5' end labelled with 32P yATP by T4 polynucleotide
kinase (T4 PNK) (Promega) incubated for 30 minutes at 37°C. The reaction contents
are:
Oligonucleotide 1 OpMoles
1 OX Buffer 2pl
32P yATP 1.85MBq
T4 PNK lunit
dH20 to 20pl final volume
The labelled oligonucleotide probe was separated from unincorporated 32P
yATP by running the mixture through a pre-wet column containing Sephadex G50
sepharose (NICK™ column, Pharmacia). Purified radiolabeled probe was eluted
from the column in IX TE.
3.8.4.3 Hybridisation of blots
Following pre-hybridization, the 32P-labelled oligonucleotide probe was
added to 25ml of Pre-hybridization solution containing freshly denatured and cooled
sheared salmon sperm DNA (1% v/v). The pre-hybridization solution was removed
from the blots and replaced with probe solution. Hybridization of the labelled
oligonucleotide to the membrane-immobilized PCR products was carried out by
incubation overnight at 42°C.
3.8.4.4 Autoradiography
Following hybridization, probe solution was removed and stored at -20°C.
Blots were washed to remove non-specifically bound probe from the membrane.
Following each wash the blots were checked using a Geiger counter, and increasingly
stringent washes were used to reduce background levels of radioactivity on the blot.
Initial washes were twice for 10 minutes in 2X SSC, 0.1% w/v SDS followed by IX
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SSC, 0.1% SDS and if necessary 0.1X SSC, 0.1% SDS. Washed membranes were
removed from the solution and drained of excess moisture on 3MM paper. Blots
were then covered in cling fdm and exposed to X-ray fdm in autoradiography
cassettes with an intensifying screen for 1 to 7 days at -70°C. Developed
autoradiographs were labeled and stored.
Radiolabelled DNA size markers were visible on autoradiographs for size
determination of bands visible through hybridization of labelled probe to the
complementary sequence of the PCR product. PCR reactions were repeated if bands
were visible in water or negative control lanes indicating contamination of the
reaction or if no bands were visible in the positive controls, indicating that the
reaction or hybridization had failed. A band of correct size in a sample lane was
considered positive, and if no band for a particular sample was visible following
exposure of the blot for 7 days, the sample was considered negative.
3.8.5 EBV Semi-quantitative PCR
In order to evaluate the EBV copy number in the PBMs of patient samples, a
semi-quantitative PCR method was established. PCR was carried out on a Namalwa
dilution series containing 107, 106, 105, 104, 103, 102, 10 and 1 EBV genome copies/
107 cells (Lawrence et al 1988). DNA was extracted from the cell mixtures and PCR
performed to amplify the highly conserved Bam HI W repeat region of the EBV
genome (Wagner et al 1992). Following electrophoresis and Southern blotting of the
PCR products, autoradiographs were analysed by scanning densitometry (Phoretix
ID Advanced package) to determine the volume of the amplified bands. In addition
to optimization of MgCl2 concentration and annealing temperature, the number of
amplification cycles was optimised such that amplification of the Bam HI W PCR
product was in the linear part of the amplification profile. This was done to ensure a
linear relationship between amplified band volume and the starting template copy
number. PCRs were performed over 20 to 30 cycles and the band volume plotted
against cycle number to determine the optimal cycle number which gave maximum
product yield in the linear portion of the graph (shown in Results Figure 4-7).
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DNA was extracted from clinical samples and controls as described, and lug
DNA used as template in all reactions. Alongside each set of clinical samples, Bam
HI W PCR was performed on the complete Namalwa dilution series. In addition a
PCR for detection of the human (3-globin gene was performed on all samples. Since
lug DNA was used for each reaction equivalent amounts of PCR product should be
detected for all samples, and no amplification or low product yield would indicate
that the DNA concentration was incorrect or the sample contained inhibitors of the
PCR reaction. This therefore acted as a control for differences between samples to
avoid misleading results. Band volumes were determined by scanning densitometry
of Bam HI W and (3-globin autoradiographs, and Bam HI W band volume figures
were adjusted on the basis of the [3-globin PCR through comparison with the BJAB
as standard control. Band volumes for Namalwa dilution series were plotted against
EBV copy number allowing EBV genome copy number in clinical samples to be
determined through reading band volume from the graph.
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4 Results
Studies were carried out to determine changes in EBV genome copy number and
EBV gene expression in patients undergoing cardiothoracic transplantation in order
to establish the influence of iatrogenic immunosuppression on EBV infection in vivo
and how this may relate to development ofPTLD.
Blood samples were taken from patients immediately prior to and at intervals
following transplantation with follow up times of up to three years. Observed
changes in EBV gene expression and genome copy number were studied in
comparison to latent infection in normal healthy carriers, individuals undergoing
symptomatic primary infection (IM) and patients with EBV associated PTLD.
4.1 EBV Semi-quantitative PCR
A semi-quantitative PCR was developed to determine EBV copy number in
the peripheral blood of transplant recipients and assess how changes in EBV load
relate to immunosuppressive therapy and clinical status.
The primers and conditions for the Bam HI W and P-Globin PCRs have been
published previously (Wagner et al 1988, Saiki et al 1985). However it was
important to optimise PCR reaction conditions.
4.1.1 Optimisation of Bam W and p-Globin PCR conditions
The reaction conditions of each PCR were standardised to ensure optimal
sensitivity and specificity of detection. It was also necessary to demonstrate that
product band intensity was proportional to starting target concentration to provide a
semi-quantitative assessment of EBV load in the samples tested. This was achieved
through determining the cycle number which gave maximum product in a linear
relationship to the target concentration.
4.1.1.1 Optimisation of MgCI2 concentration
MgCE is required for enzymatic function of Taq polymerase and varying its
concentration alters product yield (Linz et al 1990).
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1 (j.g ofDNA from a Namalwa dilution series (Materials and Methods section
3.1.5) was used in PCR reactions to determine the optimal MgCl2 concentration as
described in Materials and Methods Section 3.3.1.6. Four MgCl2 concentrations were
tested; ImM, 1.5mM, 2mM and 2.5mM under identical reaction conditions. For
optimisation of Bam HI W PCR MgCb concentration, each Namalwa dilution was
tested at each MgCE concentration to establish how MgCl2 concentration affected
reaction sensitivity (Figure 4-la and b). For the p-Globin PCR, DNA from a single
Namalwa dilution (1000 genomes/106 genomes) was used in triplicate at each MgCE
concentration (Figure 4-2). The optimal MgC^ concentration for Bam HI W PCR
was taken to be that which gave the clearest most intense band in autoradiographs
and detected the lowest concentration of EBV. A graph of Bam HI W PCR
autoradiograph band volume against EBV genome copy number with each MgCE
concentration is presented in Figure 4-3. A bar chart showing mean autoradiograph
band volume from replicates of P-globin PCRs at each MgCE concentration is shown
in Figure 4-4. From these graphs the optimal MgCE concentration for Bam HI W
and P-Globin PCRs were 1.5mM and ImM respectively.
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Figure 4-1 a & b. Bam H1 W PCR MgCI2 optimisation
Figures show autoradiographs of experiments to determine the optimal MgCl2
concentration for Bam HI W PCR. Samples from a Namalwa cell dilution series
7 7
containing 1 x 10 to 1 EBV genome in 1 x 10 cells was tested at MgCl2
concentrations of ImM, 1.5mM, 2mM and 2.5mM (Materials and Methods section
3.3.1.6). From this experiment, the optimal MgCl2 concentration was 1.5mM (lane B
at each Namalwa concentration).
Lane annotation: M: (j>X174 DNA digested with Hinfl. Fragment sizes: 726/ 713,
553, 500, 427/417/413,311,249, 200, 151, 140, 118, 100, 82.
dH20: control for contamination. Figures show EBV genome concentration, ranging
from 106 genomes/ 107 cells to 1 in 107. Each dilution was amplified under varying
MgC12 concentrations as shown: A: ImM MgCl2, B: 1.5mM MgCl2, C: 2mM
MgCl2, D: 2.5mM MgCl2.
Figure 4-la. Namalwa concentrations from 106 EBV genomes/107 cells to 104
genomes/107 cells
106 EBV
dH20 genomes/107 cells { q5/ 1Q7 { q4/ 1 Qi
M ABCDABCDABCDABCD
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Figure 4-lb. Namalwa dilutions from 103 EBV genomes/107 cells to 1 EBV genome
/10 cells. (Annotation as Figure 4-la).
103/ 107 102/ 107 10/ 107 1/107
ABCDABCDABCDABCD
^►P m *+ m m— m m m
Figure 4-2. p-globin PCR MgCI2 optimisation
Three replicate |3-Globin PCRs (Replicate 1, 2 and 3) were carried out on lpg
DNA from a single Namalwa dilution (10 EBV genomes/ 107 cells) at each MgCl2
concentration.
Lane annotation: M: Markers. (|>X174 DNA digested with Hinfl. dH20: Control for
contamination. BJAB: EBV negative cell control. A: ImM. B: 1.5mM. C: 2mM. D:
2.5mM MgCl2
Replicate 1 Replicate 2 Replicate 3
o 5 r A ^ r A ^ r A ^





Figure 4-3. Graph of Bam W MgCI2 PCR optimisation data
Graphs shows autoradiograph band volumes from Figures 4-1 and b plotted
against EBV genome copy number at each MgCl2 concentration tested. From this
graph, the MgCl2 concentration giving the most direct correlation between EBV
genome copy number and band volume is 1.5mM (green line).
EBV genome copy num ber (genom es/m illion cells)
Figure 4-4. Bar chart of [3-globin MgCI2 optimisation data
Chart shows the mean value from three replicates of each MgCl2















1 m M 1 .5 m M 2 m M 2.5mM
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4.1.1.2 Optimisation of annealing temperature
Primer annealing temperature is important in determining amplification
efficiency and specificity (Kocher & Wilson 1991). lpg DNA was amplified in a 35-
cycle reaction at the optimal MgCf concentration determined from the previous
experiments. Three different annealing temperatures were used, derived from the
calculated oligonucleotide melting temperature (Tm) (Materials and Methods section
3.3.1.6): Tm °C, Tm -5°C and Tm -10°C. The optimal annealing temperature was
determined by studying autoradiographs of PCR products and selecting the
temperature which gave the clearest, most intense bands and detection of the lowest
EBV genome concentration. Autoradiographs from annealing temperature
optimisation experiments are shown in Figure 4-5. Graphs showing scanning
densitometry band volumes from these blots are shown in Figure 4-6. From these
experiments the optimal annealing temperature was 57°C for Bam W PCR and 54°C
for (3-Globin PCR.
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Figure 4-5. Bam W PCR annealing temperature optimisation
Bam HI W PCRs were performed on DNA from a Namalwa dilution series
under reaction conditions identical in all but annealing temperature. Three annealing
temperatures were used on DNA from each dilution, LCL and water controls as
indicated: A: 62°C, B: 57°C, C: 54°C. M: <|>X174 Hinfl
Figure 4-5a. Bam W PCR annealing temperature optimisation. Namalwa dilutions
107 EBV genomes/ 107 cells to 104 genomes/ 107 cells
t n
Namalwa dilution (EBV genomes/ 10 cells)
dHiO LCL 107 / 107 106/ 107 105/ 107 104/ 107
M ABCABCABCABCABCAB C
Figure 4-5b. Bam HI W PCR annealing temperature optimisation
Namalwa dilution (EBV genomes/107 cells)
io3/ io7 102/ 107 10/107 1/ io7
M AB CAB CAB CAB C
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Figure 4-6. Graph of Bam H1 W PCR annealing temperature
optimisation
Graph of autoradiograph band volume plotted against EBV genome copy
number at three annealing temperatures. An annealing temperature of 57°C (green
line on graph) was selected because this gave the best sigmoid curve of the three
tested temperatures and greatest sensitivity, yet produced no non-specific bands
unlike when using 52°C (Figure 4-5).
EBV genome copy number (genomes / million cells)
Figure 4-7. Graph of autoradiograph band volume with differing PCR
cycle number
PCR cycle number
28 cycles was chosen as optimal for both Bam W and (5-globin PCRs as it gave the
highest product yield within the exponential phase of the reaction profile (indicated
on the graph by the black line).
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4.1.1.3 Optimisation of PCR cycle number
The reaction kinetics of PCR follow a sigmoid curve whereby the amount of
product increases exponentially with each cycle until the depletion of reagents or
accumulation of inhibitors leads to tailing off of the reaction profile. For PCR to be
quantitative the concentration of measurable product must be proportional to the
concentration of target molecule at the beginning of the reaction. Thus the reaction
must be halted during the exponential phase of the reaction when production of
amplimers is proportional to the amount of starting material. Since sensitivity of the
reaction is also important it is necessary to select the highest cycle number which
remains in the exponential phase of the reaction to give maximum product yield
while retaining proportionality to target concentration.
Bam W and p-globin PCR reactions were performed under optimised
reaction conditions on eleven identical samples containing lpg DNA from a dilution
• T f\
ofNamalwa cells in a background of EBV negative cells (1x10 EBV genomes/10
cells) since this dilution gave intermediate band intensity. A sample was removed
from the PCR machine after each complete PCR cycle between 20 and 30 cycles.
Following electrophoresis, autoradiography (Figure 4-7a and b for Bam W and P-
globin PCR respectively) and scanning densitometry, band intensity was plotted
against cycle number (Figure 4-8a and b). For both Bam W and p-Globin PCRs, 28
cycles gave maximum band intensity in the exponential phase of amplification and
was therefore used in all subsequent experiments.
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Figure 4-8. Bam H1W and p-Globin PCR cycle number optimisation
Figure 4-8a. Bam W PCR cycle number optimisation
Autoradiographs of Bam HI W PCR on Namalwa dilution DNA (103 EBV
genomes/ 107 cells) amplified for between 20 and 30 cycles as indicated.
Controls: M: <j)X174 Hinfl. 1. dH20: Water contamination control. 2. BJAB: EBV
negative BL cell line (Negative control). 3. LCL: Lymphoblastoid cell line (Positive
control)
Controls PCR cycle number
M 1 2 3 20 21 22 23 24 25 26 27 28 29 30
Figure 4-8b. p-Globin PCR cycle number optimisation
Lane annotation as for Figure 4-6a.
Controls PCR cycle number
M 1 3 20 21 22 23 24 25 26 27 28 29 30
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4.1.1.4 Effect of DNA concentration on Semi-quantitative PCR
To ensure the accuracy of semi-quantitative PCR it is important to
demonstrate that variation in target DNA concentration is reflected in the amount of
detectable amplified product. Differences in the amount of target DNA incorporated
in PCR reactions may be caused by errors in spectrophotometry, DNA dilution or
inaccuracy in aliquoting samples for PCR. An experiment to investigate the
correlation between the quantity of DNA incorporated in Bam HI W and p-Globin
PCRs was carried out using Namalwa DNA which had been serially diluted two-fold
in sterile water. Autoradiographs of Southern blots obtained from these experiments
are shown in Figures 4-9a and b and graphs of autoradiograph band volume plotted
against DNA concentration from Bam W and P-Globin PCRs are shown in Figures
4-10 and 4-11 respectively.
The results of this experiment show that autoradiograph band volume using
both Bam W and P-Globin PCRs increases in direct proportion to the amount of
template DNA included in the reaction. P-globin PCR can therefore be used to
estimate the amount of template DNA added at the start of a PCR reaction to allow
adjustment of Bam W band volume for differences in DNA concentration between
samples.
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Figure 4-9. Effect of DNA concentration on Bam H1 W and (3-Globin PCR
Autoradiography of Southern blots generated following Bam HI W and (3-
Globin PCR on a two-fold dilution series in dHaO made from Namalwa DNA (103
EBV genomes/ 107 PBMs). The amount of DNA in each dilution was 1 pg, 0.5 pg,
0.25pg, 0.125pg, 0.06pg and 0.03pg.
M: Marker: ())X 174 Hinfl digested. dH20: water control. BJAB: EBV negative cell
control. B95-8: EBV positive cell control






































































4.1.2 EBV genome copy number in control and clinical samples:
4.1.2.1 Normal Healthy individuals
A control PCR was performed alongside clinical samples to provide a
standard curve of EBV genome copy number against autoradiograph band volume,
which detected 1 EBV genome/106 PBMs (Figure 4-12). EBV semi-quantitative PCR
was performed on PBMs from thirty-six healthy EBV seropositive and three
seronegative adults. Representative autoradiographs of Bam W and P-globin PCRs
are shown in Figures 4-13a and b respectively and results for all normal healthy
individuals are presented in Table 4-1.
EBV DNA was detected in PBMs from 20 of 36 EBV seropositives (55.6%)
with EBV loads ranging from 1 to 200 EBV genomes/ 106 PBMs. The 16 samples in
which EBV was not detected (44.4%) were described as containing less than 1 copy
of the EBV genome per 106 PBMs, below the limit of sensitivity of the PCR used.
The overall median of EBV copy number in EBV seropositive individuals is 1 EBV
genome/106 PBMs. The interquartile range of EBV load was calculated as 1-40 EBV
genomes/106 PBMs, providing a measure of the central range of EBV load between
25% and 75% of the maximum. No EBV DNA was detected in the three EBV
seronegative samples tested.
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Figure 4-12a-c. Semi-quantitative EBV DNA PCR on Namalwa dilution
series
Figure 4-12a. Bam W PCR on Namalwa dilution series
Namalwa dilution: EBV genomes/106 cells
0 1 10 102 103 104 105 106
Figure 4-12b. p-Globin PCR on Namalwa dilution series
Namalwa dilution: EBV genomes/ 106 cells
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Figure 4-12c. Standard curve of Bam W autoradiograph band volume
with Namalwa dilution
EBV copy number was plotted against autoradiograph band volume for Bam W
PCR on Namalwa dilution series. This standard curve was used for calculation
ofEBV genome copy number in clinical samples.
Band Volume
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Figure 4-13a & b . Bam W & p-Globin PCR on PBM DNA from normal
EBV seropositive adults
Semi-quantitative PCR was performed on DNA from single PBM samples from 36
healthy adults. Figures show autoradiographs obtained following PCR on 10
representative samples.
Figure 4-13a. Bam W PCR
Normal EBV seropositive patient number
O °?
no
^ S 123456789 10
Figure 4-13b. (3-globin PCR
q pq oo Normal EBV seropositive patient number
EC o\ s
M -T3 mm 123456789 10
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Table 4-1. EBV copy number in normal healthy adult EBV seropositives












































Median EBV copy number =1 genome/ 106 PBMs.
Interquartile range=l-40 EBV genomes/106 PBMs
Table 4-2. EBV genome copy number in EBV seronegative adults




4.1.2.2 Multiple samples from normal healthy individuals
To assess whether EBV load in an individual fluctuates over time, EBV
quantitation was carried out on multiple samples taken over a two year period from
five normal healthy EBV seropositive adults. Autoradiographs of P-globin and Bam
W PCRs from serial samples from three patients are shown in Figures 4-14a and b
respectively, and the results summarised in Table 4-3.
The results show that EBV load remains consistently within the range
detected in single samples from normal EBV seropositives of between <1 to 200
EBV genomes/106 PBMs (Table 4-1) over extended periods of time.
Figure 4-14a. p-Globin PCR on serial samples from normal EBV
seropositives.
03
J; Subject 2 Subject 4 Subject 5
CO & a.
9) < B f ' r ^ ^
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4.1.2.3 EBV copy number acute infectious mononucleosis (IM)
EBV semi-quantitative PCR was performed on DNA extracted from PBMs
from 30 adults undergoing primary infection with EBV with acute IM aged between
17 and 34 years (mean 21.4 years). 40% of the patients tested were male, 60%
female. Patients reported suffering from symptoms typical of IM including malaise
and sore throat for periods ranging between two days and three months (mean 23
days) before visiting their general practitioner when blood samples were taken for
serological diagnosis and to provide PBMs for this study. Patients were diagnosed as
having acute IM if anti-VCA IgM antibodies were detected and the sample was
monospot positive. Only single samples were available for testing from each patient.
Representative autoradiographs of Bam W and P-Globin PCRs are shown in Figure
4-15a and b, and the results are presented in Table 4-4.
EBV DNA was detected in 27 of the 30 samples tested (90%) with a PCR
sensitivity of 10 EBV genomes/106 PBMs. The EBV copy number detected in
patients with acute IM ranged between undetectable (<10 genomes/106 PBMs) to 1 x
106 genomes/106 PBM. Median EBV load in acute IM was 1 x 104 genomes/106
PBMs (mean= 5.8 x 104 genomes/106 PBMs. Interquartile range= 40-1.5 x 104
genomes/106 PBMs). EBV load in patients with IM is significantly higher than that
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in normal EBV seropositive adults (p=0.001 by Mann Whitney U test). There was no
correlation between EBV load and duration of symptoms of IM as reported to GPs
(p=0.7 by Spearman's correlation), indicating that early acute disease is not
associated with higher EBV load and patients with extended illness did not show
signs of reduced EBV load.
Table 4-3. Temporal changes in EBV copy number in normal adults
| Subject Time of sample (days
after first)
EBV copy number * Mean EBV copy
number*
























* EBV copy number in genomes/10 PBMs. n/d: not detected
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Table 4-4. Clinical details and EBV genome copy number in PBMs from
patients with infectious mononucleosis.
Patient Age Sex Duration of EBV copy number
number (Years) symptoms prior
to sample (Days)
(genomes/106 PBMs)
1 20 M 4 4 x 10"
2 21 M n/a 3x 10'
3 24 M 4 550
4 34 F 21 200
5 17 F 2 650
6 20 M 4 200
7 22 F 2 350
8 29 M 14 <10
9 23 M 7 1 x 10"
10 18 F 14 600
11 20 F 18 30
12 21 F 18 40
13 21 F 2 200
14 19 F 90 2.75 x 10J
15 22 F 14 60
16 19 F 90 <10
17 19 M 14 <10
18 25 F 3 60
19 23 M 60 1
20 20 F 39 200
21 21 F 30 1
22 19 F 90 1
23 19 F 14 200
24 22 F 14 1.75 x 10J
25 26 M 21 600
26 19 F 30 10
27 22 M 7 1.7 x 104
28 19 M 60 6 x 10J
29 21 M 14 1.5 x 10J
30 21 F 4 1 x 10J
Total 17 to 34 40% M 2 days to 3 months Range: <10 to 1 x 10"
n=30 Mean= 21.4 60% F Mean= 23 days Median= 1 x 104
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4.1.2.4 EBV genome copy number in PBMs from patients with PTLD
EBV genome copy number was determined in PBM samples from 15
transplant recipients with EBV positive PTLD. Results and patient details are shown
in Table 4-5 and a representative Bam W PCR autoradiograph shown in Figure 4-16.
Twelve cases of PTLD occurred following kidney transplant, two in liver
transplants and one heart transplant. The samples were taken at the time of PTLD
diagnosis, occurring between 60 days and 16 years post-transplant (Mean=4.76
years). EBV copy number detected in PBMs from patients with PTLD ranged from
400 to 1 x 106 EBV genomes/106 PBMs (median=l x 104 genomes/106 PBMs.
Interquartile range=3500-l x 106 genomes/106 PBMs).
Figure 4-16a. Bam W PCR on PBM DNA from patients with PTLD
% PTLD Sample
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Figure 4-16b. p-globin PCR on PBMs from patients with PTLD
PTLD Sample
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1 Kidney MM 1924 27 000
2 Kidney IB 1297 60 000
3 Kidney PH 539 7 000
4 Kidney n/a 2245 2 250
5 Kidney IB 1989 30 000
6 Kidney n/a 2950 10 000
7 Kidney G-LN 74 400
8 Kidney IB 5879 100 000
9 Kidney IB 3137 600
10 Kidney IB 246 5 000
11 Kidney IB 267 1 000 000
12 Kidney IB 754 15 000
13 Heart IB 217 50 000
14 Liver IB 60 3 300
15 Liver IB 496 3 800




Kidney 12 1775 104 770
Heart 1 217 50 000




Median= 1 x 104 genomes/
106PBMs
Interquartile range=3500 - 1
x 106genomes/106 PBMs
PTLD diagnosis key: MM= multiple myeloma. IB=immunoblastic lymphoma.
PH= plasmacytic hyperplasia. G-LN=granulomatous lymphadenopathy.
n/a= not available.
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4.1.2.5 EBV genome copy number in PBMs from cardiothoracic
transplant recipients
This study was designed to investigate the progression of EBV infection in
cardiothoracic transplant recipients. Between January 1995 and November 1999 132
patients preparing to undergo heart, lung or combined heart and lung transplantation
were recruited for this study from Harefield Hospital, Middlesex. A heparinised
blood sample was taken, providing a 'pre-transplant' sample for analysis. Following
transplantation, blood samples were taken at intervals on outpatient visits and
patients were followed up where possible for the entire duration of the study. Patients
were lost to follow up through death, or through no longer attending outpatient
clinics at Harefield Hospital. Up to thirteen samples were obtained from each patient
(mean of 5 samples) with a follow up time of up to 1110 days from the date of
transplant (mean 415 days).
4.1.2.5.1 Pre-transplant samples
EBV genome copy number was assessed in PBMs isolated from 132 patients
immediately prior to surgery for heart, lung or combined heart and lung
transplantation (aged 20.3 to 71.2 years, median 47.2 years, 64% male, 36% female).
Twelve of these patients had their transplants cancelled and were therefore not
followed up, but their 'pre-transplant' EBV copy number data is included. Patient
details and pre-transplant EBV copy number is summarised in Table 4-6.
EBV DNA was detected in pre-transplant samples from 85 of 132 patients
tested (64.4%) with EBV genome copy number ranging from 1 to 200 EBV
genomes/ 106 PBMs. EBV DNA was not detected in the remaining 47 patients
(35.6%) indicating an EBV copy number of <1 genome/ 106 PBMs. The overall
median EBV load was 5 EBV genomes/106 PBMs. There was no significant
difference in pre-transplant EBV load according to transplant type.
Three transplant recipients were EBV seronegative pre-transplant, but all
seroconverted by the time their first post-transplant sample was obtained. The source
of infecting virus was not determined.
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Totals 132 17.34 - 71.2
Median= 47.10
years
64 36 0-2 00
Median=5
4.1.2.5.2 EBV genome copy number following transplantation
EBV DNA quantitation was performed on samples taken at intervals
following organ transplantation from 96 patients. Patients were followed for up to
1110 days after transplantation with between one and thirteen post-transplant
samples obtained from individual patients (median of 5 samples per patient). DNA
extracted from PBMs was subjected to EBV semi-quantitative PCR analysis. This
data is summarised in Table 4-7. Southern blots showing EBV detection in serial
samples from two representative patients (an EBV seropositive and an EBV
seronegative who seroconverted following transplantation) are shown in Figures 4-17
to 4-20.
EBV DNA was detected in at least one post-transplant sample from 84 of the
96 patients tested (87.5%). Post-transplant EBV copy number ranged from
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undetectable (<1 genome/106 PBMs) to 1 x 105 genomes/106 PBMs (mean=1092
genomes/106 PBMs, median=10 genomes/106 PBMs). In individual patients, the
highest EBV copy number was detected between 1 day and 755 days post-transplant.
EBV load exceeded the range detected in normal EBV positive donors in at least one
post-transplant sample from 44 transplant recipients (46%). In 12 patients (13%)
EBV load reached levels equivalent to PTLD (3500- 1 x 106 genomes/106 PBMs)
and in 32 (33%) patients EBV load reached levels equivalent to patients with IM (40-
1.5 x 104 genomes/106 PBMs). EBV load remained in the range detected in normal
individuals (<1-40 EBV genomes/106 PBMs) in 52 transplant recipients (54%).
The 12 patients with EBV loads equivalent to that in PTLD were 8 males, 4
females aged 17-60 years (mean 43 years). Two received lung transplants, 6 heart
transplants and 4 combined heart/lung. The highest EBV load (1 x 103 genomes/106
PBMs) was detected in a 17 year-old EBV seronegative patient given combined
heart/lung transplant for cystic fibrosis. Her first post-transplant sample was taken 9
months after surgery, by which time she had seroconverted for EBV, with an EBV
copy number of 50 genomes/106 PBMs. The source of EBV infection is not known,
although EBV DNA was not detected in archival spleen tissue from the 11-year-old
organ donor. The patient's EBV copy number fluctuated (Figure 4-20) but showed a
general increase to reach a maximal level of 1 x 105 genomes/106 PBMs by 1 year
post-transplant, with the same level of EBV load detected in 2 of 3 further samples
taken up to 18 months post-transplant when the patient died from chronic graft
rejection and organ failure. EBV load increased to this maximum level following
switching of the principal immunosuppression from cyclosporin to FK506. There
was no evidence of PTLD in this patient despite detection of EBV load within the
range in patients with PTLD. Autoradiographs of Bam W and (3-globin PCRs and a
graph of changes in post-transplant EBV load and drug dose are shown in Figures 4-
19 and 4-20.
Underlying factors were investigated using Spearman's correlation to
determine associations with whether EBV loads in transplant recipients reached
levels equivalent to those seen in IM or PTLD. There was no association with age
(p=0.327), sex (p=0.532) or transplanted organ (p=0.821).
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60 40 <1 to 1 x 105
Median= 10
Heart and lung 23 17.34-47.72
Median= 33.79
80 20 <1 to 1 x 105
Median = 17.5
Total 96 17.34 - 65.36
Median= 46.80
66 34 0 to 1 x 10s
Median= 12
Figure 4-17a & b. Bam W and p-Globin PCR on serial samples from an
EBV seropositive cardiothoracic transplant recipient.
Samples shown in these blots include the Pre-transplant sample (Pre-Tx) and
subsequent samples obtained following transplantation (labelled .1 to .12). A graph
ofEBV load in these samples and its change over time is shown in Figure 4-18.
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Figure 4-17b. p-Globin PCR
Blood Samples
H
M ® 3 (X .1 .2 .3 .4 .5 .6 .7 .8 .9 .10 .11 .12
Figure 4-18. Graph of EBV load and immunosuppressive drug dose in
an EBV seropositive transplant recipient.
EBV load (logio of EBV genome copy number/ 106 PBMs) and levels of cyclosporin
(CsA) and prednisolone plotted against time in serial samples from an EBV
seropositive transplant recipient (EBV load data derived from autoradiographs
presented in Figure 4-17a & b).
Days post-transplant
Key:




Figure 4-19. Bam H1 W and {3-Globin PCR on serial samples from an
EBV seronegative cardiothoracic transplant recipient.
Autoradiographs of Bam HI W and |3-Globin PCR on serial samples from a patient
who was EBV seronegative pre-transplant, and seroconverted following
transplantation. Samples included were taken pre-transplant (Pre-Tx) and at intervals
post transplant (samples .1 to .10). A graph of EBV load and drug dose in these
samples is shown in Figure 4-20.
Figure 4-19a. Bam H1 W PCR.
A positive control was included in the PCR reaction, but was not run on the gel from
which this blot was derived. Bl00d Samples
Figure 4-19b. p-globin PCR. Blood Samples
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Figure 4-20. Graph of EBV load and immunosuppressive drug dose in
an EBV seronegative transplant recipient.
EBV load (logio ofEBV genome copy number/106 PBMs) and levels ofcyclosporin
(CsA), Methylprednisolone (Mpred) and FK506 plotted against time in serial
samples from an EBV seronegative transplant recipient (EBV load data derived from
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4.1.3 Statistical analysis of EBV quantitation data
The results ofEBV quantitation in control groups (normal EBV seropositives
and patients with IM and PTLD) and patients undergoing transplantation were
analysed to identify statistical differences between these groups. Results of these
analyses are presented in this section.
4.1.3.1 EBV load pre-transplant in patients awaiting cardiothoracic
transplantation
EBV load in patients awaiting transplantation were compared on the basis of
sex, age and organ to be transplanted, using the Mann Whitney U test to compare the
median values of pairs of groups (Table 4-8). There was no significant difference
between each transplant type in pre-transplant EBV load (p>0.5). There was no
significant difference in the distribution of patient age, sex or EBV load in different
transplant groups by the Kruskall-Wallace test, shown in Table 4-9. The Kruskall-
Wallace test is a non-parametric test to determine whether several independent
samples have the same distribution.
Table 4-8. Comparison of EBV load in pre-transplant samples using




Lung : Heart p = 0.649
Heart: Heart and lung p = 0.972
Lung : Heart and lung p = 0.724
EBV load was compared between patients with different transplanted organs using
the Mann Whitney U test. EBV load in each group is shown in Table 4-6.
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Table 4-9. Results of Kruskall-Wallace test on overall distribution of






EBV load pre-transplant p-0.895 p = 0.465 p = 0.459
Patients receiving different organ transplant types were compared on the basis of pre-
transplant EBV load, sex and age at transplant. There was no significant difference in
these factors with different transplant types.
4.1.3.2 Comparison of EBV copy number in normal controls, patients
with IM, patients with PTLD and pre- and post-transplant
samples.
To assess the overall distribution of EBV load in transplant recipients and
patients with EBV-associated diseases, Mann-Whitney U tests were used to compare
the medians ofEBV copy number between patient groups. Results are summarised in
Table 4-10. EBV load in patients awaiting transplantation is equivalent to that in
normal EBV seropositives (p=0.542), demonstrating that overall, EBV load in
transplant recipients is within the normal range prior to surgery. EBV load in PBMs
from patients with PTLD is significantly higher than that in patients with IM
(p<0.001). However there is overlap in the range of EBV load detected in patients
with IM and PTLD, demonstrating the difficulty in distinguishing between the two
diseases on the basis of EBV load. EBV load in IM and PTLD is significantly higher
than in normal EBV carriers and patients awaiting transplantation (p< 0.001 for all
tests). Therefore EBV associated disease is associated with significantly increased
EBV load. In post-transplant samples, EBV load in individual patients ranged from 5
to 1 x 106 EBV genomes/ 106 PBMs (median of EBV load in all post-transplant
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samples = 10 EBV genomes/ 106 PBMs, mean= 1319 genomes/ 106 PBMs), and
overall showed a highly significant difference from pre-transplant levels (p<0.001).
The number of transplant recipients with EBV loads in the interquartile range
detected in EBV associated diseases is shown in Table 4-11. In 18 transplant
recipients, the pre-transplant EBV load was within the interquartile range detected in
patients with IM. However, the highest EBV load detected pre-transplant was 200
genomes/106 PBMs, a level detected in normal donors. Post-transplant, 12 patients
(14%) had EBV loads within the range detected in patients with PTLD and levels
equivalent to IM in 34 patients (40%). In 38 patients (45%) EBV loads remained in
the range detected in normal healthy carriers.
Using linear regression analysis there was a significant association between
EBV copy number and time post-transplant (p=0.013). A scatter plot of EBV load
against time for all samples, both pre- and post-transplant, is shown in Figure 4-21
showing a positive correlation between time post-transplant and EBV load
(Pearsons' correlation coefficient r= 0.521).
Table 4-10. Comparison of distribution of EBV copy number between
patient groups.
Table shows the results of Mann-Whitney U tests to compare EBV load pre- and
post-transplant with the levels detected in controls and patients with EBV associated
disease. Pre- and post transplant EBV loads assessed were the combined values for







(comparison of columns 1 & 2)
Pre-transplant 0-200 (3) Post-transplant 0-1 x 103 (10) P0.001
Normals 0-200(1) P=0.542
IM 0-1 x 10° (1 x 104) P=0.001
PTLD P=0.001
Post-transplant 0- 103 (10) Normals 0-200 (1) P0.001
IM 0-1 x 10° (1 x 104) P0.001
PTLD 400-1 x 10° (1 x 104) P0.001
IM 0-1 x 10° (1 x 104) PTLD 400-1 x 10° (1 x 104) P=0.001
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Table 4-11. Transplant recipients with EBV copy number equivalent to
that in EBV associated conditions
Table shows the number and percentage of transplant recipients with at least
one sample having an EBV load within the interquartile range determined for other
patient and control groups.
Range and interquartile range ofEBV load in control groups.
Number and % of transplant recipients with EBV load within the same























64 (78%) 18 (22%) 0
Post-transplant
(0- 1 x 105EBV
genomes/106 PBMs)
38 (45.2%) 34 (40.5%) 12 (14.3%)
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Figure 4-21. Scatter plot of EBV genome copy number against sample
date for all post-transplant samples
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4.1.3.3 Influence of immunosuppression on EBV copy number
The influence of iatrogenic immunosuppression on EBV load in transplant
recipients was investigated by assessing associations between EBV load and dose of
immunosuppressive drugs received by patients in the month prior to taking blood
samples for quantitative EBV PCR. Also the cumulative dose of each drug was
assessed, that is the total dose received prior to sampling. The agents studied were
cyclosporin A, azathioprine, prednisolone, methylprednisolone and FK506. These
results are presented in Table 4-12.
Significant associations were found between mean daily dose of cyclosporin
and increased EBV load when analysed by linear regression (p=0.001). Therefore
increased dose of cyclosporin is associated with, and in part may be responsible for,
increased EBV copy number following transplantation. There were also significant
correlations between increased cumulative dose of cyclosporin, azathioprine and
prednisolone and increased EBV load (p= 0.021, 0.003 and 0.002 respectively by
linear regression analysis). This indicates that increased duration of exposure to the
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standard immunosuppression regime is associated with increased EBV load, and
confirms the data shown in Figure 4-21, whereby EBV load shows an increase with
time post-transplant.
No significant associations were found using analysis of variance (ANOVA)
of EBV load when drug doses were categorized as high, moderate or low, based on
the interquartile range of doses. The two patients with the highest post-transplant
EBV loads were both treated with FK506, but there was no significant association
between EBV load and FK506 dose.
Table 4-12. Association between immunosuppressive drug dose and
EBV genome copy number
Drug doses categorized from the interquartile range. Cumulative drug doses and associated EBV loads
are not shown. Significant associations using linear regression analysis of continuous variables of
EBV and drug dose are asterisked.































































4.2 Analysis of EBVgene expression by RT-PCR
Having shown that EBV load is significantly elevated post-transplant further
experiments were carried out to determine whether this was due to lytic replication of
EBV or expansion of B-lymphoblasts. This was done to establish whether the pattern
of EBV gene expression in PBMs following organ transplantation could predict
PTLD development.
cDNA derived from PBMs and tumour biopsies was analysed by PCR to
amplify transcripts from the human P-actin gene and the EBV genes EBER1, LMP1,
LMP2a/b, gp350 and EBNA3C. These PCR reactions were selected to provide an
overall assessment of the pattern of EBV gene expression in a given sample, that is,
detection of EBV gene expression (EBER1); latent membrane protein expression
(LMP1, LMP2a and b); lytic replication (gp350), and full LCL-like latent antigen
expression (EBNA 3c). As described in the introduction, three basic patterns ofEBV
gene expression were described by Rowe et al (1992), termed Latency I, Latency II
and Latency III which are associated with distinct cell phenotypes in EBV infected
cell lines and particular EBV associated diseases in vivo. EBERs transcripts are
detected in all forms of EBV latency described. To summarise, Latency I is
characterized by EBNA1 expression in the absence of other EBV latent genes and
lytic replication and is seen in Burkitt's lymphoma tumour cells in vivo and at early
passage in vitro. Latency II involves expression of EBNA1 in the absence of the
other EBNAs, expression of LMP1 and sometimes LMP 2a and 2b but no lytic
replication. Latency II is seen in nasopharyngeal carcinoma tumour cells. Latency III
is characterized by expression of all latent antigens; that is EBNAs 1, 2, 3a, 3b and
3c, EBNA-LP, LMP1, 2a and 2b. This pattern is seen in immunoblastic PTLD
tumour cells and in LCLs in vitro. In this study the terms Latency I, II and III are
used to compare patterns of EBV gene expression to forms of EBV latency
previously described. Detection of EBNA3c mRNA is taken as indicative of Latency
III, since the EBNA transcripts are transcribed together from a single promoter.
Detection of gp350 transcripts is taken to indicate EBV replication since this late
lytic transcript is only expressed in cell undergoing productive infection.
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4.2.1 Optimisation of RT-PCR conditions
The reaction conditions of each PCR were standardised to ensure optimal
sensitivity and specificity of detection. Primer and probe sequences were derived
from previously published sources or were designed for this study from the B95-8
prototype EBV sequence. Sequences are shown in Materials and Methods Table 3-2.
Reaction conditions were optimised for MgCl2 concentration and annealing
temperature (Materials and Methods 3.8.1.6), and in the case of (3-actin, for cycle
number to provide a semi-quantitative assessment of the amount of amplifiable RNA
present in a sample. Optimised reaction conditions are summarised in Table 4-13.
The sensitivity of each PCR was demonstrated through amplification of
cDNA generated from RNA from a B95-8 dilution series. Specificity of each PCR
was confirmed by PCR of cDNA generated from total cellular RNA extracted from
EBV infected control cell lines and tumour material which exhibit a known
characteristic pattern of EBV gene expression: cl9, M148 and IB4. Representative
autoradiographs of RT-PCRs showing the sensitivity and specificity of each reaction
are shown in Figure 4-22. Nested RT-PCRs to amplify mRNA encoding EBERs,
LMP1, LMP2a, LMP2b and EBNA3c detect transcripts in as few as 100 B95-8 cells
in a background of 106 EBV negative cells. RT-PCR to detect the EBV lytic
transcript gp350 detects transcripts in 10 B59-8 cells in 106 EBV negative cells.
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Table 4-13 Summary of optimal MgCI2 concentration and annealing








EBNA 3c 1st Round 1.5mM 50°C
EBNA 3c Nested 1.5mM 56°C
LMP1 1st Round lmM 55 °C
LMP1 Nested 1.5mM 64 °C
LMP2a 1st Round 1.5mM 51 °C
LMP2a Nested lmM 58 °C
LMP2b 1st Round 2mM 52 °C
LMP2b Nested lmM 58 °C
gp350 3mM 53 °C
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Figure 4-22 Southern blots demonstrating sensitivity and specificity of
RT-PCR reactions
PCRs were performed on RNA from a dilution series of B95-8 with appropriate
positive and negative control cells. The following controls were included in each
PCR although individual blots for each PCR may not show all controls.
Lane annotation:
dH20: water control, dHzO N: nested PCR water control (taken from 1st round product)
BJAB: EBV negative BL cell line. M148: EBV positive BL cell line:
CI9: EBV positive NPC cell line. IB4: EBV positive BL cell line
B95-8: EBV positive LCL
Dilutions: U: undiluted. -1: 10s B95-8/ 106 cells. —2: 104/ 106. -3: 103/ 106.
-4: 102/ 10s. -5: 10/ 106. -6: 1/ 106.
4-22a EBERs PCR B95-8 Dilution Series
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4-22b LMP1 Nested PCR
B95-8 Dilution Series
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4-22f. EBNA 3c Nested PCR
B95-8 Dilution Series
4.2.2 EBV gene expression in normal healthy donors
RNA was extracted from PBMs isolated from heparinised blood from 36
normal healthy EBV seropositive adults and 3 EBV seronegatives. cDNA was
generated as described in Materials and Methods section 3.3.1.4 from lpg RNA and
P-actin PCR performed on all samples to confirm that amplifiable cDNA was present
(Figure 4-23a). RT-PCR for detection of EBV encoded transcripts were performed
on p-actin positive RNA from all 36 donors to determine the pattern of EBV gene
expression in PBMs from these individuals. Autoradiographs showing representative
PCR analysis of each transcript are shown in Figures 4-23a to g and data for all
normal donors is summarized in Table 4-14.
P-Actin mRNA was detected in the absence of any detectable EBV transcripts
in 7 normal EBV seropositives. EBERs transcripts were detected in 28 of 36 samples
(77.8%). EBERs encoding transcripts were the only EBV transcripts detected in 6
subjects. LMP2a-encoding transcripts were detected with EBERs in 20 subjects and
LMP2a and b were detected in the same sample from 3 subjects. LMP1, EBNA3c or
gp350 mRNAs were not detected.
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Table 4-14. Summary of EBV gene expression in normal EBV
seropositive and seronegative individuals
Sample no. Actin EBER1 LMP1 LMP2a LMP2b gp350 EBNA3c
I + - - - - - -
2 + + - - - - -
3 + + - + - - -
4 + + - + + - -
5 + + - - - - -
6 + + - - - - -
7 + + - + - - -
8 + + - - - - -
9 + + - + - - -
10 + + - + - - -
11 + + - + - - -
12 + + - + - - -
13 + + - + - - -
14 + + - + - - -
15 + + - + - - -
16 + + - + - - -
17 + + - + + - -
18 + + - + - - -
19 + + - + - - -
20 + + - + - - -
21 + + - - - - -
22 + + - + - - -
23 + + - + - - -
24 + - - - - - -
25 + + - - - - -
26 + - - - - - -
27 + + - + - - -
28 + - - - - - -
29 + + - + - - -
30 + + - + + - -
31 + - - - - - -
32 + + - + - - -
33 + - - - - - -
34 + + - + - - -
35 + + - + - - -
36 + - - - - - -
EBV sero+ve
(n=36)
36 28 0 23 3 0 0
EBV sero-ve
(n=3)
3 0 0 0 0 0 0
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Figure 4-23. RT-PCR on PBM RNA from normal EBV seropositives
4-23a. p-actin PCR
m oo Sample number
< ^ ^



















23 45678 9 10
182bp
4-23d. LMP2a nested PCR
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4.2.3 EBVgene expression in infectious mononucleosis (IM)
RT-PCR was carried out on cDNA from PBMs from 40 patients with acute
IM to determine the pattern of EBV gene expression in these individuals.
Autoradiographs of PCRs on representative samples for each transcript are shown in
Figure 4-24a to g and data for all patients with IM is summarised in Table 4-15a and
b.
EBERs encoding transcripts were detected in 19 of 28 human (3-actin positive
IM samples tested patients (67.9%). EBERs were the only EBV transcripts detected
in 6 patients (21.4%). LMP2a was detected in 1 patient and LMP2a with LMP2b
detected in another individual. EBNA3c transcripts were detected in 2 patients (7%)
and EBNA3c with gp350 was detected in 4 patients (14.3%). In 5 patients (18%),
gp350 was detected in the absence of EBNA3c mRNA. These combinations of EBV
gene expression contrast with the pattern ofEBV gene expression detected in normal
EBV positive individuals, where no LMP1, EBNA3c or gp350-encoding transcripts
were detected.
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Figure 4-24. RT-PCR on RNA from PBMs from patients with IM
4-24a. p-actin PCR
IM Sample Number
O 5 ^ _
M ? m 123456789 10 11 12
4-24b. EBERs PCR
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4-24c. LMP1 nested PCR
4-24d. LMP2a nested PCR
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4-24e. LMP2b nested PCR
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4-24g. EBNA3c nested PCR
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Actin EBER1 LMP1 LMP2a LMP2b gp350 EBNA3c
1 + + - + - + -
2 + + - - - -
3 + + - + - -
4 + + - + + + +
5 + + - - - -
6 + - - - - " -
7 + + - - - + -
8 + + + + + + +
9 + - - - - -
10 + + - - - " -
11 + - - - - -
12 + - - - - " -
13 + - - - - -
14 + - - - - -
15 + + - - - " -
16 + - - - - -
17 + - - - - " -
18 + + - - - - -
19 + + + - - -
20 + + - - - - -
21 + + + + + + +
22 + + - - - + -
23 + + + + - + -
24 + - - - - -
25 + + + + + - +
26 + + - + + + -
27 + + - + + + +
28 + + - + + " +




(18%) (36%) (25%) (32%) (21%)
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4.2.4 EBV gene expression in PTLD tumours, PBMs from cases of
PTLD and SCID passaged tumourmaterial
RNA was extracted from PBMs from eleven transplant recipients with PTLD
and subjected to RT-PCR to detect human P-actin and EBV encoded transcripts.
RNA was extracted from tumour biopsy material from 6 patients with PTLD and
PBMs were also available from 3 of these patients. Tumour material from 5 patients
had been passaged in SCID mice (carried out by Dr I. Johannessen). Patient details
are shown in Table 4-16.
RT-PCR for detection of EBV encoded transcripts was performed on P-Actin
positive samples to determine the pattern of EBV gene expression. Autoradiographs
of PCRs for each transcript in representative samples are shown in Figure 4-25 and
data for all samples is summarised in Table 4-16.
In all six PTLD biopsy samples, EBV gene expression was equivalent to that
in LCLs, with detection of Latency Ill-like transcription (EBERs, EBNA3c, LMP1
and LMP2a and b) in addition to lytic replication (gp350). In tumours passaged in
SCID mice the same pattern of EBV gene expression was detected as in the biopsy
from which it was derived; that is latency III and lytic replication in all cases.
EBERs transcripts were detected in all 11 PBM samples from transplant
recipients with PTLD, but the pattern of EBV gene expression varied in different
patients (Table 4-16). In 10 of 11 samples (91%) LMP1, EBNA3c or gp350
transcripts were detected, transcripts which were not detected in normal healthy EBV
carriers. In PBMs from 5 patients with PTLD (patients 3, 6, 10, 14 and 15) EBNA3c
and gp350 transcripts were detected (latency III transcription with lytic replication).
The other 6 patients had more restricted patterns of EBV transcription with LMP1
only in 2 cases and LMP1 with lytic replication, and in 1 case each; LMP2a only,
LMP1 and LMP2a, and lytic replication with EBERs.
Where both PBMs and biopsy material were available (patients 1, 3 and 6)
two patients (patients 3 and 6) had identical EBV gene expression in PBMs and
biopsy material (Latency III plus lytic replication) but in patient 1 only LMP1 and
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gp350 were detected in PBMs while latency III and lytic replication was detected in
the corresponding biopsy material.
These results demonstrate that in PBMs from patients with PTLD, EBV
genes are expressed which are not detected in normal healthy EBV carriers (that is,
LMP1, EBNA3c and lytic replication).
In 6 patients both EBV genome copy number and EBV gene expression data
was available (patients 1, 3, 6, 9, 10 and 11). In 3 patients (patients 3, 6 and 10) with
Latency III plus lytic replication in RNA from PBMs, EBV copy number was 3.3 x
103, 5 x 104 and 1 x 104 EBV genomes/106 PBMs respectively. In 2 patients with
LMP1 detected in PBMs (9 and 12), the EBV genome copy number was 400 and
1250 genomes/106 PBMs respectively and in patient 1, in whom LMP1 and lytic
replication was detected, the EBV copy number was 2.7 x 104 genomes/106 PBMs.
The number of patients in this group is insufficient for statistical analysis, but it
appears that detection of Latency III and lytic replication in PBMs is associated with
high EBV load.
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4.2.5 EBV gene expression in PBMs from cardiothoracic transplant
recipients
Having shown that EBV load is significantly elevated post-transplant and in
PTLD, experiments were carried out to determine whether the pattern of EBV gene
expression in PBMs following transplantation could predict PTLD development.
These results were compared with those from normal donors and patients with IM or
PTLD.
cDNA generated from RNA extracted from PBMs was analysed by PCR to
amplify transcripts from the human P-actin gene and the EBV genes EBER1, LMP1,
LMP2a/b, gp350 and EBNA3c. Autoradiographs of PCRs on serial samples from a
representative patient are shown in Figure 4-26a-g.
Figure 4-26a-g. RT-PCR on serial samples from an EBV seropositive
cardiothoracic transplant recipient.
Sample numbers shown represent serial samples from a single transplant
recipient. Sample 1 was taken pre-transplant, and subsequent samples were taken
post-transplant.
Figure 4-26a. p-actin PCR
Sample number
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Figure 4-26b. EBER PCR
Sample number
O 5 °? ^^
M ^ ffl ffl 123456
Figure 4-26c. LMP1 nested PCR
Sample number
144
Figure 4-26d. LMP2a PCR
5 pq oo Sample number
^ <; ^ ^ * -
12345678 9 10
Figure 4-26e. LMP2b PCR
Sample number
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Figure 4-26f. EBNA3c PCR
Sample number
Figure 4-26g. gp350 PCR
^
„ oo Sample number
O ^ * ^
M -dpQffl 123456
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4.2.5.1 EBV gene expression in pre-transplant samples
Pre-transplant samples from 95 patients were initially screened for the
presence of amplifiable RNA using RT-PCR to detect human [l-actin transcripts. P-
actin RNA was detected in 77 of 95 samples (81.1%) and these samples were then
tested for EBERs mRNA. Since this highly expressed transcript is expected to be
present in all EBV infected cells, EBERs negative samples were eliminated from
further analysis. This approach was justified by the previous analysis of EBV
transcription in patients with IM (Table 4-15) in which LMP1, LMP2aJ b, gp350 and
EBNA3c EBV transcripts were only detected in EBERs positive samples. Examples
of autoradiographs obtained following PCR to detect EBV transcripts in serial
samples from a representative EBV seropositive patient are shown in Figures 4-26a
to g. RT-PCR results for all patients are summarised in Table 4-17.
EBERs mRNA was detected in 47 of 77 P-actin positive pre-transplant
samples screened (61%) and these samples were subsequently tested for the EBV
encoded latent transcripts LMP1, LMP2a, LMP2b and EBNA3c and the lytic
transcript gp350. The combination of EBV transcripts detected in each sample was
summarized according to previously described patterns of EBV gene expression in
vitro and in vivo. Five patterns ofEBV gene expression were identified:
1. Restricted EBV transcription, equivalent to that in normal EBV carriers:
that is EBERs only, LMP2a/b or no detectable EBV transcription.
2. LMP1 transcription with or without LMP2a/b
3. Restricted latent gene expression with lytic replication (gp350 with no
detectable EBNA3c).
4. EBNA3c without detectable lytic replication (unrestricted latency)
5. EBNA3c with gp350 (Unrestricted LCL-like latent and lytic
transcription)
The patterns of EBV gene expression detected pre-transplant are shown in
Table 4-17a. Restricted EBV transcription equivalent to that in normal healthy EBV
carriers was detected in pre-transplant PBM samples from 64 of 77 patients (83%).
Pre-transplant samples from 13 patients (17%) contained additional EBV transcripts
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including EBNA3c in 2 patients (2.6%), EBNA3c and gp350 in 1 patient (1.3%),
gp350 in the absence of EBNA3c in 2 patients (2.6%) and LMP1 in 8 patients
(10.4%). Pre-transplant diagnosis of patients in whom additional transcripts were
detected is shown in Table 4-17b.
Table 4-17a. EBV gene expression patterns pre- and post-transplant in
cardiothoracic transplant recipients
EBV transcription pattern



















26 (65) 4(10) 2(5) 7(18) 1(3) 40
1-6
months
101 (79) 11(9) 7(6) 7(6) 2(2) 128
6-18
months
47 (66) 10(14) 1(1) 9(18) 4(6) 71
18-30
months
31 (63) 4(8) 7(14) 4(8) 3(6) 49
30-42
months
8(47) 4(24) 2(12) 2(12) 1(6) 17
Total 277 41 21 31 12 382
The table shows the number and % of PBM samples in which each pattern of EBV
gene expression was detected during the time periods indicated.
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Table 4-17b. Pre-operative diagnosis and transplanted organ in patients




H L H/L Can¬
celled.
Pre transplant diagnosis (number)
LMP1 (n=8) 4 2 1 1 DCM (2), ICM (1), Post-partum CM (1), eisenmengers




1 1 Emphysema (1)
Previous mitral valve replacement + coronary artery bypass
graft(1)
Latency III (n=2) 2 ICM (1)
Post-partum CM (1)
Lat III + gp350 1 COAD
CM: Cardiomyopathy. DCM: Dilated CM. ICM: Ischemic CM. IHD: Ischemic heart disease. COAD:
Chronic obstructive arterial disease.
149
4.2.5.2 EBV gene expression in post-transplant samples
P-actin transcription was detected in RNA from 382 of 488 post-transplant
PBM samples tested (78.3%) from 90 transplant recipients. EBERs transcripts were
detected in 187 samples (49% of P-actin positive samples), which were then tested
for the EBV encoded latent transcripts LMP1, LMP2a, LMP2b and EBNA3c and the
lytic transcript gp350 (Results shown in Table 4-17). Additional EBV transcripts to
those detected in healthy EBV seropositive donors were detected in 46 transplant
recipients (51%). EBNA3c mRNA was detected post-transplant in 15 patients
(16.7%) and lytic replication was also detected in 5 of these patients (5.6%). The
patients in whom EBNA3c was detected were 9 males, 7 females aged 17 to 62
(mean 41.5 years). There was no association between detection of EBNA3c
transcripts and patient age, sex or transplant type (p=0.126, 0.739 and 0.297
respectively, using Spearman's correlation). Lytic replication was detected with
restricted latent gene expression in 23 patients (25.6%). There was no association
between detection of gp350 and patient age, sex or transplant type (p=0.716, 0.334
and 0.075 respectively by Spearman's correlation). In 14 patients (15.6%) the only
additional EBV transcript to be detected post-transplant, other than EBERs or LMP2
a/b, was LMP1. EBNA3c, LMP1 and gp350 mRNAs are not detectable in PBMs
from normal donors, but are associated with EBV-associated disease (PTLD and
IM). These EBV transcripts are also detectable pre- and post-transplant in transplant
patients who show no signs ofPTLD.
Samples were grouped according to the time post-transplant at which they
were taken, that is the first month post-transplant, up to 6 months post-transplant, and
subsequent 12 month periods: 6-18 months, 18-30 months, 30-42 months post-
transplant. A summary of EBV transcription at each time point is shown in Table 4-
17 and a bar chart showing the percentage of samples expressing each pattern of
EBV gene expression during each time point is shown in Figure 4-27. There was a
significant increase in detection of lytic replication with restricted latent gene
expression from 3% pre-transplant to 18% in the first month post-transplant
(p=0.028). This increase in lytic transcription was detected despite routine use of
prophylactic low-dose acyclovir in the first three months post-transplant. In the
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subsequent period up to 6 months post-transplant, the distribution of EBV
transcription patterns returns to pre-transplant levels (83% pre-transplant, 79% in 1-6
months post-transplant, p=0.462). With increasing follow-up time, there is a steady
decrease in the proportion of samples with a 'normal' pattern of EBV gene
expression and a corresponding increase in the proportion of samples with detectable
lytic replication (with and without EBNA3c), and in the proportion of samples in
which more unrestricted latency was detected (EBNA3c and LMP1). The proportion
of samples in which additional EBV transcripts were detected becomes significantly
different from pre-transplant levels by 30 months post-transplant (p=0.002).
Figure 4-27. EBV gene expression in PBMs at different time points
following cardiothoracic transplantation
Time post transplant
Graph shows the percentage of samples expressing different EBV gene expression patterns at
each time point pre- and post-transplant.
EBV transcription patterns:
Summarised EBV transcription patterns are based upon detection of the following transcripts:
'Normal': Restricted EBV gene expression, equivalent to normal EBV carriers (EBERs only,
LMP2a/b or no detected EBV transcripts).
Restr. + lytic: Restricted latency (no EBNA3c) with gp350.
Latency ID: EBNA3c.
Latency III + lytic: EBNA3c and gp350.
LMP1: LMP1 in the absence ofEBNA3c (Latency II)
151
Results showing pre-transplant EBV gene expression for all patients and
corresponding post-transplant changes are shown in Table 4-18. Thirty-four of 77
transplant recipients (44.2%) with restricted pre-transplant EBV gene expression had
additional EBV transcripts (LMP1, EBNA3c or gp350) detected in one or more post-
transplant samples. Thirty-five patients (45.5%) with normal EBV transcription pre-
transplant did not have detectable levels of additional EBV transcripts in post-
transplant samples. Only pre-transplant samples were available from 8 patients.
Of 13 transplant recipients with LMP1, EBNA3c or gp350 mRNAs detected
pre-transplant, 6 patients continued to express additional EBV transcripts post-
transplant, whereas EBV gene expression in post-transplant samples from 5 patients
was equivalent to normal carriers.
Table 4-18. Post-transplant changes in EBV gene expression














Post-transplant EBV gene expression









EBNA3c + gp350 3 1
Restricted latency + lytic 17 1
LMP1 9
Table shows a summary of post-transplant changes in patients separated on the basis
of pre-transplant EBV gene expression. Numbers of patients with each pattern of EBV
gene expression pre-transplant is shown across the top of the table, and the pattern
of gene expression detected post-transplant in the corresponding group is shown at
the side.
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4.2.6 Statistical analysis ofEBV transcription
4.2.6.1 Influence of immunosuppression on EBV transcription
Post-transplant EBV transcription was analysed in comparison to that
detected in normal EBV carriers and was defined as remaining equivalent to normal
EBV carriers or as containing additional transcripts. There was no association
between detection of additional transcripts and transplant type or patient sex
(p=0.270 and 0.689 respectively by Spearman's correlation).
The immunosuppressive regime initially given to all transplant recipients was
decreasing doses of cyclosporin, azathioprine and prednisolone with treatment for
rejection using methylprednisolone. Twelve patients (14.6%) had their principal
immunosuppressive treatment switched from cyclosporin to FK506 during the
follow-up period. Using the Spearman correlation there was no association between
use of FK506 and change in EBV transcription pattern (p=0.066). CMV viremia was
noted in 21 transplant recipients (25.6%) but there was no association between CMV
viremia and EBV transcription pattern (p=0.229). There was also no significant
difference in EBV transcription pattern (p=0.267) between patients who did or did
not experience acute graft rejection episodes (acute rejection in 33 patients (40.2%)).
These results are summarised with patient numbers for each group in Table 4-19.
Linear regression analysis was used to assess associations between detection
of additional transcripts to normal donors (ie LMP1, EBNA3c and gp350), and
treatment in the period immediately preceding sampling (Table 4-20). There was no
significant association with occurrence of rejection episodes, whether assessed by
noting rejection in the previous month from clinical notes, or dose of
methylprednisolone received in the preceding 2 weeks, or preceding month. There
was no association between dose of cyclosporin received in the preceding month and
detection ofEBV transcripts.
The influence of long term immunosuppression on EBV gene expression in
the PBMs of transplant recipients was assessed by multivariate analysis (analysis of
variance) (Table 4-21). The total cumulative level of immunosuppressive therapy
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received prior to samples being taken was assessed in relation to detection alternative
patterns of EBV gene expression. No significant differences were detected in the
pattern of EBV transcription and cumulative dose of cyclosporin, prednisolone or
methylprednisolone. Detection of LMP1 alone (latency II) was associated with
significantly higher cumulative dose of azathioprine than that associated with other
transcripts (p=0.003). Detection of EBNA3c (Latency III) is associated with high
cumulative dose of FK506 (p=0.005). Use of FK506 therefore appears to be
associated with unrestricted latent gene expression in transplant recipients.
Table 4-19. Changes in EBV transcription in patients under FK506
treatment or experiencing CMV viremia or rejection episodes
EBV transcription pattern (number of patients)
Detection of additional EBV
transcripts post-transplant
Restricted post-transplant
Factor (number of patients)
FK506 (12) p= 0.066 10 2
Cyclosporin (70) 37 33
CMV + (21) p=0.229 14 7
CMV-(61) 33 28
Rejection (33) p= 0.267 20 13
No rejection (49) 27 22
Table shows the number of transplant recipients with altered EBV gene expression post-transplant
separated on the basis of the drug regime used (FK506 or cyclosporin), or whether patients
experienced CMV viremia or acute rejection episodes.
Table 4-20. Analysis of immunosuppression dose and rejection
episodes in period immediately prior to sampling and influence on EBV
transcription post-transplant.
Treatment in period preceding sample Linear regression analysis
p value.
Methylprednisolone dose in previous 2 weeks .387
Methylprednisolone dose in previous month .542
Rejection in previous month .579
Mean daily cyclosporin dose in month preceding
sample
.862
Linear regression analysis was used to determine whether detection of additional EBV
transcripts to those in normal EBV carriers was associated with graft rejection or dose of
immunosuppressive drugs in the period preceding the sample. No significant association
was found between any of the parameters tested and detection of unrestricted EBV gene
expression.
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Table 4-21. Multivariate analysis of association between cumulative
immunosuppressive drug dose and detection of EBV transcripts.
Table shows cumulative drug dose associated with detection of alternative patterns of EBV
transcription in transplant recipients. Variation between groups was analysed by ANOVA, and
multiple cross comparisons were made by Tukeys ANOVA. Significant differences in drug dose
associated with particular transcription patterns are highlighted (*).







CSA Restricted 44048.1 0 21138 none
Rest. + lytic 52725.1 1291 166908
Latency III 77474.2 0 163441
Lat. Ill + lytic 84477.3 9084 172860.5
Lat. II (LMP1) 59353.5 0 208110
AZA Restricted 11690.2 0 121250 Lat ll>
Restricted
P=0.003
Rest. + lytic 20416.3 545 106975
Latency III 23501 280 96220
Lat. Ill + lytic 14435 11960 19385
Lat. II (LMP1) 26614* 150 114675
Pred Restricted 1735.6 0 6647.5 none
Rest. + lytic 1795.0 225 7027.8
Latency III 1972.7 692.8 4254.6
Lat. Ill + lytic 2307.9 670 3573.8
Lat. II (LMP1) 1957 0 6247.5
Mpred Restricted 1101.2 100 5250 none
Rest. + lytic - - -
Latency III 3000 1250 4750
Lat. Ill + lytic - - -
Lat. II (LMP1) 3089.3 500 9250










Rest. + lytic 2394.4 2029.9 2758.9
Latency III 248829.3* 248430 249228.6
Lat. Ill + lytic 1254.8 1131.3 1377.9
Lat. II (LMP1) 52438.7 557.1 249977.9
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4.2.6.2 Association between EBV gene expression and EBV copy
number in transplant recipients
In all normal healthy individuals and 83% of patients awaiting transplantation
EBV gene expression is restricted and EBV genome copy number is low (<1 to 200
genomes/106 PBMs). Following transplantation EBV copy number increases to
levels equivalent to cases of IM (35.4% of patients) or PTLD (12.5% of patients) and
EBV transcripts are detected which are not present in normal donors, notably
transcripts associated with unrestricted latency (EBNA3c) and lytic replication
(gp350). Detection of these latent and lytic transcripts in transplant recipients without
PTLD indicates that following transplantation there is a loss of restriction in EBV
transcription, which may contribute to increased EBV copy number. EBV genome
copy number in PBMs could increase post-transplant through lytic replication
producing high numbers of EBV genomes in individual productively infected cells or
proliferating EBV infected B-lymphocytes could lead to high numbers of latently
infected cells in peripheral blood.
EBV copy number in samples displaying different combinations of EBV gene
expression is shown in Table 4-22. Mann-Whitney U tests were used to assess the
association between individual EBV transcripts and EBV copy number (Table 4-23).
Using this test there was a highly significant correlation between increased EBV
copy number and detection of all EBV transcripts when tested as separate variables
(p<0.005 in each case): EBERs, LMP2a, LMP2b, LMP1, gp350 and EBNA3c. This
association may be interpreted as being due to more ready detection of the EBV
transcripts with increased numbers of infected cells in samples with increased EBV
load. A box-plot of EBV load in samples with different patterns of EBV gene
expression is shown in Figure 4-28.
The highest EBV loads were found in samples in which latency III and lytic
replication were detected together (20 to 1 x 105 genomes/106 PBMs, mean = 1.9 x
104 genomes/106 PBMs) (Figure 4-27) (p<0.001 compared to EBNA3c or LMP1,
p=0.004 compared to restricted latency with lytic replication). EBV load in samples
expressing lytic replication and restricted latent transcription (mean=2 x 103
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genomes/106 PBMs) are not significantly higher than in samples expressing EBNA3c
or LMP1 without lytic replication (p=0.103 and 0.142 respectively). A combination
of unrestricted latent gene expression and lytic replication are therefore involved in
increasing EBV copy number in PBMs of transplant recipients. Samples with
EBNA3c (Latency III) without lytic replication have EBV loads equivalent to
samples with LMP1 (p=0.604) but EBV load with both of these forms of latent gene
expression are significantly higher than in samples with restricted latent gene
expression (p=0.04 and <0.001 respectively). The combination of latency III and
lytic replication is clearly associated with high EBV copy number following
transplantation, and it is this pattern of EBV gene expression that is most commonly
detected in biopsies and PBMs of patients with PTLD.




EBV copy number (genomes/ 10B PBMs)
Range Median Mean
No EBV mRNA detected 0-1.5 x 103 1 40
EBERs only 0-1 x 104 1 205
LMP2a/b only 0-1 x 104 20 276
LMP1 + LMP2a/ b 0-2 x 103 57 196
LMP1 only 0-90 50 42
Restricted latency +
lytic replication (gp350)
0-7 x 103 60 766
Latency III (EBNA3c) 0-3 x 104 20 2.8 x 103
Latency III + lytic 60-1 x 105 1.5 x 103 1.95 x 104
157
Table 4-23. Association between individual EBV transcripts and EBV
copy number.




P<0.001 PcO.OOl P=0.001 P=0.001 P<0.001 P=0.005
Mann-Whitney U tests were performed to analyze the association between expression of
EBV transcripts and EBV copy number. There was a highly significant association between detection
ofall transcripts and increased EBV copy number.
Figure 4-28. Boxplot of EBV copy number in post-transplant PBM




















Restr. + lytic Latency III + lytic
LMP1 Latency III
EBV gene expression
Red boxes show the interquartile range and bold black horizontal lines show the median
EBV copy number for samples displaying the pattern ofEBV gene expression indicated .EBV load in
samples with latency III with lytic replication are significantly higher than EBNA3c or LMP1 alone
(p<0.001) and is significantly higher than samples with restricted latency with lytic replication
(p=0.004). Samples expressing EBNA3c or LMP1 have significantly higher EBV load than in
samples with restricted latency (p=0.04 & <0.001 respectively). EBV load in samples expressing
EBNA3c, LMP1 and restricted transcription with lytic replication are not significantly different.
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4.2.6.3 Comparison of EBV gene expression in PBMs from transplant
recipients with normal donors and patients with IM and PTLD
The patterns of EBV gene expression detected in transplant recipients was
compared with that detected in patients with IM, or PTLD and with normal healthy
EBV seropositives. The numbers and percentage of samples from each group
displaying each pattern of EBV gene expression are shown in Table 4-24. In all
normal EBV carriers tested restricted EBV latency was detected. Restricted EBV
latency, equivalent to that in normal EBV carriers was also detected in PBMs from
84% of patients awaiting transplantation, 57% of patients with IM and 27% of
patients with PTLD. In 45.5% of patients with PTLD latency III with lytic replication
can be detected in the peripheral blood whereas this pattern of EBV gene expression
is only detected in 14% of patients with IM.
Levels of EBV DNA equivalent to that in patients with PTLD or IM were
detected in transplant recipients without apparent disease. EBV gene expression in
the corresponding samples from each patient is shown in Table 4-25. It is clear from
this data that unrestricted EBV latent and lytic gene expression is associated with
increased viral load in transplant recipients, although in some patients additional
transcripts are detectable without accompanying high viral load. In all samples with
high EBV load, equivalent to patients with PTLD (3 500 - 1 x 106 genomes/106
PBMs), a less restricted pattern ofEBV gene expression to that in normal donors was
detected. Lytic replication was detected in 58% of samples with high EBV load, and
lytic replication was detected together with EBNA3c in 33% of patients. Lytic
replication was detected in 42% of patients with EBV loads equivalent to IM, but in
39% of IM patients, lytic replication was detected with restricted latent gene
expression.
Eighty-two percent of patients with EBV loads equivalent to normal donors
(0-40 genomes/106 PBMs) also have the same restricted EBV gene expression.
However, additional transcripts to those detected in normal controls are present in
patients whose EBV load remains low: lytic replication was detected in 3 patients,
EBNA3c detected in 1 patient, and LMP1 in 2 patients.
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Table 4-24. Summary of EBV gene expression in transplant recipients
and controls













Count % Count % Count % Count % Count %
pre tx'. 64 83.8% 2 2.7% 2 2.7% 1 1.4% 8 9.5%
post, tx^ 213 69.8% 29 9.5% 19 6.2% 11 3.6% 33 10.8%
Normals^5 36 100.0%
IM 16 57.1% 5 17.9% 2 7.1% 4 14.3% 1 3.6%
PTLD 3 27.3% 1 9.1% 5 45.5% 2 18.2%
1. Pre tx. : pre- transplant. 2. Post tx.: all post-transplant samples tested. 3. Normal healthy
donors. 4. Restricted latency: EBV gene expression equivalent to healthy EBV seropositives
(ie EBERS, LMP2a/b, or no detectable EBV transcripts)
Table 4-25. EBV gene expression in transplant recipients with EBV load
equivalent to that in EBV-associated diseases and normal carriers
Post-transplant EBV transcription pattern
Patients with post-tx






























































Interquartile range of EBV load in patient groups: 1. PTLD: 3500-1 x 106 genomes/106 PBMs. 2. IM:
40-1500 genomes/106 PBMs. Normal donors: 1-40 genomes/106 PBMs.
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4.2.7 Predictive value of testing for EBV load and EBV gene
expression in detecting PTLD
The effectiveness of a diagnostic test is dependent on a balance between the
sensitivity and specificity of the test, since it should be able to correctly distinguish
the disease state (specificity), and not produce false negative results (sensitivity). The
intervention, which would follow a postive diagnostic test, is also a factor, in terms
of whether the therapy is costly or harmful to the patient, in which case false positive
tests are undesirable.
In the case of PTLD, whilst increased EBV load and detection of EBNA3C
and lytic transcripts distinguish transplant recipients and patients with PTLD from
normal donors, these factors are not specific indicators of PTLD development since
they are also detected in some transplant recipients who do not develop disease.
However since many early PTLDs respond to reduced immunosuppression, and
regress without invasive or damaging treatments, diagnostic tests for PTLD do not
need to be highly specific since it would not harm a patient to be treated on a
precautionary principal, even if they would not have ultimately developed PTLD
without treatment.
Therefore detection of high EBV loads (over 1500 genomes/106 PBMs, the
upper level detected in IM) or detection of EBV transcripts not normally detected in
healthy donors (such as EBNA3C or gp350) could be used as precautionary
indicators to highlight patients who may be at risk of developing PTLD and
immunosuppressive therapy could be modulated as appropriate. EBV load appears to
be the most sensitive diagnostic test available for detecting development of PTLD,
because all patients with PTLD had high EBV loads, but some patients with PTLD
did not have detectable EBNA3C or gp350 transcripts in PBMs. Therefore it is less
likely that a patient developing PTLD would be missed by routine quantitative PCR




This study set out to investigate the course of EBV infection following
cardiothoracic transplantation in order to examine whether virological factors could
be used to predict development of PTLD. The occurrence of EBV-associated PTLD
in transplant recipients suggests that iatrogenic immunosuppression leads to a
disruption of the balance between EBV persistence and immunological control of
EBV that normally allows a stable lifelong infection in healthy EBV seropositive
individuals.
Previous studies on the pathogenesis of PTLD have been of limited value,
tending to involve low numbers of transplant recipients in prospective studies or have
been retrospective studies of patients with PTLD. The majority of studies have been
on paediatric transplant recipients. In contrast, this study prospectively followed all
adults preparing to undergo cardiothoracic transplantation between January 1995 and
November 1999 at Harefield Hospital (n=96). This allows unbiased investigation of
the influence of immunosuppressive therapy on EBV infection and insights into the
factors that may be involved in PTLD development. The fact that none of the 96
transplant recipients studied developed PTLD during the follow-up period of up to 3
years demonstrates the necessity for unbiased large-scale investigations into factors
that cause certain patients to progress to disease.
5.2 Experimental design
The aim of the study was to prospectively follow a group of transplant
recipients and monitor changes in EBV genome copy number and transcription
pattern. These factors were compared with control groups and related to drug dose
and clinical events.
PCRs were developed for semi-quantitative DNA analysis to determine EBV
genome copy number and RT-PCRs to examine the pattern of EBV latent and lytic
gene expression in PBMs from transplant recipients and controls.
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Pre-transplant blood samples were available from 132 patients of which 96
were followed for up to 1110 days post-transplant (mean 415 days). In addition,
blood samples were taken from 36 normal healthy EBV seropositive adults, 30 adults
with acute IM and 15 transplant recipients with PTLD from Harefield Hospital and
other UK transplant centres.
5.2.1 Semi-quantitative DNA PCR
A semi-quantitative PCR was developed based on detection of the Bam H1W
repeat region of the EBV genome which was reproducibly capable of detecting 1 to
10 EBV genomes/106 cells (section 4-1). Several previously published studies have
used BamHIW sequences as targets for semi-quantitative PCR (Saito et al 1989,
Knecht et al 1991, Snijdjers et al 1990, Wagner et al 1992, Savoie et al 1994,
Laroche et al 1995) and similar assays have been developed to detect EBNA1
(Telenti et al 1990) and EBNA2-encoding sequences (Sixby et al 1989). Other
approaches for quantitative PCR were considered at the outset of this study, based on
the method developed by Fox et al (1992) to quantify CMV DNA. In this assay the
test sample is spiked with known quantity of plasmid DNA containing a sequence
identical to the viral target apart from a few base changes engineered to produce a
unique restriction site. This allows quantitation of target DNA through comparison of
the proportion of amplified sample and control amplimers following digestion and
electrophoresis of PCR products. The advantage of this method is that the control
DNA is amplified in the same tube as the target sequence providing an internal
standard which eliminates error due to inter-tube variation in amplification
efficiency. However it was decided to continue with the semi-quantitative BamW
PCR approach to avoid post-amplification processing which would greatly increase
the time taken to analyze large numbers of samples. The Bam W method proved
simple and reliable in providing comparison ofEBV copy number between groups of
subjects and in multiple samples from individual patients. Since the study began
quantitative-competitive and real-time PCR techniques to quantify EBV copy
number have been developed, such as those reported by Rowe et al (1997) and
Kimura et al (1999). Real-time PCR methods utilizing fluorescent-tagged primers to
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directly follow the production of amplimers are faster than the semi-quantitative or
quantitative-competitive approach, and may prove to be an ideal method for
accurately analyzing large numbers of samples. However, the start-up costs of
purchasing equipment dedicated to this technique are prohibitive for research
laboratories which are not routinely screening high numbers of samples. The
diversity of approaches for quantitation of EBV and other herpesviruses makes
comparison of data between research groups problematic, and it is therefore essential
that methods should be standardized to allow meaningful assessment of the
significance of virus DNA quantitation in a clinical or research setting.
5.2.2 RT-PCR
To assess EBV transcription in controls and transplant recipients, it was vital
to select a panel of PCRs that gave a clear picture of the combination of genes
expressed. Various primer-probe combinations were assessed to establish which
assays provided the best sensitivity and reproducibility in detecting EBV transcripts.
PCR to detect gp350 mRNA, encoding the major EBV envelope
glycoprotein, was chosen since its detection would indicate productive infection.
EBNA3c PCR was chosen to detect latency Ill-like unrestricted EBNA expression
since it was the most sensitive and reproducible PCR tested. Detection of EBNA3c
was taken to indicate the other EBNA mRNAs were also transcribed, since the Cp or
Wp promoter initiates transcription of a polycistronic message including all the
EBNA genes. PCRs to detect LMP1 were included since this protein has profound
effects on cell growth and is associated with most EBV positive tumours. PCRs for
LMP2a and 2b were included to give a complete indication of latent gene expression
in clinical samples. The PCRs used were capable of detecting latent gene mRNA
(EBERs, EBNA3c, LMPs 1, 2a and 2b) from 100 B95-8 cells in a background of 1 x
106 EBV negative cells, and gp350 PCR detected 10 B95-8 cells/106 cells. Other
PCRs, which were assessed but not used to test clinical samples, included detection
of EBNA2 mRNA, mRNAs derived from Cp or Wp promoters (transcribing the
polycistronic EBNA-encoding mRNA) (Woisetschlager et al 1989) and PCRs to
detect EBNA1 mRNAs transcribed from alternative promoters (Schaefer et al 1995).
164
These PCRs were not used because they were insufficiently sensitive, or, in the case
of PCRs to detect the various forms of EBNA1, required too many reactions to give
an indication of gene expression, and were therefore too cumbersome for use with
large numbers of samples.
In normal EBV seropositives and patients with IM, EBERs mRNA was the
most consistently detected transcript (Tables 4-14 and 4-15). No other EBV mRNAs
were detected in EBERs negative samples, and therefore this abundantly expressed
transcript was used to screen samples from transplant recipients to determine whether
they contained detectable levels of EBV transcripts. EBERs negative samples were
eliminated from further analysis and EBERs mRNA positive samples were used for
subsequent PCR analysis to detect the EBV transcripts EBNA3c, LMP2a, LMP2b,
LMP1 and gp350.
5.3 EBV infection in clinical samples
A detailed model of EBV infection, persistence and reactivation has been
proposed by David Thorley-Lawson and co-workers (reviewed in Thorley-Lawson &
Babcock 1999) whereby EBV survives in the immunocompetent host through
exploiting the normal pathways of B-cell activation and differentiation. The results of
the present report are discussed in relation to this model.
5.3.1 Primary infection and infectious mononucleosis
EBV is first thought to infect nai've B-cells in the oropharyngeal submucosal
epithelium. EBV latent transcription then occurs, promoting proliferation of latently
infected B-lymphoblasts mirroring infection of resting B-cells with EBV in vitro.
Initiation of EBV transcription in newly infected B-cells is thought to occur
through induction of the complement induced B-cell activation pathway by
gp350/220 binding to the C3d complement receptor CD21 on the cell surface. The
first EBV promoter to be activated is Wp, which transcribes the EBNA complex of
genes, leading to B-cell activation and proliferation (Woisetschlager et al 1990). The
mechanism and phenotype of B-cell activation induced by EBV gene products
closely resembles that of normal B-cells that become blasts after encountering
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antigen with T-cell help. Unlike normal B-cell activation by antigen however, EBV
infected lymphoblasts are blocked in their differentiation and continue to proliferate.
5.3.1.1 EBV gene expression and virus copy number in patients with
symptomatic primary EBV infection (infectious mononucleosis
(IM))
Single blood samples from 30 adults with acute IM were used to establish the
EBV load and pattern of EBV transcription in peripheral blood during this self-
limiting EBV-associated lymphoproliferative disorder.
EBV load in IM was significantly higher than in normal EBV seropositive
donors (p=0.001) with levels up to 1 x 106 genomes/106 PBMs (median 1 x 104
genomes/106 PBMs) (Table 4-10). Previous reports have identified correlations
between progression of primary infection and levels of EBV in peripheral blood,
since EBV copy number reduces during convalescence following IM (Rocci et al
1977, Laroche et al 1995, Yamamoto et al 1995, Kimura et al 1999). However, no
significant correlation was found between reported duration of symptoms before
presentation (indicating the time since primary infection) and EBV load in this group
(p=0.7). Since follow-up samples were not available it is not possible to draw
conclusions about how EBV load changes during establishment of persistent
infection in this patient group.
RT-PCR analysis performed on PBM RNA samples from 28 patients with
acute IM demonstrated that during primary EBV infection, infected cells express
EBV latent and lytic genes which are not detectable during persistent infection
(Table 4-15). Unrestricted latent gene expression was detected in 6 patients
(detection of EBNA3c mRNA), LMP1 was detected in 1 patient and lytic replication
detected in 9 patients (32%). There was a strong correlation between short duration
of symptoms of IM and unrestricted latent gene expression (p=0.031), indicating that
early in IM cells expressing these antigens are able to persist and proliferate,
establishing a persistent infection before establishment of functional immunity to
EBV.
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Niedobitek et al (1997b) assessed EBV gene expression in lymphoreticular
biopsies from IM patients directly using immunocytochemistry and in-situ
hybridization. The combinations of EBV genes expressed in individual cells did not
necessarily correspond to the accepted latency I, II, III models of EBV transcription.
A diverse population of EBV infected cells may be in circulation during IM, with
different combinations of latent and lytic transcription. The various combinations of
EBV transcripts are therefore not necessarily expressed together in individual cells,
and care should be taken in interpreting RT-PCR results from what may be a mixed
population of EBV infected cells in the blood. Detection of each EBV transcript
indicates expression in some of the population of cells, and assumptions should not
be made as to associated expression of other transcripts in individual cells.
The occurrence of EBV replication during IM is supported by a report by
Prang et al (1997) in which late lytic transcripts were detected in B-cells from 25%
of IM patients. EBV DNA has also been detected in the serum or plasma of patients
with IM, suggesting lytic replication and release of infectious virions into the blood
(Gan et al 1994, Laroche et al 1995, Yamamoto et al 1995). Detection of EBV DNA
in serum could occur through release of latent EBV genomes by cell lysis, resulting
from immunologically mediated lysis in situ or ex vivo processing of samples. High
levels of EBV shedding into saliva have also been reported during acute IM,
therefore it appears that some lymphoblasts enter the lytic cycle and produce
infectious virus particles in the peripheral blood and oropharynx during acute IM.
5.3.1.2 Establishment of persistent infection
Despite development of CTL responses against the highly immunogenic
latent proteins expressed by EBV infected lymphoblasts, EBV establishes a
persistent infection. It is proposed that some EBV infected B-lymphoblasts
differentiate to become memory B-cells, which are detectable in healthy EBV
seropositives (Miyashita et al 1997). The lymphoblasts detected in patients with IM
therefore represent a transient stage that is required for expansion of the population
of latently infected cells in the body through lymphoblastoid cell proliferation and
infection of naive cells following lytic replication.
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Differentiation of EBV infected lymphoblasts into resting memory B-cells is
essential for the virus to maintain a persistent infection in the face of immunological
responses against latent antigens. EBV infected B-blasts are proposed to enter the
lymph node where they proliferate in the same way as centroblasts in a germinal
centre reaction. For infected B-cells to differentiate and become memory cells,
EBNA gene expression must be switched off, since these growth-promoting proteins
induce the activated B-cell phenotype and drive proliferation. Indeed if EBNA2
expression is switched off in the presence of activated c-myc, expression of the latent
proteins stops and the cells differentiate and acquire the non-proliferative centrocytic
phenotype (Polack et al 1996). Thorley-Lawson & Babcock (1999) report that
EBNA2 negative, LMP1 and LMP2a and b positive centrocytes occur in the tonsils
of healthy donors (Thorley-Lawson & Babcock unpublished observations) and
propose that these cells could be rescued from apoptosis in lymph nodes by LMP2a
and LMP1, and differentiate into resting memory B-cells. The mechanism of this
LMP2a and LMP1 driven differentiation is thought to be another example of EBV
utilizing the normal behaviour of antigen activated B-cells.
LMP2a contains an ITAM motif which is also present on the B-cell receptor
molecule and which provides signaling when the receptor binds antigen. The LMPa
ITAM motif binds src tyrosine kinases and may provide the equivalent of cell-
survival signaling provided by antigen binding the B-cell receptor, thus rescuing the
activated B-blast from apoptosis (Lam et al 1997). LMP1 acts like a constitutively
active CD40 molecule, providing to an EBV infected memory B-cell the equivalent
of T-helper cell signaling. In this theory LMP1 and LMP2a together can provide the
signals necessary to rescue EBV-infected centroblasts from apoptosis, allowing them
to become plasma cells or memory cells. These cells undergo apoptosis unless they
encounter CD40 plus antigen and specific cytokines. Under these conditions the cells
undergo terminal differentiation to form plasma cells. Ultimately prolonged CD40
signaling pushes remaining B-cells to form memory B-cells (Arpin et al 1995); the
cell type in which EBV is exclusively detected in the peripheral blood (Miyashita et
al 1997).
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RT-PCR analysis of EBV gene expression in healthy EBV seropositives
consistently revealed restricted latent gene expression. Neither EBNA3c- nor gp350-
encoding mRNAs were detected in any normal EBV seropositives. These findings
are consistent with previous reports although there is no definitive description of the
pattern of EBV gene expression in persistent infection. Prang et al (1997) found that
although transcripts encoding the lytic transactivator BZLF1 were detected in 77% of
subjects there was no detectable late lytic transcription. Therefore despite initiation
of lytic replication in normal EBV carriers, this may not lead to virion production,
suggesting immunological elimination of cells undergoing productive infection in the
peripheral blood. Despite the proposed role of LMP1 in establishing persistent
infection LMP1-encoding mRNA was not detected in PBMs from normal healthy
individuals in this study, and has not been reported elsewhere. LMP1 mRNA may be
rapidly degraded following differentiation of lymphoblasts into memory cells, and
can therefore not be detected in the circulation.
LMP2a is the only consistently detected EBV transcript in healthy donors
(this report, Miyashita et al 1995 & 1997, Babcock et al 1998, Tierney et al 1994, Qu
& Rowe 1992). Miyashita et al (1997) found that over 90% of EBV infected cells in
normal donors were resting (CD23-ve) B-lymphocytes, and LMP2a mRNA was the
only EBV transcript detected in this population. The role of LMP2a in maintaining
persistent infection could be in providing B cell receptor signaling to encourage
survival of the resting memory B-cell, mimicking the uninfected memory cells
requirement for low levels of antigen for survival (Gray & Skarvall 1988). LMP2a
may also be necessary for maintenance of viral latency and evasion of
immunosurveillance through repression of reactivation (Miller et al 1995). LMP2a is
a target for CTL (Khanna et al 1995) although the infected cells do not express the
costimulatory molecule B7 (Miyashita et al 1995) and are therefore protected from
eliciting a memory CTL response. Secreted LMP2a protein could act as a CTL
epitope, but the persistence of cells expressing LMP2a mRNA suggests that the
protein may not be expressed at sufficiently high levels to elicit a response. Thorley-
Lawson suggests that EBV may in fact be transcriptionally silent in memory B-cells
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and that LMP2a mRNA in circulating B-cells is residual from differentiation of
reactivated memory cells or reinfection of naive B-cells in lymphoid tissue.
In this study LMP2b transcripts were detected together with LMP2a in 3/36
normal donors. LMP2b has not been reported previously in normal donors, but this
may reflect the low numbers of samples tested in other studies (4 in the case of Qu &
Rowe 1992, 6 in the case of Tierney et al 1994 and 2 in the case of Miyashita et al
1997). LMP2b interacts with LMP2a molecules in the cell membrane, modulating
the activity of LMP2a, which may be important in maintaining latency (Longnecker
& Miller 1996).
5.3.1.3 Maintenance of persistent infection and virus reactivation
In normal healthy donors, levels of EBV detectable in the peripheral blood
remain low (<1 to 200 genomes/ 106 PBMs) and relatively constant over several
years (this report, Wagner et al 1992, Laroche et al 1995, Kenagy et al 1995, Gan et
al 1994, Khan et al 1996, Haque et al 1997, Rowe et al 1997, Maeda et al 1999). For
EBV infection in an individual to be maintained the population of infected cells must
be regenerated to restore losses through cell death or immunological elimination of
infected cells. Also virus particles must be produced to enable infection of new hosts.
Thorley-Lawson & Babcock (1999) propose that recirculating EBV-infected
memory B-cells migrate to mucosal lymphoid tissue and undergo activation through
normal B-cell activation pathways (Anagnostopoulos et al 1995, Casamayor et al
1995). It is proposed that IL10 and TGFp signaling cause switching to IgA
expression, homing cells to mucosal epithelium (Defrance et al 1992). TGFp has also
been shown to induce viral reactivation in vitro (Di Renzo et al 1994). This induces
memory B-cells to undergo terminal differentiation to become plasma cells and this
in turn is thought to initiate EBV lytic replication, producing infectious virus
particles which are released into the oropharynx (Anagnostopoulos et al 1995).
Released virus could infect other nai've B-cells in the region which become
proliferating lymphoblasts. The CTL response against EBV latent antigens expressed
by lymphoblastoid cells would eliminate the majority if these cells but some could
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evade the CTL response by entering lymph nodes and repeating the cycle, and
differentiate into memory cells to repopulate the pool of latently infected cells in the
circulation.
In healthy individuals, this balance maintains a low-level latent infection
without detectable lymphoblasts in the circulation. EBV persistence therefore
involves two stages: firstly, low levels of tightly latent (or transcriptionally silent)
infected resting memory B-cells which provide the reservoir of latent EBV infection,
and secondly, the periodic activation of latent memory B-cells in the mucosal
lymphoid tissue to release infectious virus. Latently infected memory cells are
tolerated since they are at low levels, but the CTL response would be activated once
levels increase above a certain, unknown, threshold. The CTL response is therefore a
critical controlling factor in maintenance of stable persistent infection with EBV.
5.3.2 EBV infection under disrupted cellular immunity: cardiothoracic
transplant recipients
Cardiothoracic transplant recipients were prospectively studied to monitor
changes in EBV load and gene expression in patients with impaired cellular
immunity. These individuals are at risk of developing EBV-associated PTLD which
is thought to occur through an inability to eliminate proliferating lymphoblasts which
are proposed to be spontaneously generated in mucosal lymphoid tissue. No large-
scale prospective study has previously followed a group of transplant recipients to
monitor changes in EBV copy number and EBV transcription. Our results will be
discussed in relation to the only comparable report, by Babcock et al (1999), which
studied 28 liver and kidney transplant recipients at a single time point and
investigated EBV gene expression in 4 of these. A recent report investigated the
predictive value of EBV quantitation combined with RT-PCR for detection of the
immediate early transcript BZLF1 in paediatric liver transplant recipients (Vajro et al
2000). BZLF1 mRNA was detected in 70% of 44 patients. The parameters were not
predictive of PTLD when considered alone.
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5.3.2.1 Pre-transplant
EBV transcription was equivalent to that in normal EBV carriers in the
majority of pre-transplant samples (83%); that is no detectable EBV transcription or
EBERs with or without detectable LMP2a and LMP2b transcripts. In 13 patients
(17%), additional transcripts were detected (Table 4-17b). There was no apparent
association between patients' underlying disease, age or sex and detection of
additional EBV transcripts to those detected in normal EBV carriers. CTL activity in
patients awaiting transplantation is significantly reduced compared with normal EBV
positive donors (Haque et al 1997). However, in the results presented here there was
no associated elevation in EBV genome copy number pre-transplant compared to
normal carriers (p=0.542 Table 4-10). Despite underlying immunosuppression,
which may allow persistence of cells expressing normally antigenic EBV latent
proteins, EBV infection remains under control in patients awaiting transplantation.
5.3.2.2 Post-transplant
The cohort of transplant recipients was studied to examine whether EBV copy
number and transcription pattern changed following transplantation and if so whether
specific patterns predisposed to development ofPTLD.
In at least one post-transplant sample from 55% of patients EBV copy
number exceeded the range detected in normal EBV seropositives (interquartile range
of 0-40 genomes/106 PBMs). The remaining 40 transplant recipients (45%) had EBV
copy numbers which remained within the normal range. In 12 patients (14.3%), EBV
copy number was equivalent to that ofpatients with PTLD (3500 to 1 x 106 genomes/
106 PBMs) and equivalent to patients with IM (30-1.5 x 104) in 32 patients (40%).
EBV gene expression in patient samples with EBV loads equivalent to EBV-diseases
are shown in Table 4-25.
The 12 patients with EBV loads equivalent to patients with PTLD were 8
males, 4 females, aged 17-60 (mean 43 years). Two received lung transplants, 6
hearts, and 3 heart/lung. The highest detected EBV load was in a 17 year-old female
with cystic fibrosis who received a heart/lung transplant, seroconverted with EBV
immediately post-transplant and survived for 18 months post-transplant. The source
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of the infecting EBV is not known, although EBV was not detected in DNA
extracted from archival spleen tissue from the 11 year-old organ donor. EBV copy
number fluctuated, but showed a steady increase, reaching a maximum of 1 x 105
genomes/ 106 PBMs which was detected in 3 out of 4 samples received between 1
year and 18 months post-transplant (Figure 4-20).
Patients with EBV loads equivalent to cases of IM or PTLD were analysed to
investigate associations with underlying factors. There was no association with
patient age (p=0.327), sex (p=0.532) or transplanted organ (p=0.821). The two
patients with the highest detected EBV load were treated with FK506, but there was
no significant association between use of FK506 and elevated EBV load (p=0.078).
EBV copy number increased with follow-up time (p=0.013) and there was a highly
significant association with cumulative dose of cyclosporin (p=0.001 by linear
regression analysis. Table 4-12). This indicates that increasing cumulative exposure
to immunosuppressive agents leads to increased EBV load.
Additional EBV transcripts to those found in normal EBV carriers were
detected in 46 transplant recipients (51%) (Table 4-25). EBNA3c-encoding
transcripts were detected post-transplant in 15 transplant recipients (16.7%) and lytic
replication was also detected in 5 of these patients (5.6%). These transcripts were not
detected in any of the 36 healthy EBV seropositive donors tested but were detected in
PBMs from patients with PTLD and IM. Thus while unrestricted EBV latent and
lytic gene expression in the peripheral blood is associated with EBV associated
disease the detection of these transcripts in some healthy transplant recipients
indicates that it is not on its own predictive of PTLD.
Patients in whom EBNA3c was detected were 8 males, 7 females aged 17 to
62 (mean 41.5). There was no association between detection ofEBNA3c and age, sex
or transplant type (p= 0.126, 0.739, 0.297 respectively). The only factors found to
correlate with detection of EBNA3c were cumulative dose of cyclosporin (p=0.005)
and use of FK506 (p=0.032) which was given to 42% of patients who tested positive
for EBNA3c compared with 14% of EBNA3c negative patients. Since there is a
correlation between cyclosporin dose, EBNA3c and high EBV load, this result
suggests that cyclosporin is at least in part responsible for increased EBV load
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through reducing CTL activity which allows persistence and proliferation of infected
cells expressing EBNA3c.
Lytic replication was detected in combination with restricted latent gene
expression in 23 patients (25.6%). The only factor found to correlate with detection
of gp350 mRNA was use of ATG (p=0.045) which was given to 32% of patients
testing gp350 positive, compared with 12% of gp350 negative patients. There was no
association with patient age (p=0.716), sex (p=0.334) or transplant type (p=0.075). In
14 patients (15.6%), the only additional transcript to be detected was LMP1, but
there were no associations with patient age, sex, transplant type or
immunosuppressive regime.
The most significant factor associated with high EBV load was detection of
gp350 (p<0.001). In samples in which latency III and lytic replication were detected
together, EBV load was overall significantly higher than in samples expressing lytic
replication with restricted latent transcription (p=0.004). Latency III and lytic
replication therefore are most significant factors involved in increasing EBV copy
number in the PBMs of transplant recipients. There is an increase in the occurrence
of lytic replication in the early post-transplant period (Figure 3-21), and an increase
in the detection ofmore unrestricted patterns of latent and lytic gene expression with
increasing follow-up time.
Lymphoblastoid cells expressing unrestricted latent antigens have been
reported in the peripheral blood of transplant recipients previously on only one
occasion (Hornef et al 1995) when the cells were directly visualized by
immunocytochemistry. Only one previous report has investigated EBV gene
expression and EBV load in transplant recipients without PTLD (Babcock et al
1999). Twenty-eight solid organ transplant recipients were studied, concluding that
EBV copy number increased post-transplant in two-thirds of patients due to increased
numbers of latently infected resting B-lymphocytes, the same population of infected
cells detected in healthy EBV carriers (Miyashita et al 1997). EBV latent gene
expression was assessed by RT-PCR in just 4 patients. The only transcript detected
was LMP2a in 1 patient, with no EBV transcripts detected in the other 3 samples.
Latency III transcription (EBNA2) or EBNA1 were not detected. The authors suggest
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that lytic replication is the most significant contributor to increased viral burden in
these patients since lytic replication was demonstrated by detection of linear EBV
genomes in 3 of 7 transplant recipients when assessed by Gardella gel
electrophoresis. The present study demonstrates that unrestricted latent gene
expression, associated with lymphoblastoid cell proliferation, is detected in
transplant recipients without PTLD. Lytic replication was also detected in PBMs
from transplant recipients in the present study, and was the most significant
contributor to increased EBV load. However EBNA3c transcripts were also detected
and statistically associated with high EBV load, indicating a significant contribution
of lymphoblastoid cells in increased EBV load. This contrasts with the model
proposed by Thorley-Lawson, in which EBV lymphoblasts are restricted to the
lymphoid tissue.
5.3.3 PTLD
EBV copy number in PBMs from patients with PTLD was significantly
higher than in normal EBV seropositive donors and patients with IM (p=0.001 in
both cases (Table 4-10)). Previous studies have shown an association between high
EBV load in peripheral blood and development of PTLD and suggest that this can be
used as a predictive and prognostic marker for PTLD (Riddler et al 1994, Savoie et
al 1994, Kenagy et al 1995, Rowe DT et al 1997, Cacciarelli et al 1998).
Lymphoblastoid-cell-like latent and lytic gene expression was detected in all
six PTLD biopsies analysed. 10 of 11 (91%) PBM samples from patients with PTLD
showed a less restricted pattern of EBV latent and lytic gene expression than that
detected in normal EBV seropositives. Lytic replication was detected in 6 patients
and EBNA3c detected in 5 patients. To our knowledge, EBV gene expression in the
peripheral blood of patients with PTLD has not been reported previously (Rowe et al
2000, Vajro et al 2000). These unrestricted transcription patterns are also detected
during symptomatic primary infection (IM) (this study Section 4.2.3 and Tierney et
al 1994). The circulating cells in PTLD may be tumour cells that have escaped from
lymphoid tissue to enter the circulation or may represent a more generalized
transcriptional activation.
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Previous analyses of PTLD biopsies at a single cell level by in-situ
hybridization or immunohistochemistry have demonstrated heterogeneous EBV gene
expression in tumour cells within an individual lymphoma biopsy (Rea et al 1994,
Delecluse et al 1995, Oodjans et al 1995, Brink et al 1997). Brink et al (1997)
described a correlation between tumour cell morphology and EBV gene expression,
with latency I in small tumour cells, latency III in intermediate sized cells and latency
II-like gene expression (LMP1 with little or no EBNA2) in large immunoblasts or
Reed-Sternberg-like cells. Lytic replication was detected in all PTLD biopsies tested
by Brooks and Thomas (1995) although only a small proportion of tumour cells
express lytic transcripts.
The lymph node microenvironment is thought to play a crucial role in
development of PTLD through provision of growth factors by T-helper cells which
are abundant in tumours (Pereira et al 1998). The mechanism of EBV persistence
proposed by Thorley-Lawson & Babcock (1999) suggests that this microenvironment
may induce EBV replication and secondary infection of nai've B-cells which undergo
unrestricted latent gene expression. In healthy individuals this would be a transient
event, since CTLs would eliminate lymphoblastoid cells. The majority of PTLD
tumours are restricted to lymph nodes which suggests that disease results from
proliferation of EBV infected cells following activation by processes that occur in
healthy carriers. More malignant extranodal tumours are associated with cellular
genetic abnormalities which may permit aberrant cell migration (Knowles et al
1995). However, as shown in immunosuppressed transplant recipients and patients
with PTLD, tumour-like cells appear to persist and are detectable in the peripheral
blood. These results suggest that PTLD represents an extreme manifestation of loss
of control of EBV replication and B-cell proliferation which is also detected in
transplant recipients who do not have apparent disease. Alternatively it may be that
EBV reactivation alone is insufficient to cause PTLD, and genetic events may be
required for disease to occur.
The heterogeneous phenotype of cells within PTLD biopsies may reflect
transitional phases in B cell development and differentiation associated with different
EBV transcripts as proposed by the Thorley-Lawson model of EBV persistence and
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reactivation. It is possible that similarly diverse cell phenotypes may exist in the
peripheral circulation of patients with PTLD, but are not discernable by RT-PCR on
a mixture of cells. In one case of PTLD a more restricted pattern of EBV gene
expression was detected in the peripheral blood compared with the corresponding
tumour, indicating that there may be different populations of cells, or different
restrictions on phenotype, in different sites. This may indicate that even in
immunosuppressed individuals with PTLD, tumour cells expressing unrestricted
EBV gene transcription either do not enter the peripheral circulation or are
eliminated by residual CTL activity.
5.4 Conclusions
None of the patients in this study group developed PTLD during the follow-
up period of up to 3.5 years (mean follow-up time of 415 days). Since the transplant
recipients studied were all adults, and mostly EBV seropositive, it might be expected
that cases of PTLD would occur after a longer period post-transplant. The results of
this study show that in many transplant recipients there are indications of unrestricted
EBV latent and lytic gene expression equivalent to that detected in PBMs of patients
with PTLD, yet have no apparent EBV associated disease. This demonstrates that
although transplant recipients are severely immunosuppressed they are apparently
able to retain control of persistent EBV infection. Diagnosis and prediction of risk
factors for PTLD is therefore highly complex, indicating the necessity of careful
monitoring of patients who show symptoms ofPTLD and have high EBV load. With
increasing exposure to immunosuppressive drugs there is an increase in the EBV
load and detection of unrestricted latent gene expression. This correlates with
previous observations that PTLD occurs 5-10 years post-transplant in seropositive
adult transplant recipients (Penn et al 1988). CTL activity has been shown to recover
following the initial 6 month period of profound immunosuppression (Haque et al
1997) although maintenance immunosuppression is given for life. It may be that
there is gradual loss of residual EBV-specific CTL activity with increasing exposure
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to immunosuppression which ultimately allows EBV infected lymphoblasts to
replicate to levels which cause disease.
The detection of lymphoblastoid-cell-like EBV gene expression in peripheral
blood of patients without EBV-associated disease shows that additional factors other
than EBV-infection must be involved in PTLD development. These could be cellular
genetic factors or provision of growth factors which could allow EBV-infected
lymphoblast to accumulate to sufficiently high levels to cause apparent disease. The
majority of primary tumours do not carry mutations of the tumour suppressor genes
or cellular oncogenes, indicating that the tumours arise as a result of EBV-driven
proliferation of normal B-lymphocytes. However, mutations have been detected in
PTLD, notably associated with more aggressive disseminated tumours which often
result during recurrence of the disease. This indicates a multi-step mechanism in
progression of EBV infection from asymptomatic reactivation through polyclonal
refractory PTLD to monoclonal malignancy.
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